Pharmaceutical compositions containing particles and mRNA and methods for preparing and storing same - Patents.com
Patent Information
- Application Number
- JP2023528680
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-18
- Filing Date
- 2021-11-15
- Publication Date
- 2024-11-22
AI Technical Summary
Current nanoparticle formulations containing ionizable lipids for delivering mRNA face challenges in achieving sufficient shelf life stability at temperatures applicable for pharmaceutical use, requiring freezing at -80°C or below, which is impractical for the cold chain, and standard stabilization techniques are ineffective.
A method involving the preparation of lipid nanoparticles (LNPs) with cationically ionizable lipids and mRNA, excluding NaCl, KCl, citrate, and phosphate anions, and adjusting the formulation pH to the pK of the lipid, followed by freezing or lyophilization, to achieve stability at -25°C or higher for up to 30 months.
The method stabilizes LNPs, maintaining particle size and integrity for at least 12 months, preferably 24 months, and up to 36 months, at temperatures suitable for pharmaceutical storage without the need for extreme cold, ensuring product quality and safety.
Smart Images

Figure 2022101486000001 
Figure 2022101486000002 
Figure 2022101486000003
Abstract
Description
Technical field
[0001] Technical field The present invention relates generally to the field of pharmaceutical compositions comprising particles, particularly lipid nanoparticles (LNPs) and mRNA, methods of preparing and storing such pharmaceutical compositions, and the use of pharmaceutical compositions in therapy. [Background technology]
[0002] background The use of recombinant nucleic acids (eg, DNA or RNA) to deliver foreign genetic information to target cells is well known. Advantages of using RNA include transient expression and non-transforming characteristics. RNA does not need to enter the nucleus to be expressed, and furthermore cannot be integrated into the host genome, thus eliminating multiple risks such as carcinogenesis.
[0003] Recombinant nucleic acids can be administered to a subject in need thereof in naked form; however, usually recombinant nucleic acids are administered using pharmaceutical compositions. For example, RNA can be prepared by so-called nanoparticle formulations comprising RNA and a nanoparticle-forming medium, such as a cationic lipid (e.g. a permanently charged cationic lipid), a mixture of a cationic lipid and one or more additional lipids, or a cationic polymer. can be delivered. The fate of such nanoparticle formulations is controlled by a variety of key factors, such as nanoparticle size and size distribution. These factors are, for example, referred to as special attributes to be analyzed and identified in the FDA "Liposomal Drug Guidance" from 2018. A limitation to the clinical application of current nanoparticle formulations may be due to the lack of homogeneous, pure and well-characterized nanoparticle formulations.
[0004] LNPs containing ionizable lipids may show advantages in terms of targeting and efficacy compared to other RNA nanoparticle products. However, it is difficult to obtain sufficient shelf life required for normal pharmaceutical use. For example, LNPs containing ionizable lipids cannot be stabilized by freezing at -20 °C under conditions that are applicable with similar lipid-based nanoparticle formulations containing permanently charged cationic lipids. Also, other techniques used to improve shelf life stability such as dehydration are not possible with standard protocols. Rather, for stabilization, LNPs containing ionizable lipids need to be frozen at much lower temperatures, such as -80 °C, which imposes a considerable burden on the cold chain or only obtain limited stability. It can only be stored at temperatures above freezing, for example 5°C. [Summary of the invention] [Problem to be solved by the invention]
[0005] Therefore, (i) pharmaceutical compositions comprising LNPs comprising ionizable lipids and mRNA, which are stable and capable of being stored in a temperature range consistent with normal technology in pharmaceutical practice, in particular at temperatures of about -25°C or higher; ii) There is still a need in the art for methods of preparing and storing such compositions. The present invention addresses these and other needs. [Means to solve the problem]
[0006] The inventors have surprisingly discovered that the methods and pharmaceutical compositions described herein meet the above needs. In particular, certain parameters (e.g., the pK of cationically ionizable lipids using the pH of the formulation used in the manufacture of the pharmaceutical composition) a By adhering to the following conditions: eliminating the addition of NaCl and / or KCl; eliminating citrate anions in the formulation; and / or eliminating phosphate anions in the formulation), it is stable and approximately -25 °C It has been shown that it is possible to prepare pharmaceutical compositions in frozen or lyophilized form that can be stored for up to 30 minutes or longer.
[0007] summary In a first aspect, the invention provides a method of manufacturing a pharmaceutical composition comprising: (I) preparing a formulation comprising lipid nanoparticles (LNPs), wherein the LNPs comprise a cationically ionizable lipid and mRNA, and one or more of the following are applied: (i) step (I) does not include the addition of NaCl and / or KCl; (ii) The pH of the formulation is the pK of the cationically ionizable lipid. a lower; (iii) the formulation is substantially free of citrate anions; (iv) the formulation is substantially free of inorganic phosphate anions; and (II) freezing the formulation to about -10°C or below, thereby obtaining the pharmaceutical composition in frozen form; Provide a method, including.
[0008] In certain embodiments, particularly if it is desired to prepare the pharmaceutical composition in lyophilized form, the method of the first aspect further comprises lyophilizing the frozen formulation, thereby preparing the pharmaceutical composition in lyophilized form. The method includes a step (III) of obtaining.
[0009] In the first subgroup of the first embodiment, at least one of criteria (i) to (iv) is applied. For example, in certain embodiments of this first subgroup, at least step (I) does not include the addition of NaCl or does not include the addition of KCl or does not include the addition of NaCl and KCl. In a further embodiment of this first subgroup, at least the pH of the formulation is the pK of the cationically ionizable lipid. a lower. In a further embodiment of this first subgroup, at least the formulation is substantially free of citrate anions. In a further embodiment of this first subgroup, at least the formulation is substantially free of inorganic phosphate anions.
[0010] In the second subgroup of the first embodiment, at least two of criteria (i) to (iv) are applied. For example, in certain embodiments of this second subgroup, at least the pH of the formulation is the pK of the cationically ionizable lipid. a and step (I) does not include the addition of NaCl or does not include the addition of KCl or does not include the addition of NaCl and KCl. In a further embodiment of this second subgroup, at least the formulation is substantially free of citrate anions and step (I) does not involve the addition of NaCl or does not involve the addition of KCl or does not involve the addition of NaCl and KCl. Not included. In a further embodiment of this second subgroup, at least the formulation is substantially free of inorganic phosphate anions and step (I) does not include the addition of NaCl or does not include the addition of KCl or the addition of NaCl and KCl. Does not include. In a further embodiment of this second subgroup, at least the pH of the formulation is the pK of the cationically ionizable lipid. a lower and the formulation is substantially free of citrate anions. In a further embodiment of this second subgroup, at least the pH of the formulation is the pK of the cationically ionizable lipid. a lower and the formulation is substantially free of inorganic phosphate anions. In further embodiments of this second subgroup, at least the formulation is substantially free of citrate anions and substantially free of inorganic phosphate anions.
[0011] In the third subgroup of the first embodiment, at least three of criteria (i) to (iv) apply. For example, in certain embodiments of this third subgroup, at least the pH of the formulation is the pK of the cationically ionizable lipid. a Lower, the formulation is substantially free of citrate anions and step (I) does not include the addition of NaCl or does not include the addition of KCl or does not include the addition of NaCl and KCl. In a further embodiment of the third subgroup, at least the pH of the formulation is equal to or greater than the pK of the cationically ionizable lipid. a Lower, the formulation is substantially free of inorganic phosphate anions and step (I) does not include the addition of NaCl or does not include the addition of KCl or does not include the addition of NaCl and KCl. In a further embodiment of the third subgroup, at least the formulation is substantially free of citrate anions and substantially free of inorganic phosphate anions and step (I) does not include the addition of NaCl or the addition of KCl. or without the addition of NaCl and KCl. In a further embodiment of the third subgroup, at least the pH of the formulation is equal to or greater than the pK of the cationically ionizable lipid. a lower and the formulation is substantially free of citrate anions and substantially free of inorganic phosphate anions.
[0012] In the fourth subgroup of the first embodiment, at least all of criteria (i) to (iv) apply. That is, in this fourth subgroup, at least the pH of the formulation is close to the pK of the cationically ionizable lipid. a lower, the formulation is substantially free of citrate anions and substantially free of inorganic phosphate anions and step (I) includes no addition of NaCl or no addition of KCl or addition of NaCl and KCl. Does not include.
[0013] In certain embodiments of the first aspect (particularly in certain embodiments of the first, second, third or fourth subgroups of the first aspect), the formulation comprises a buffer system and / or a cryoprotectant. . For example, in some embodiments (particularly in some embodiments of the above first, second, third or fourth subgroups of the first aspect), the formulation comprises a buffer system. In a further embodiment (particularly in a further embodiment of the first, second, third or fourth subgroup above of the first aspect), the formulation comprises a cryoprotectant. In a further embodiment (particularly in a further embodiment of the first, second, third or fourth subgroup above of the first aspect), the formulation comprises a buffer system and a cryoprotectant. Specific examples of these implementations are thus: (1) the formulation includes a buffer system and step (I) does not include the addition of NaCl or does not include the addition of KCl or does not include the addition of NaCl and KCl; (2) the formulation includes a cryoprotectant and step (I) does not include the addition of NaCl or does not include the addition of KCl or does not include the addition of NaCl and KCl; (3) the formulation includes a buffer system and a cryoprotectant and step (I) does not include the addition of NaCl or does not include the addition of KCl or does not include the addition of NaCl and KCl; (4) The pH of the formulation is the pK of cationically ionizable lipids. a lower and the formulation contains a buffer system; (5) The pH of the formulation is the pK of cationically ionizable lipids. a lower and the formulation contains a cryoprotectant; (6) The pH of the formulation is the pK of cationically ionizable lipids. a lower and the formulation includes a buffer system and a cryoprotectant; (7) the formulation is substantially free of citrate anions and includes a buffer system; (8) the formulation is substantially free of citrate anions and includes a cryoprotectant; (9) the formulation is substantially free of citrate anions and includes a buffer system and a cryoprotectant; (10) the formulation is substantially free of inorganic phosphate anions and includes a buffer system; (11) the formulation is substantially free of inorganic phosphate anions and includes a cryoprotectant; (12) the formulation is substantially free of inorganic phosphate anions and includes a buffer system and a cryoprotectant; (13) The formulation contains a buffer system, and the pH of the formulation is the pK of the cationically ionizable lipid. a lower and step (I) does not include the addition of NaCl or does not include the addition of KCl or does not include the addition of NaCl and KCl; (14) The formulation includes a cryoprotectant system, and the pH of the formulation is the pK of the cationically ionizable lipid. a lower and step (I) does not include the addition of NaCl or does not include the addition of KCl or does not include the addition of NaCl and KCl; (15) The formulation contains a buffer system and a cryoprotectant, and the pH of the formulation is the pK of the cationically ionizable lipid. a lower and step (I) does not include the addition of NaCl or does not include the addition of KCl or does not include the addition of NaCl and KCl; (16) the formulation includes a buffer system and is substantially free of citrate anions and step (I) does not include the addition of NaCl or does not include the addition of KCl or does not include the addition of NaCl and KCl; (17) the formulation includes a cryoprotectant and is substantially free of citrate anions and step (I) does not include the addition of NaCl or does not include the addition of KCl or does not include the addition of NaCl and KCl; (18) The formulation includes a buffer system and a cryoprotectant and is substantially free of citrate anions and step (I) does not include the addition of NaCl or does not include the addition of KCl or includes the addition of NaCl and KCl. do not have; (19) the formulation includes a buffer system and is substantially free of inorganic phosphate anions and step (I) does not include the addition of NaCl or does not include the addition of KCl or does not include the addition of NaCl and KCl; (20) the formulation includes a cryoprotectant and is substantially free of inorganic phosphate anions and step (I) does not include the addition of NaCl or does not include the addition of KCl or does not include the addition of NaCl and KCl; (21) The formulation includes a buffer system and a cryoprotectant and is substantially free of inorganic phosphate anions and step (I) does not include the addition of NaCl or does not include the addition of KCl or does not include the addition of NaCl and KCl. Not included; (22) The pH of the formulation is the pK of the cationically ionizable lipid. a and the formulation is substantially free of citrate anions and includes a buffer system; (23) The pH of the formulation is the pK of the cationically ionizable lipid. a lower and the formulation is substantially free of citrate anions and contains a cryoprotectant; (24) The pH of the formulation is the pK of the cationically ionizable lipid. a and the formulation is substantially free of citrate anions and includes a buffer system and a cryoprotectant; (25) The pH of the formulation is the pK of the cationically ionizable lipid. a and the formulation is substantially free of inorganic phosphate anions and includes a buffer system; (26) The pH of the formulation is the pK of the cationically ionizable lipid. a and the formulation is substantially free of inorganic phosphate anions and includes a cryoprotectant; (27) The pH of the formulation is the pK of the cationically ionizable lipid. a lower and the formulation is substantially free of inorganic phosphate anions and includes a buffer system and a cryoprotectant; (28) the formulation is substantially free of citrate anions and substantially free of inorganic phosphate anions and includes a buffer system; (29) the formulation is substantially free of citrate anions and substantially free of inorganic phosphate anions and includes a cryoprotectant; (30) the formulation is substantially free of citrate anions and substantially free of inorganic phosphate anions and includes a buffer system and a cryoprotectant; (31) The formulation contains a buffer system, and the pH of the formulation is the pK of the cationically ionizable lipid. a lower, the formulation is substantially free of citrate anions and step (I) does not include the addition of NaCl or does not include the addition of KCl or does not include the addition of NaCl and KCl; (32) The formulation contains a cryoprotectant, and the pH of the formulation is the pK of the cationically ionizable lipid. a lower, the formulation is substantially free of citrate anions and step (I) does not include the addition of NaCl or does not include the addition of KCl or does not include the addition of NaCl and KCl; (33) The formulation contains a buffer system and a cryoprotectant, and the pH of the formulation is the pK of the cationically ionizable lipid. a lower, the formulation is substantially free of citrate anions and step (I) does not include the addition of NaCl or does not include the addition of KCl or does not include the addition of NaCl and KCl; (34) The formulation contains a buffer system, and the pH of the formulation is the pK of the cationically ionizable lipid. a lower, the formulation is substantially free of inorganic phosphate anions and step (I) does not include the addition of NaCl or does not include the addition of KCl or does not include the addition of NaCl and KCl; (35) The formulation contains a cryoprotectant, and the pH of the formulation is the pK of the cationically ionizable lipid. a lower, the formulation is substantially free of inorganic phosphate anions and step (I) does not include the addition of NaCl or does not include the addition of KCl or does not include the addition of NaCl and KCl; (36) The formulation contains a buffer system and a cryoprotectant, and the pH of the formulation is the pK of the cationically ionizable lipid. a lower, the formulation is substantially free of inorganic phosphate anions and step (I) does not include the addition of NaCl or does not include the addition of KCl or does not include the addition of NaCl and KCl; (37) The formulation includes a buffer system, the formulation is substantially free of citrate anions and substantially free of inorganic phosphate anions, and step (I) does not include the addition of NaCl or does not include the addition of KCl. or without the addition of NaCl and KCl; (38) The formulation includes a cryoprotectant, the formulation is substantially free of citrate anions and substantially free of inorganic phosphate anions, and step (I) does not include the addition of NaCl or does not include the addition of KCl. Contains no or no addition of NaCl and KCl; (39) The formulation includes a buffer system and a cryoprotectant, the formulation is substantially free of citrate anions and substantially free of inorganic phosphate anions, and step (I) does not include the addition of NaCl or KCl or without the addition of NaCl and KCl; (40) The pH of the formulation is the pK of the cationically ionizable lipid. a lower, the formulation is substantially free of citrate anions and substantially free of inorganic phosphate anions and the formulation includes a buffer system; (41) The pH of the formulation is the pK of the cationically ionizable lipid. a lower, the formulation is substantially free of citrate anions and substantially free of inorganic phosphate anions and the formulation includes a cryoprotectant; (42) The pH of the formulation is the pK of the cationically ionizable lipid. a lower, the formulation is substantially free of citrate anions and substantially free of inorganic phosphate anions and the formulation includes a buffer system and a cryoprotectant; (43) The formulation contains a buffer system, and the pH of the formulation is the pK of the cationically ionizable lipid. alower, the formulation is substantially free of citrate anions and substantially free of inorganic phosphate anions and step (I) includes no addition of NaCl or no addition of KCl or addition of NaCl and KCl. does not contain; (44) The formulation contains a cryoprotectant, and the pH of the formulation is the pK of the cationically ionizable lipid. a lower, the formulation is substantially free of citrate anions and substantially free of inorganic phosphate anions and step (I) includes no addition of NaCl or no addition of KCl or addition of NaCl and KCl. does not contain; (45) The formulation contains a buffer system and a cryoprotectant, and the pH of the formulation is the pK of the cationically ionizable lipid. a lower, the formulation is substantially free of citrate anions and substantially free of inorganic phosphate anions and step (I) includes no addition of NaCl or no addition of KCl or addition of NaCl and KCl. Does not include.
[0014] In certain embodiments of the first aspect (in particular in any of the embodiments (1) to (45) listed above, the first, second, third or fourth subgroup of the first aspect) In certain embodiments), the pH of the formulation is at most 6.5, preferably at most 6.4, at most 6.3, at most 6.2, at most 6.1 or at most 6.0. In certain embodiments of the first aspect (in particular in any of the embodiments (1) to (45) listed above, the first, second, third or fourth subgroup of the first aspect) In some embodiments), the pH of the formulation is in the range 5.5-6.5, such as 5.6-6.4, 5.7-6.6, 5.8-6.2 or 5.9-6.1. In certain embodiments of the first aspect (in particular in any of the embodiments (1) to (45) listed above, the first, second, third or fourth subgroup of the first aspect) In certain embodiments), the pH of the formulation is about 6.0.
[0015] In certain embodiments of the first aspect, wherein the formulation comprises a buffer system (in particular the first, second, second, second, or In certain embodiments of the third or fourth subgroup), the buffer system comprises water (especially deionized water, such as water for injection) and a buffering substance. In certain embodiments, the buffer system includes any one of HEPES, histidine, Tris, and acetic acid as a buffering substance, such as any one of HEPES, histidine, and Tris as a buffering substance. In certain preferred embodiments, the buffer system includes HEPES as the buffering substance. In certain embodiments of the first aspect (in particular in any of the embodiments (1) to (45) listed above, the first, second, third or fourth subgroup of the first aspect) In certain embodiments), the formulation comprises a buffer system comprising water (especially deionized water, such as water for injection) and HEPES as a buffering substance.
[0016] In certain embodiments of the first aspect, wherein the formulation comprises a buffer system (in particular the first, second, second, second, or In some embodiments of the third or fourth subgroup), the concentration of the buffer in the formulation is up to 50 mM, preferably up to 45 mM, more preferably up to 40 mM, more preferably up to 35 mM, more preferably up to 30 mM, more preferably Up to 25mM, more preferably up to 20mM. In certain embodiments of the first aspect (in particular in any of the embodiments (1) to (45) listed above, the first, second, third or fourth subgroup of the first aspect) In certain embodiments), the concentration of the buffer in the formulation ranges from 5mM to 50mM, such as from 5mM to 40mM, from 10mM to 30mM or from 15mM to 25mM.
[0017] In certain embodiments of the first aspect, wherein the formulation comprises a cryoprotectant (in particular the first, second, or In some embodiments of the third or fourth subgroup), the cryoprotectant comprises one or more carbohydrates. For example, it may contain any of the cryoprotectants sucrose, trehalose, glucose or combinations thereof. In a preferred embodiment of the first aspect (in particular in any of the above-mentioned embodiments (1) to (45)) said first, second, third or fourth subgroup of the first aspect In some embodiments), the formulation comprises sucrose and / or trehalose as cryoprotectants.
[0018] In certain embodiments of the first aspect, wherein the formulation comprises a cryoprotectant (in particular the first, second, or In some embodiments of the third or fourth subgroup), the concentration of cryoprotectant in the formulation is at least 1% w / v, such as at least 2% w / v, at least 3% w / v, at least 4% w / v. v, at least 5%w / v, at least 6%w / v, at least 7%w / v or at least 8%w / v. In certain embodiments, the concentration of cryoprotectant in the formulation is up to 25%w / v, such as up to 20%w / c, up to 19%w / v, up to 18%w / v, up to 17%w / v, up to 16%w / v, maximum 15%w / v, maximum 14%w / v, maximum 13%w / v, maximum 12%w / v or maximum 11%w / v. In certain embodiments, the concentration of cryoprotectant in the formulation is 1%w / v to 20%w / v, such as 2%w / v to 19%w / v, 3%w / v to 18%w / v, 4%w / v~17%w / v, 5%w / v~16%w / v, 5%w / v~15%w / v, 6%w / v~14%w / v, 7% w / v~13%w / v, 8%w / v~12%w / v, 9%w / v~11%w / v or about 10%w / v. In certain embodiments of the first aspect (in particular in any of the embodiments (1) to (45) listed above, the first, second, third or fourth subgroup of the first aspect) In certain embodiments), the formulation is 5%w / v to 15%w / v, such as 6%w / v to 14%w / v, 7%w / v to 13%w / v, 8%w / v Cryoprotectants (particularly sucrose and / or trehalose) at a concentration of v~12%w / v or 9%w / v~11%w / v or about 10%w / v.
[0019] In certain preferred embodiments of the first aspect, wherein the formulation comprises a buffer system and a cryoprotectant, in particular the first aspect of the first aspect as in any of the embodiments (1) to (45) listed above. , in certain preferred embodiments of the second, third or fourth subgroup), the buffer system comprises HEPES as buffering substance and the cryoprotectant comprises sucrose and / or Contains trehalose.
[0020] In certain embodiments of the first aspect (in particular in any of the embodiments (1) to (45) listed above, the first, second, third or fourth subgroup of the first aspect) In some embodiments), the formulation further comprises a poloxamer.
[0021] In particular, in another embodiment of the first embodiment, particularly in any of the embodiments (1) to (45) listed above, the formulation comprises HEPES as a buffering substance. In certain embodiments of the first, second, third or fourth subgroup), the formulation does not contain a poloxamer.
[0022] In certain embodiments of the first aspect (in particular in any of the embodiments (1) to (45) listed above, the first, second, third or fourth subgroup of the first aspect) In some embodiments), the cationically ionizable lipid comprises a head group that includes at least one nitrogen atom that can be protonated under physiological conditions. For example, a cationically ionizable lipid has the formula (I): [ka] or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer structure thereof, where L 1 ,L 2 ,G 1 ,G 2 ,G 3 ,R 1 ,R 2 and R 3 is as defined herein. Preferably, the cationically ionizable lipid is selected from: structures I-1 to I-36 (as shown here); and / or structures A to F (as shown here); and / or N ,N-dimethyl-2,3-dioleyloxypropylamine (DODMA), 1,2-dioleoyl-3-dimethylammonium-propane (DODAP), heptatriaconta-6,9,28,31-tetraene-19- yl-4-(dimethylamino)butanoate (DLin-MC3-DMA) and 4-((di((9Z,12Z)-octadeca-9,12-dien-1-yl)amino)oxy)-N,N- Dimethyl-4-oxobutan-1-amine (DPL-14).
[0023] In certain embodiments of the first aspect (in particular the first, second, third or fourth subgroups of the first aspect, such as in any of the embodiments (1) to (45) listed above) In some embodiments), the LNP further comprises one or more additional lipids. Preferably, the one or more additional lipids are selected from the group consisting of polymer-conjugated lipids, neutral lipids, steroids, and combinations thereof. In a preferred embodiment of the first aspect (in particular in any of the above-mentioned embodiments (1) to (45)) said first, second, third or fourth subgroup of the first aspect In some embodiments), the LNP is a cationically ionizable lipid described herein, a polymer-conjugated lipid (e.g., a pegylated lipid or a polysarcosine-lipid conjugate or a conjugate of polysarcosine and a lipid-like substance), Includes neutral lipids (eg DSPC) and steroids (eg cholesterol).
[0024] In certain embodiments of the first aspect, wherein the LNP further comprises a polymer-conjugated lipid as one or more additional lipids, particularly as in any of embodiments (1) to (45) listed above. In certain embodiments of the first, second, third or fourth subgroup of the first aspect), the polymer conjugate lipid is a pegylated lipid. For example, a pegylated lipid has the following structure: [ka] or a pharmaceutically acceptable salt, tautomer or stereoisomer structure thereof, where R 12 ,R 13 and w are as defined herein.
[0025] In certain embodiments of the first aspect, wherein the LNP further comprises a polymer-conjugated lipid as one or more additional lipids, particularly as in any of embodiments (1) to (45) listed above. In certain embodiments of the first, second, third or fourth subgroup of the first aspect), the polymer-conjugated lipid is a polysarcosine-lipid conjugate or a conjugate of polysarcosine and a lipid-like substance. . For example, polysarcosine-lipid conjugates or polysarcosine and lipid-like substance conjugates include polysarcosine-diacylglycerol conjugates, polysarcosine-dialkyloxypropyl conjugates, polysarcosine-phospholipid conjugates, polysarcosine-ceramide conjugates. and mixtures thereof.
[0026] In certain embodiments of the first aspect, wherein the LNP further comprises a neutral lipid as one of the one or more additional lipids, in particular a neutral lipid as in any of the embodiments (1) to (45) listed above. In certain embodiments of the first, second, third or fourth subgroup of one embodiment), the neutral lipid is a phospholipid. Such phospholipids are preferably selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidic acid, phosphatidylserine and sphingomyelin. Specific examples of phospholipids are distearoyl phosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dimyristoyl phosphatidylcholine (DMPC), dipentadecanoylphosphatidylcholine, dilauroyl phosphatidylcholine, dipalmitoylphosphatidylcholine (DPPC), dialachidoyl Phosphatidylcholine (DAPC), dibehenoylphosphatidylcholine (DBPC), ditricosanoylphosphatidylcholine (DTPC), dilignoceroylphatidylcholine (DLPC), palmitoyloleoyl-phosphatidylcholine (POPC), 1,2-di-O-octadecenyl -sn-glycero-3-phosphocholine (18:0 Diether PC), 1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), dioleoylphosphatidylethanolamine (DOPE), distearoyl-phosphatidylethanolamine (DSPE), dipalmitoyl-phosphatidylethanolamine (DPPE), dimyristoyl-phosphatidylethanolamine (DMPE), dilauroyl-phosphatidylethanolamine amine (DLPE) and diphytanoyl-phosphatidylethanolamine (DPyPE).
[0027] In some embodiments of the first aspect, wherein the LNP further comprises a steroid as one or more additional lipids, particularly in the first embodiment as in any of embodiments (1) to (45) listed above. In certain embodiments of the above first, second, third or fourth subgroup of aspects), the steroid is a sterol, such as cholesterol.
[0028] In certain embodiments of the first aspect (in particular in any of the embodiments (1) to (45) listed above, the first, second, third or fourth subgroup of the first aspect) In some embodiments), the formulation further comprises a chelating agent such as EDTA. In certain embodiments of the first aspect, wherein the formulation comprises a chelating agent (in particular the first, second, second or third aspect of the first aspect as in any of the embodiments (1) to (45) listed above) In certain embodiments of the third or fourth subgroup), the concentration of the chelating agent in the formulation is at most 20 mM, preferably at most 15 mM, more preferably at most 10 mM, more preferably at most 5 mM.
[0029] In another embodiment of the first aspect (in particular the first, second, third or fourth sub-subject of the first aspect as in any of the embodiments (1) to (45) listed above) In another embodiment of the group), the formulation is free of chelating agents.
[0030] In certain embodiments of the first aspect (in particular in any of the embodiments (1) to (45) listed above, the first, second, third or fourth subgroup of the first aspect) In certain embodiments), the ratio of cationically ionizable lipid to mRNA is between 2:1 and 12:1, such as between 2:1 and 10:1 or between 4:1 and 8:1.
[0031] In certain embodiments of the first aspect (in particular in any of the embodiments (1) to (45) listed above, the first, second, third or fourth subgroup of the first aspect) In certain embodiments), the mRNA is encapsulated or bound to the LNP.
[0032] In certain embodiments of the first aspect (in particular in any of the embodiments (1) to (45) listed above, the first, second, third or fourth subgroup of the first aspect) In some embodiments), the mRNA includes a modified nucleoside in place of uridine. For example, the modified nucleoside may be selected from pseudouridine (ψ), N1-methyl-pseudouridine (m1ψ) and 5-methyl-uridine (m5U).
[0033] In certain embodiments of the first aspect (in particular in any of the embodiments (1) to (45) listed above, the first, second, third or fourth subgroup of the first aspect) (b) 5'UTR; (c) 3'UTR; and (d) a polyA sequence comprising at least 100 nucleotides. It may contain one or more of the A sequences.
[0034] In certain preferred embodiments of the first aspect (in particular in any of the embodiments (1) to (45) listed above, the first, second, third or fourth sub-subject of the first aspect) In certain preferred embodiments of the group), the mRNA encodes one or more polypeptides. For example, one or more polypeptides can include an epitope for inducing an immune response against an antigen in a subject. In a preferred embodiment, the mRNA encodes an amino acid sequence comprising the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof.
[0035] In certain embodiments of the first aspect (in particular in any of the embodiments (1) to (45) listed above, the first, second, third or fourth subgroup of the first aspect) In some embodiments), the formulation is at a temperature in the range of about -30°C to about -10°C, such as about -25°C to about -15°C, or about -25°C to about -20°C, or a temperature of about -20°C. Freeze until
[0036] In some embodiments of the first embodiment, the method comprises lyophilizing the frozen formulation of step (III), particularly of the first embodiment as in any of embodiments (1) to (45) listed above. In certain embodiments of the first, second, third or fourth subgroup above), the frozen formulation is lyophilized until the pharmaceutical composition is substantially free of water contained in the frozen formulation. For example, a frozen formulation may be prepared in which the pharmaceutical composition contains less than 1.0% by weight of water, such as less than 0.8%, less than 0.7%, less than 0.6%, less than 0.5%, less than 0.4%, less than 0.3%, 0.2% by weight. % or 0.1% by weight of water.
[0037] In certain embodiments of the first aspect (in particular in any of the embodiments (1) to (45) listed above, the first, second, third or fourth subgroup of the first aspect) In some embodiments), step (I) comprises (a) preparing an mRNA solution comprising water (especially deionized water, such as water for injection) and a buffer system; (b) a cationically ionizable lipid; preparing an ethanolic solution containing one or more additional lipids, if present; and (c) mixing the mRNA solution prepared under (a) with the ethanolic solution prepared under (b); A formulation containing LNPs is then prepared. In order to remove undesired components (e.g. ethanol), in a preferred embodiment step (I) is selected from dilution and filtration after step (c), such as tangential flow filtration and / or diafiltration. Further comprising one or more steps. In certain embodiments of the first aspect (in particular the first, second, third or fourth subgroups of the first aspect, such as in any of the embodiments (1) to (45) listed above) In certain embodiments), the mRNA solution prepared in step (I)(a) is less than 0.2% w / v, such as less than 0.15% w / v, less than 0.10% w / v, less than 0.05% w / v, or Contains NaCl and KCl at a combined concentration of less than 0.01 w / v.
[0038] In another embodiment of the first aspect (in particular the first, second, third or fourth sub-subject of the first aspect as in any of the embodiments (1) to (45) listed above) In another embodiment of the group), step (I) comprises (a') the preparation of a liposome or colloidal preparation of a cationically ionizable lipid and, if present, one or more additional lipids in an aqueous phase; and (b') preparation of an mRNA solution containing water and a buffer system; and (c') mixing of the liposome or colloid preparation prepared under (a') and (b') the mRNA solution prepared below. include. In a preferred embodiment, step (I) further comprises one or more dilution steps after step (c'). In certain embodiments of the first aspect (in particular in any of the embodiments (1) to (45) listed above, the first, second, third or fourth subgroup of the first aspect) In certain embodiments), the mRNA solution prepared in step (I)(b') is less than 0.2% w / v, such as less than 0.15% w / v, less than 0.10% w / v, less than 0.05% w / v or containing NaCl and KCl in a combined concentration of less than 0.01 w / v.
[0039] In a second aspect, the invention provides a method for storing a pharmaceutical composition, comprising preparing a pharmaceutical composition by the method of the first aspect, and storing the pharmaceutical composition at a temperature of about -30°C or above, such as about -25°C. ℃ or higher. For example, frozen pharmaceutical compositions may be frozen at a temperature in the range of about -30°C to about -10°C, such as about -25°C to about -15°C or about -25°C to about -20°C, or at a temperature of about -20°C. Can be stored. Lyophilized pharmaceutical compositions may be stored at temperatures ranging from about -25°C to about room temperature, such as from about -15°C to about 8°C, from about -10°C to about 2°C, or from about -5°C to about 0°C. . In certain embodiments of the second aspect, the storage of the pharmaceutical composition is for at least 3 months, preferably at least 6 months, more preferably at least 12 months, more preferably at least 18 months, more preferably at least 24 months, more preferably At least 30 months, more preferably at least 36 months.
[0040] Any of the embodiments described herein in the first aspect (in particular, in any of the above-mentioned embodiments (1) to (45) above) or any embodiment of the fourth subgroup) may be applied to any of the embodiments of the second aspect.
[0041] In a third aspect, the invention provides a frozen pharmaceutical composition that can be prepared by the method of the first aspect. In certain embodiments of the third aspect, the pharmaceutical composition may be stored at a temperature of about -30°C or higher, such as about -25°C or higher. For example, the frozen pharmaceutical composition of the third embodiment may be prepared at a temperature in the range of about -30°C to about -10°C, such as about -25°C to about -15°C or about -25°C to about -20°C, or about - Can be stored at a temperature of 20°. In certain embodiments of the third aspect, the pharmaceutical composition is administered for at least 3 months, preferably at least 6 months, more preferably at least 12 months, more preferably at least 18 months, more preferably at least 24 months, more preferably at least It can be stored for 30 months, more preferably at least 36 months. In certain embodiments of the third aspect, the size of the LNPs after thawing the frozen pharmaceutical composition (Z 平均 ) is about 50 nm to about 500 nm. In certain embodiments of the third aspect, the size of the LNPs after thawing the frozen pharmaceutical composition (Z 平均 ) (and / or size distribution and / or polydispersity index (PDI)) is the size (Z 平均 )(and / or size distribution and / or PDI). In certain embodiments of the third aspect, the PDI of the LNPs after thawing the frozen pharmaceutical composition is less than 0.3, preferably less than 0.2, more preferably less than 0.1, such as less than 0.05. In certain embodiments of the third aspect, the size of the LNPs after thawing the frozen pharmaceutical composition (Z 平均 ) is about 50 nm to about 500 nm, and the size of LNP after thawing the frozen pharmaceutical composition (Z 平均 ) (and / or size distribution and / or PDI) is the size of LNPs before freezing (Z 平均 )(and / or size distribution and / or PDI). In certain embodiments of the third aspect, the size of the LNPs after thawing the frozen pharmaceutical composition (Z 平均 ) is about 50 nm to about 500 nm, and the PDI of LNPs after thawing the frozen pharmaceutical composition is less than 0.3 (preferably less than 0.2, more preferably less than 0.1, for example less than 0.05).
[0042] Any of the embodiments described herein in the first or second aspect (in particular, in any of the embodiments (1) to (45) listed above) , any embodiment of the third or fourth subgroup) may be applied to any of the embodiments of the third aspect.
[0043] In a fourth aspect, the invention provides a lyophilized pharmaceutical composition that can be prepared by the method of the second aspect. In certain embodiments of the fourth aspect, the pharmaceutical composition may be stored at a temperature of about -30°C or higher, such as about -25°C or higher. For example, the lyophilized pharmaceutical composition of the fourth aspect may be prepared at a temperature of about -25° to about room temperature, such as about -15°C to about 8°C, about -10°C to about 2°C or about -5°C to about 0°C. Can be stored at a range of temperatures. In certain embodiments of the fourth aspect, the pharmaceutical composition is administered for at least 3 months, preferably at least 6 months, more preferably at least 12 months, more preferably at least 18 months, more preferably at least 24 months, more preferably at least It can be stored for 30 months, more preferably at least 36 months. In certain embodiments of the fourth aspect, the size of the LNPs (Z 平均 ) is about 50 nm to about 500 nm. In certain embodiments of the fourth aspect, the size of the LNPs (Z 平均 ) and / or size distribution and / or PDI is the size of LNPs before lyophilization (Z 平均 ) and / or size distribution and / or equal to PDI. In certain embodiments of the fourth aspect, the PDI of the LNPs after reconstitution of the lyophilized pharmaceutical composition is less than 0.3, preferably less than 0.2, more preferably less than 0.1, such as less than 0.05. In certain embodiments of the fourth aspect, the size of the LNPs (Z 平均 ) is about 50 nm to about 500 nm, and the size (Z 平均 ) and / or size distribution and / or PDI is the size of LNPs before lyophilization (Z 平均 ) and / or size distribution and / or equal to PDI. In certain embodiments of the fourth aspect, the size of the LNPs (Z 平均 ) is about 50 nm to about 500 nm, and the PDI of the LNPs after reconstitution of the lyophilized pharmaceutical composition is less than 0.3 (preferably less than 0.2, more preferably less than 0.1, eg less than 0.05).
[0044] Any of the embodiments described herein in the first, second or third aspect (in particular the first above of the first aspect as in any of the embodiments (1) to (45) listed above) , any embodiment of the second, third or fourth subgroup) may also apply to any of the embodiments of the fourth aspect.
[0045] In a fifth aspect, the invention provides a method for preparing a ready-to-use pharmaceutical composition, comprising: preparing a frozen pharmaceutical composition prepared by the method of the first aspect; A method is provided comprising the step of thawing the composition, thereby obtaining a ready-to-use pharmaceutical composition.
[0046] Any embodiment described herein in the first, second, third or fourth aspect (in particular of the first aspect as in any of the embodiments (1) to (45) listed above) It is understood that the embodiments of any of the first, second, third or fourth subgroups above may also be applied to any of the embodiments of the fifth aspect.
[0047] In a sixth aspect, the invention provides a method for preparing a ready-to-use pharmaceutical composition, comprising providing a lyophilized pharmaceutical composition prepared by the method of the second aspect and reconstituting the frozen pharmaceutical composition. and thereby obtaining a ready-to-use pharmaceutical composition.
[0048] Any of the embodiments described herein in the first, second, third, fourth or fifth aspect (in particular the first as in any of the embodiments (1) to (45) listed above) It is understood that the embodiments of any of the above first, second, third or fourth sub-groups of the aspect) may be applied to any of the embodiments of the sixth aspect.
[0049] In a seventh aspect, the invention provides a ready-to-use pharmaceutical composition that can be prepared by the method of the fifth or sixth aspect.
[0050] The first, second, third, fourth, fifth or sixth aspect (in particular, the first aspect of the first aspect as in any of the embodiments (1) to (45) listed above, It is understood that any of the embodiments of the second, third or fourth subgroup) may also apply to any of the embodiments of the seventh aspect.
[0051] In an eighth aspect, the invention provides a pharmaceutical composition comprising LNPs, wherein the LNPs comprise a cationically ionizable lipid and an mRNA, wherein one or more of the following applies: (i) the pharmaceutical composition comprises NaCl and KCl in a combined amount of less than 0.20% by weight based on the total amount of lipids and mRNA in the pharmaceutical composition; (ii) when in aqueous liquid form, the pH of the pharmaceutical composition is the pK of the cationically ionizable lipid; a lower; (iii) the pharmaceutical composition is substantially free of citrate anions; (iv) the pharmaceutical composition is substantially free of inorganic phosphate anions; Here, the pharmaceutical composition is in frozen or lyophilized form.
[0052] In certain embodiments of the eighth aspect, the pharmaceutical composition is less than 10% by weight, preferably less than 9% by weight, preferably less than 8% by weight, preferably less than 8% by weight, based on the total weight of lipids and mRNA in the pharmaceutical composition. Less than 7% by weight, preferably less than 6% by weight, preferably less than 5% by weight, preferably less than 4% by weight, preferably less than 3% by weight, preferably less than 2% by weight, preferably less than 1% by weight, preferably 0.9 less than 0.8% by weight, preferably less than 0.7% by weight, preferably less than 0.6% by weight, preferably less than 0.5% by weight, preferably less than 0.4% by weight, preferably less than 0.3% by weight, preferably less than 0.2% by weight %, preferably less than 0.1% by weight.
[0053] In the first subgroup of the eighth aspect, at least one of criteria (i) to (iv) is applied. For example, in certain embodiments of this first subgroup, at least the pharmaceutical composition comprises NaCl and KCl in a combined amount of less than 10% by weight, based on the total amount of lipids and mRNA in the pharmaceutical composition. In a further embodiment of this first subgroup, at least when in aqueous liquid form, the pH of the pharmaceutical composition is determined by the pK of the cationically ionizable lipid. a lower. In a further embodiment of this first subgroup, at least the pharmaceutical composition is substantially free of citrate anions. In a further embodiment of this first subgroup, at least the pharmaceutical composition is substantially free of inorganic phosphate anions.
[0054] In the second subgroup of the eighth aspect, at least two of criteria (i) to (iv) are applied. For example, in certain embodiments of this second subgroup, at least the pharmaceutical composition comprises NaCl and KCl in a combined amount of less than 10% by weight, based on the total amount of lipids and mRNA in the pharmaceutical composition, and When in liquid form, the pH of the pharmaceutical composition is the pK of the cationically ionizable lipid. a lower. In a further embodiment of this second subgroup, at least the pharmaceutical composition comprises NaCl and KCl in a combined amount of less than 10% by weight, based on the total amount of lipid and mRNA in the pharmaceutical composition and citrate anion. Substantially not included. In a further embodiment of this second subgroup, the pharmaceutical composition comprises NaCl and KCl in a combined amount of less than 10% by weight and an inorganic phosphate anion, based on the total amount of lipid and mRNA in the pharmaceutical composition. Substantially not included. In a further embodiment of this second subgroup, at least when in aqueous liquid form, the pH of the pharmaceutical composition is determined by the pK of the cationically ionizable lipid. a lower and the pharmaceutical composition is substantially free of citrate anions. In a further embodiment of this second subgroup, at least when in aqueous liquid form, the pH of the pharmaceutical composition is determined by the pK of the cationically ionizable lipid. a lower and the pharmaceutical composition is substantially free of inorganic phosphate anions. In further embodiments of this second subgroup, at least the pharmaceutical composition is substantially free of citrate anions and substantially free of inorganic phosphate anions.
[0055] In the third subgroup of the eighth embodiment, at least three of criteria (i) to (iv) apply. For example, in certain embodiments of this third subgroup, at least the pharmaceutical composition comprises NaCl and KCl in a combined amount of less than 10% by weight, based on the total amount of lipids and mRNA in the pharmaceutical composition, and comprises an aqueous liquid. form, the pH of the pharmaceutical composition is the pK of the cationically ionizable lipid. a lower and the pharmaceutical composition is substantially free of citrate anions. In a further embodiment of the third subgroup, at least the pharmaceutical composition comprises NaCl and KCl in a combined amount of less than 10% by weight, based on the total amount of lipids and mRNA in the pharmaceutical composition, and is in aqueous liquid form. When the pH of the pharmaceutical composition is the pK of the cationically ionizable lipid a lower and the pharmaceutical composition is substantially free of inorganic phosphate anions. In a further embodiment of the third subgroup, at least the pharmaceutical composition comprises NaCl and KCl in a combined amount of less than 10% by weight, based on the total amount of lipids and mRNA in the pharmaceutical composition, and the pharmaceutical composition comprises citric acid. Substantially free of acid anions and substantially free of inorganic phosphate anions. In a further embodiment of the third subgroup, at least when in aqueous liquid form, the pH of the pharmaceutical composition is equal to or greater than the pK of the cationically ionizable lipid. a and the pharmaceutical composition is substantially free of citrate anions and substantially free of inorganic phosphate anions.
[0056] In the fourth subgroup of the eighth aspect, at least all of criteria (i) to (iv) apply. That is, in this fourth subgroup, at least when the pharmaceutical composition comprises NaCl and KCl in a combined amount of less than 10% by weight, based on the total amount of lipids and mRNA in the pharmaceutical composition, and is in aqueous liquid form. , the pH of the pharmaceutical composition is the pK of the cationically ionizable lipid. a and the pharmaceutical composition is substantially free of citrate anions and substantially free of inorganic phosphate anions.
[0057] In certain embodiments of the eighth aspect (particularly in certain embodiments of the first, second, third or fourth subgroups above of the eighth aspect), the pharmaceutical composition comprises a buffer system and / or a cryoprotectant. including. For example, in certain embodiments (particularly in certain embodiments of the first, second, third or fourth subgroups above of the eighth aspect), the pharmaceutical composition comprises a buffer system. In a further embodiment (particularly in a further embodiment of the first, second, third or fourth subgroup above of the eighth aspect), the pharmaceutical composition comprises a cryoprotectant. In a further embodiment (particularly in a further embodiment of the first, second, third or fourth subgroup above of the eighth aspect), the pharmaceutical composition comprises a buffer system and a cryoprotectant. Specific examples of these implementations are thus: (1) the pharmaceutical composition comprises NaCl and KCl in a combined amount of less than 10% by weight based on the total amount of lipid and mRNA in the pharmaceutical composition and comprises a buffer system; (2) the pharmaceutical composition comprises NaCl and KCl in a combined amount of less than 10% by weight based on the total amount of lipids and mRNA in the pharmaceutical composition and comprises a cryoprotectant; (3) the pharmaceutical composition comprises NaCl and KCl in a combined amount of less than 10% by weight, based on the total amount of lipids and mRNA in the pharmaceutical composition, and comprises a buffer system and a cryoprotectant; (4) When in aqueous liquid form, the pH of the pharmaceutical composition is the pK of the cationically ionizable lipid. a and the pharmaceutical composition comprises a buffer system; (5) When in aqueous liquid form, the pH of the pharmaceutical composition is the pK of the cationically ionizable lipid. a lower and the pharmaceutical composition comprises a cryoprotectant; (6) When in aqueous liquid form, the pH of the pharmaceutical composition is the pK of the cationically ionizable lipid. a lower and the pharmaceutical composition includes a buffer system and a cryoprotectant; (7) the pharmaceutical composition is substantially free of citrate anions and includes a buffer system; (8) the pharmaceutical composition is substantially free of citrate anions and includes a cryoprotectant; (9) the pharmaceutical composition is substantially free of citrate anions and includes a buffer system and a cryoprotectant; (10) the pharmaceutical composition is substantially free of inorganic phosphate anions and includes a buffer system; (11) the pharmaceutical composition is substantially free of inorganic phosphate anions and includes a cryoprotectant; (12) the pharmaceutical composition is substantially free of inorganic phosphate anions and includes a buffer system and a cryoprotectant; (13) The pharmaceutical composition comprises NaCl and KCl in a combined amount of less than 10% by weight based on the total amount of lipids and mRNA in the pharmaceutical composition and comprises a buffer system and is in an aqueous liquid form. The pH of a substance is the pK of cationically ionizable lipids. a lower; (14) when the pharmaceutical composition comprises NaCl and KCl in a combined amount of less than 10% by weight based on the total amount of lipid and mRNA in the pharmaceutical composition and comprises a cryoprotectant system and is in aqueous liquid form; The pH of a pharmaceutical composition is determined by the pK of the cationically ionizable lipid. a lower; (15) The pharmaceutical composition comprises NaCl and KCl in a combined amount of less than 10% by weight, based on the total amount of lipids and mRNA in the pharmaceutical composition, and comprises a buffer system and a cryoprotectant, and is in aqueous liquid form. When the pH of the pharmaceutical composition is the pK of the cationically ionizable lipid a lower; (16) The pharmaceutical composition comprises NaCl and KCl in a combined amount of less than 10% by weight, based on the total amount of lipids and mRNA in the pharmaceutical composition, comprises a buffer system, and is substantially free of citrate anions. ; (17) The pharmaceutical composition comprises NaCl and KCl in a combined amount of less than 10% by weight based on the total amount of lipid and mRNA in the pharmaceutical composition, comprises a cryoprotectant, and substantially comprises a citrate anion. do not have; (18) The pharmaceutical composition contains NaCl and KCl in a combined amount of less than 10% by weight, based on the total amount of lipids and mRNA in the pharmaceutical composition, contains a buffer system and a cryoprotectant, and contains substantially no citrate anion. does not include; (19) The pharmaceutical composition comprises NaCl and KCl in a combined amount of less than 10% by weight based on the total amount of lipid and mRNA in the pharmaceutical composition and comprises a buffer system and substantially comprises an inorganic phosphate anion. do not have; (20) The pharmaceutical composition comprises NaCl and KCl in a combined amount of less than 10% by weight based on the total amount of lipid and mRNA in the pharmaceutical composition and comprises a cryoprotectant and substantially contains an inorganic phosphate anion. Not included; (21) The pharmaceutical composition comprises NaCl and KCl in a combined amount of less than 10% by weight based on the total amount of lipids and mRNA in the pharmaceutical composition and comprises a buffer system and a cryoprotectant and an inorganic phosphate anion. Contains substantially no; (22) When in aqueous liquid form, the pH of the pharmaceutical composition is the pK of the cationically ionizable lipid. a and the pharmaceutical composition is substantially free of citrate anions and includes a buffer system; (23) When in aqueous liquid form, the pH of the pharmaceutical composition is the pK of the cationically ionizable lipid. a and the pharmaceutical composition is substantially free of citrate anions and includes a cryoprotectant; (24) When in aqueous liquid form, the pH of the pharmaceutical composition is the pK of the cationically ionizable lipid. a and the pharmaceutical composition is substantially free of citrate anions and includes a buffer system and a cryoprotectant; (25) When in aqueous liquid form, the pH of the pharmaceutical composition is the pK of the cationically ionizable lipid. a and the pharmaceutical composition is substantially free of inorganic phosphate anions and includes a buffer system; (26) When in aqueous liquid form, the pH of the pharmaceutical composition is the pK of the cationically ionizable lipid. a and the pharmaceutical composition is substantially free of inorganic phosphate anions and includes a cryoprotectant; (27) When in aqueous liquid form, the pH of the pharmaceutical composition is the pK of the cationically ionizable lipid. a and the pharmaceutical composition is substantially free of inorganic phosphate anions and includes a buffer system and a cryoprotectant; (28) the pharmaceutical composition is substantially free of citrate anions and substantially free of inorganic phosphate anions and includes a buffer system; (29) the pharmaceutical composition is substantially free of citrate anions and substantially free of inorganic phosphate anions and includes a cryoprotectant; (30) the pharmaceutical composition is substantially free of citrate anions and substantially free of inorganic phosphate anions and includes a buffer system and a cryoprotectant; (31) The pharmaceutical composition comprises NaCl and KCl in a combined amount of less than 10% by weight based on the total amount of lipids and mRNA in the pharmaceutical composition and comprises a buffer system and is in an aqueous liquid form. The pH of a substance is the pK of cationically ionizable lipids. a and the pharmaceutical composition is substantially free of citrate anions; (32) The pharmaceutical composition comprises NaCl and KCl in a combined amount of less than 10% by weight based on the total amount of lipids and mRNA in the pharmaceutical composition and comprises a cryoprotectant and is in an aqueous liquid form. The pH of the composition is the pK of the cationically ionizable lipid. a and the pharmaceutical composition is substantially free of citrate anions; (33) The pharmaceutical composition comprises NaCl and KCl in a combined amount of less than 10% by weight, based on the total amount of lipid and mRNA in the pharmaceutical composition, and comprises a buffer system and a cryoprotectant, and is in an aqueous liquid form. When the pH of the pharmaceutical composition is the pK of the cationically ionizable lipid a and the pharmaceutical composition is substantially free of citrate anions; (34) The pharmaceutical composition comprises NaCl and KCl in a combined amount of less than 10% by weight based on the total amount of lipids and mRNA in the pharmaceutical composition and comprises a buffer system and is in aqueous liquid form. The pH of a substance is the pK of cationically ionizable lipids. a and the pharmaceutical composition is substantially free of inorganic phosphate anions; (35) The pharmaceutical composition comprises NaCl and KCl in a combined amount of less than 10% by weight based on the total amount of lipids and mRNA in the pharmaceutical composition and comprises a cryoprotectant and is in an aqueous liquid form. The pH of the composition is the pK of the cationically ionizable lipid. a and the pharmaceutical composition is substantially free of inorganic phosphate anions; (36) The pharmaceutical composition comprises NaCl and KCl in a combined amount of less than 10% by weight, based on the total amount of lipids and mRNA in the pharmaceutical composition, and comprises a buffer system and a cryoprotectant, and is in aqueous liquid form. When the pH of the pharmaceutical composition is the pK of the cationically ionizable lipid a and the pharmaceutical composition is substantially free of inorganic phosphate anions; (37) The pharmaceutical composition comprises NaCl and KCl in a combined amount of less than 10% by weight, based on the total amount of lipids and mRNA in the pharmaceutical composition, comprises a buffer system, and is substantially free of citrate anions. and substantially free of inorganic phosphate anions; (38) The pharmaceutical composition comprises NaCl and KCl in a combined amount of less than 10% by weight based on the total amount of lipid and mRNA in the pharmaceutical composition, comprises a cryoprotectant, and substantially comprises a citrate anion. Substantially free of inorganic phosphate anions; (39) The pharmaceutical composition contains NaCl and KCl in a combined amount of less than 10% by weight, based on the total amount of lipids and mRNA in the pharmaceutical composition, contains a buffer system and a cryoprotectant, and contains substantially no citrate anion. substantially free of inorganic phosphate anions; (40) When in aqueous liquid form, the pH of the pharmaceutical composition is the pK of the cationically ionizable lipid. a lower, the pharmaceutical composition is substantially free of citrate anions and substantially free of inorganic phosphate anions and the pharmaceutical composition includes a buffer system; (41) When in aqueous liquid form, the pH of the pharmaceutical composition is the pK of the cationically ionizable lipid. a lower, the pharmaceutical composition is substantially free of citrate anions and substantially free of inorganic phosphate anions and the pharmaceutical composition includes a cryoprotectant; (42) When in aqueous liquid form, the pH of the pharmaceutical composition is the pK of the cationically ionizable lipid. a lower, the pharmaceutical composition is substantially free of citrate anions and substantially free of inorganic phosphate anions, and the pharmaceutical composition includes a buffer system and a cryoprotectant; (43) The pharmaceutical composition comprises NaCl and KCl in a combined amount of less than 10% by weight based on the total amount of lipids and mRNA in the pharmaceutical composition and comprises a buffer system and is in aqueous liquid form. The pH of a substance is the pK of cationically ionizable lipids. a and the pharmaceutical composition is substantially free of citrate anions and substantially free of inorganic phosphate anions; (44) The pharmaceutical composition comprises NaCl and KCl in a combined amount of less than 10% by weight based on the total amount of lipids and mRNA in the pharmaceutical composition and comprises a cryoprotectant and is in an aqueous liquid form. The pH of the composition is the pK of the cationically ionizable lipid. a and the pharmaceutical composition is substantially free of citrate anions and substantially free of inorganic phosphate anions; (45) The pharmaceutical composition comprises NaCl and KCl in a combined amount of less than 10% by weight, based on the total amount of lipid and mRNA in the pharmaceutical composition, and comprises a buffer system and a cryoprotectant, and is in an aqueous liquid form. When the pH of the pharmaceutical composition is the pK of the cationically ionizable lipid a and the pharmaceutical composition is substantially free of citrate anions and substantially free of inorganic phosphate anions.
[0058] In certain embodiments of the eighth aspect (in particular as in any of the embodiments (1) to (45) listed above for the eighth aspect) In certain embodiments of the fourth subgroup), when in aqueous liquid form, the pH of the pharmaceutical composition is at most 6.5, preferably at most 6.4, at most 6.3, at most 6.2, at most 6.1 or at most 6.0. In certain embodiments of the eighth aspect (in particular as in any of the embodiments (1) to (45) listed above for the eighth aspect) In certain embodiments of the fourth subgroup), the pH of the formulation is in the range 5.5-6.5, such as 5.6-6.4, 5.7-6.6, 5.8-6.2 or 5.9-6.1. In certain embodiments of the eighth aspect (in particular as in any of the embodiments (1) to (45) listed above for the eighth aspect) In certain embodiments of the fourth subgroup), the pH of the formulation is about 6.0.
[0059] In certain embodiments of the eighth aspect, wherein the pharmaceutical composition comprises a buffer system (in particular as in any of the embodiments (1) to (45) listed above for the eighth aspect) In certain embodiments of the first, second, third or fourth subgroup), the buffer system comprises water (especially deionized water, such as water for injection) and a buffering substance. In certain embodiments, the buffer system includes any one of HEPES, histidine, Tris, and acetic acid as a buffering substance, such as any one of HEPES, histidine, and Tris as a buffering substance. In certain preferred embodiments, the buffer system includes HEPES as the buffering substance. In certain embodiments of the eighth aspect (in particular as in any of the embodiments (1) to (45) listed above for the eighth aspect) In certain embodiments of the fourth subgroup), the formulation comprises water (especially deionized water, such as water for injection) and a buffer system comprising HEPES as a buffering substance.
[0060] In certain embodiments of the eighth aspect, wherein the pharmaceutical composition comprises a buffer system (in particular as in any of the embodiments (1) to (45) listed above for the eighth aspect) In certain embodiments of the first, second, third or fourth subgroup), the amount of buffering substance in the pharmaceutical composition is up to 4 mmol per g of total weight of lipid and mRNA in the pharmaceutical composition; Preferably up to 3.6 mmol, more preferably up to 3.2 mmol, more preferably up to 2.8 mmol, more preferably up to 2.4 mmol, more preferably up to 2.0 mmol, more preferably up to 1.8 mmol. In certain embodiments of the eighth aspect (in particular as in any of the embodiments (1) to (45) listed above for the eighth aspect) In certain embodiments of the fourth subgroup), the amount of buffering substance in the pharmaceutical composition is from 0.4 mmol to 4 mmol, such as from 0.4 mmol to 3.2 mmol, per g of total weight of lipid and mRNA in the pharmaceutical composition. , 0.8mmol~2.8mmol, 0.8mmol~2.4mmol, 1.2mmol~2.0mmol or 1.4mmol~1.6mmol.
[0061] In certain embodiments of the eighth aspect, in particular as in any of embodiments (1) to (45) listed above for the eighth aspect, the pharmaceutical composition comprises a cryoprotectant. In some embodiments of the first, second, third or fourth subgroup above), the cryoprotectant comprises one or more carbohydrates. For example, it may contain any of the cryoprotectants sucrose, trehalose, glucose or combinations thereof. In certain preferred embodiments of the eighth aspect (in particular, in any of the above-mentioned first, second or second embodiments of the eighth aspect, such as in any of the embodiments (1) to (45) listed above for the eighth aspect) In certain embodiments of the third or fourth subgroup), the pharmaceutical composition comprises sucrose and / or trehalose as a cryoprotectant.
[0062] In certain embodiments of the eighth aspect, particularly as in any of embodiments (1) to (45) listed above for the eighth aspect, the pharmaceutical composition comprises a cryoprotectant. In some embodiments of the first, second, third or fourth subgroup above), the concentration of the cryoprotectant in the pharmaceutical composition is at least 80% by weight, such as at least 81%, at least 82%, at least 83% by weight. % by weight, at least 84% by weight, at least 85% by weight or at least 86% by weight (preferably (i) the total amount of the pharmaceutical composition free of any solvent contained in the pharmaceutical composition if the pharmaceutical composition is in frozen form) or (ii) based on the total amount of the pharmaceutical composition if the pharmaceutical composition is in lyophilized form). In certain embodiments, the concentration of cryoprotectant in the pharmaceutical composition is up to 95% by weight, such as up to 94%, up to 93%, up to 92%, up to 91%, or up to 90%, or up to 89% by weight. (preferably (i) the total amount of the pharmaceutical composition free of any solvents contained in the pharmaceutical composition if the pharmaceutical composition is in frozen form or (ii) the pharmaceutical composition if the pharmaceutical composition is in lyophilized form) (based on the total amount of things). In certain embodiments, the concentration of cryoprotectant in the pharmaceutical composition is between 80% and 95% by weight, such as between 81% and 94%, 82% and 93%, 83% and 92%, 84% by weight. %~91wt%, 84wt%~91wt%, 85wt%~91wt%, 86wt%~91wt%, 87wt%~91wt%, 88wt%~89wt% or about 89wt% (preferably (i) the total amount of the pharmaceutical composition free of any solvents contained in the pharmaceutical composition if the pharmaceutical composition is in frozen form or (ii) the pharmaceutical composition if the pharmaceutical composition is in lyophilized form) (based on the total amount of things). In certain preferred embodiments of the eighth aspect (especially as in any of the embodiments (1) to (45) listed above for the eighth aspect) or in some embodiments of the fourth subgroup), the pharmaceutical composition is 85% to 95% by weight, such as 85% to 94% by weight, 86% to 93% by weight, 87% to 92% by weight. or a cryoprotectant (especially sucrose and / or trehalose) in a concentration of 88% to 91% by weight (preferably (i) free of any solvent contained in the pharmaceutical composition if the pharmaceutical composition is in frozen form) (ii) based on the total amount of the pharmaceutical composition if the pharmaceutical composition is in lyophilized form).
[0063] In certain preferred embodiments of the eighth aspect, the pharmaceutical composition comprises a buffer system and a cryoprotectant (in particular a pharmaceutical composition as in any of embodiments (1) to (45) listed above for the eighth aspect). In certain preferred embodiments of the first, second, third or fourth subgroup above of embodiment 8), the buffer system comprises HEPES as buffering substance and the cryoprotectant is preferably as defined above. Contains sucrose and / or trehalose in amounts / concentrations.
[0064] In certain embodiments of the eighth aspect (in particular as in any of the embodiments (1) to (45) listed above for the eighth aspect) In certain embodiments of the fourth subgroup), the pharmaceutical composition further comprises a poloxamer.
[0065] In another embodiment of the eighth aspect, in particular the pharmaceutical composition comprises HEPES as a buffering substance (as in any of the embodiments (1) to (45) listed above for the eighth aspect). In certain embodiments of the first, second, third or fourth subgroup of the eighth aspect), the pharmaceutical composition does not contain a poloxamer.
[0066] In certain embodiments of the eighth aspect (in particular as in any of the embodiments (1) to (45) listed above for the eighth aspect) In certain embodiments of the fourth subgroup), the cationically ionizable lipid comprises a head group containing at least one nitrogen atom that can be protonated under physiological conditions. For example, a cationically ionizable lipid has the formula (I): [ka] or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer structure thereof, where L 1 ,L 2 ,G 1 ,G 2 ,G 3 ,R 1 ,R 2 and R 3 is as defined herein. Preferably, the cationically ionizable lipid is selected from: structures I-1 to I-36 (as shown here); and / or structures A to F (as shown here); and / or N ,N-dimethyl-2,3-dioleyloxypropylamine (DODMA), 1,2-dioleoyl-3-dimethylammonium-propane (DODAP), heptatriaconta-6,9,28,31-tetraene-19- yl-4-(dimethylamino)butanoate (DLin-MC3-DMA) and 4-((di((9Z,12Z)-octadeca-9,12-dien-1-yl)amino)oxy)-N,N- Dimethyl-4-oxobutan-1-amine (DPL-14).
[0067] In certain embodiments of the eighth aspect (in particular as in any of the embodiments (1) to (45) listed above for the eighth aspect) In certain embodiments of the fourth subgroup), the LNP further comprises one or more additional lipids. Preferably, the one or more additional lipids are selected from the group consisting of polymer conjugated lipids, neutral lipids, steroids and combinations thereof. In a preferred embodiment of the eighth aspect (in particular as in any of the embodiments (1) to (45) listed above for the eighth aspect) In some embodiments of the fourth subgroup), the LNPs are cationically ionizable lipids, polymer conjugated lipids (e.g., pegylated lipids or polysarcosine-lipid conjugates or polysarcosine and lipid-like substances) as described herein. conjugates), neutral lipids (eg, DSPC), and steroids (eg, cholesterol).
[0068] In certain embodiments of the eighth aspect (particularly of embodiments (1)-(45) listed above for the eighth aspect), the LNP further comprises a polymer-conjugated lipid as one or more additional lipids. In certain embodiments of the above first, second, third or fourth subgroup of the eighth aspect, as in any), the polymer conjugate lipid is a pegylated lipid. For example, a pegylated lipid has the following structure: [ka] or a pharmaceutically acceptable salt, tautomer or stereoisomer structure thereof, where R 12 ,R 13 and w are as defined herein.
[0069] In certain embodiments of the eighth aspect (particularly of embodiments (1)-(45) listed above for the eighth aspect), the LNP further comprises a polymer-conjugated lipid as one or more additional lipids. In some embodiments of the above first, second, third or fourth subgroup of the eighth aspect, as in any), the polymer conjugated lipid is a polysarcosine-lipid conjugate or a polysarcosine and a lipid-like substance. It is a conjugate of For example, polysarcosine-lipid conjugates or polysarcosine and lipid-like substance conjugates include polysarcosine-diacylglycerol conjugates, polysarcosine-dialkyloxypropyl conjugates, polysarcosine-phospholipid conjugates, polysarcosine-ceramide conjugates. and mixtures thereof.
[0070] In certain embodiments of the eighth aspect (in particular any of embodiments (1) to (45) listed above for the eighth aspect), wherein the LNP further comprises a neutral lipid as one of the one or more additional lipids. In certain embodiments of the first, second, third or fourth subgroup of the eighth aspect, such as in), the neutral lipid is a phospholipid. Such phospholipids are preferably selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidic acid, phosphatidylserine and sphingomyelin. Specific examples of phospholipids are distearoyl phosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dimyristoyl phosphatidylcholine (DMPC), dipentadecanoylphosphatidylcholine, dilauroyl phosphatidylcholine, dipalmitoylphosphatidylcholine (DPPC), dialachidoyl phosphatidylcholine (DAPC), dibehenoyl phosphatidylcholine (DBPC), ditricosanoyl phosphatidylcholine (DTPC), dilignocyloyl phosphatidylcholine (DLPC), palmitoyloleoyl-phosphatidylcholine (POPC), 1,2-di-O-octadecenyl- sn-glycero-3-phosphocholine (18:0 Diether PC), 1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine ( C16 Lyso PC), dioleoylphosphatidylethanolamine (DOPE), distearoyl-phosphatidylethanolamine (DSPE), dipalmitoyl-phosphatidylethanolamine (DPPE), dimyristoyl-phosphatidylethanolamine (DMPE), dilauroyl-phosphatidylethanolamine (DLPE) and diphytanoyl-phosphatidylethanolamine (DPyPE).
[0071] In certain embodiments of the eighth aspect, particularly in any of embodiments (1) to (45) listed above for the eighth aspect, the LNP further comprises a steroid as one or more additional lipids. In certain embodiments of the first, second, third or fourth subgroup of the eighth aspect), the steroid is a sterol, such as cholesterol.
[0072] In certain embodiments of the eighth aspect (in particular as in any of the embodiments (1) to (45) listed above for the eighth aspect) In certain embodiments of the fourth subgroup), the pharmaceutical composition further comprises a chelating agent such as EDTA. In certain embodiments of the eighth aspect, wherein the pharmaceutical composition comprises a chelating agent, particularly as in any of embodiments (1) to (45) listed above for the eighth aspect. In certain embodiments of the first, second, third or fourth subgroup), the amount of chelating agent in the pharmaceutical composition is up to 0.8 mmol per g of total weight of lipid and mRNA in the pharmaceutical composition; Preferably up to 0.6 mmol, more preferably up to 0.4 mmol, more preferably up to 0.2 mmol
[0073] In another embodiment of the eighth aspect (in particular as in any of the embodiments (1) to (45) listed above for the eighth aspect) or in another embodiment of the fourth subgroup), the pharmaceutical composition is free of chelating agents.
[0074] In certain embodiments of the eighth aspect (in particular as in any of the embodiments (1) to (45) listed above for the eighth aspect) In certain embodiments of the fourth subgroup), the ratio of cationically ionizable lipid to mRNA is 2:1 to 12:1, such as 2:1 to 10:1 or 4:1 and 8:1. .
[0075] In certain embodiments of the eighth aspect (in particular as in any of the embodiments (1) to (45) listed above for the eighth aspect) In certain embodiments of the fourth subgroup), the mRNA is encapsulated or associated with the LNP.
[0076] In certain embodiments of the eighth aspect (in particular as in any of the embodiments (1) to (45) listed above for the eighth aspect) In certain embodiments of the fourth subgroup), the mRNA comprises a modified nucleoside in place of uridine. For example, the modified nucleoside may be selected from pseudouridine (ψ), N1-methyl-pseudouridine (m1ψ) and 5-methyl-uridine (m5U).
[0077] In certain embodiments of the eighth aspect (in particular as in any of the embodiments (1) to (45) listed above for the eighth aspect) (in certain embodiments of the fourth subgroup), the mRNA comprises a polynucleotide comprising (a) a 5' cap; (b) a 5' UTR; (c) a 3' UTR; and (d) at least 100 nucleotides. It may include one or more polyA sequences, such as the A sequence.
[0078] In certain preferred embodiments of the eighth aspect (especially as in any of the embodiments (1) to (45) listed above for the eighth aspect) or in certain preferred embodiments of the fourth subgroup), the mRNA encodes one or more polypeptides. For example, one or more polypeptides can include an epitope for inducing an immune response against an antigen in a subject. In a preferred embodiment, the mRNA encodes an amino acid sequence comprising the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof.
[0079] In certain embodiments of the eighth aspect (in particular as in any of the embodiments (1) to (45) listed above for the eighth aspect) In some embodiments of the fourth subgroup), the formulation is administered at a temperature in the range of about -30°C to about -10°C, such as about -25°C to about -15°C, or about -25°C to about -20°C, or about Freeze to a temperature of -20℃.
[0080] In certain embodiments of the eighth aspect (in particular as in any of the embodiments (1) to (45) listed above for the eighth aspect) In certain embodiments of the fourth subgroup), the pharmaceutical composition may be stored at a temperature of about -30°C or higher, such as about -25°C or higher. For example, the frozen pharmaceutical composition of the eighth aspect may be prepared at a temperature in the range of about -30°C to about -10°C, such as about -25°C to about -15°C or about -25°C to about -20°C or about -20°C. It can be stored at temperatures of °C. The lyophilized pharmaceutical composition of the eighth aspect can be used at temperatures ranging from about -25°C to about room temperature, such as from about -15°C to about 8°C, from about -10°C to about 2°C, or from about -5°C to about 0°C. Can be stored at temperature.
[0081] In certain embodiments of the eighth aspect (in particular as in any of the embodiments (1) to (45) listed above for the eighth aspect) In certain embodiments of the fourth subgroup), the pharmaceutical composition is administered for at least 3 months, preferably at least 6 months, more preferably at least 12 months, more preferably at least 18 months, more preferably at least 24 months, more preferably can be stored for at least 30 months, more preferably at least 36 months.
[0082] In certain embodiments of the eighth aspect (in particular as in any of the embodiments (1) to (45) listed above for the eighth aspect) In certain embodiments of the fourth subgroup), the size of the LNPs (Z 平均 ) is about 50 nm to about 500 nm.
[0083] In certain embodiments of the eighth aspect (in particular as in any of the embodiments (1) to (45) listed above for the eighth aspect) In certain embodiments of the fourth subgroup), the size of the LNPs after thawing the frozen pharmaceutical composition (Z 平均 ) and / or size distribution and / or PDI are the size of LNPs before freezing (Z 平均) and / or size distribution and / or size of LNPs equal to PDI or after reconstitution of the lyophilized pharmaceutical composition (Z 平均 ) and / or size distribution and / or PDI is the size of LNPs before lyophilization (Z 平均 ) and / or size distribution and / or equal to PDI. In certain embodiments of the eighth aspect (in particular as in any of the embodiments (1) to (45) listed above for the eighth aspect) In certain embodiments of the fourth subgroup), the PDI of the LNPs after thawing the frozen pharmaceutical composition or reconstituting the lyophilized pharmaceutical composition is less than 0.3, preferably less than 0.2, more preferably less than 0.1, such as less than 0.05. .
[0084] In certain embodiments of the eighth aspect (in particular as in any of the embodiments (1) to (45) listed above for the eighth aspect) In certain embodiments of the fourth subgroup), the size of the LNPs (Z 平均 ) is about 50 nm to about 500 nm, and (i) the size of LNP after thawing the frozen pharmaceutical composition (Z 平均 ) and / or size distribution and / or PDI are the size of LNPs before freezing (Z 平均 ) and / or equal to the size distribution and / or PDI or (ii) the size of the LNPs after lyophilized pharmaceutical composition reconstitution (Z 平均 ) and / or size distribution and / or PDI is the size of LNPs before lyophilization (Z 平均 ) and / or size distribution and / or equal to PDI. In certain embodiments of the eighth aspect (in particular as in any of the embodiments (1) to (45) listed above for the eighth aspect) In certain embodiments of the fourth subgroup), the size of the LNPs (Z 平均 ) is from about 50 nm to about 500 nm, and the PDI of LNPs after thawing the frozen pharmaceutical composition or reconstituted from the lyophilized pharmaceutical composition is less than 0.3 (preferably less than 0.2, more preferably less than 0.1, eg less than 0.05).
[0085] In certain embodiments of the eighth aspect, particularly as in any of embodiments (1) to (45) listed above for the eighth aspect, the pharmaceutical composition is in lyophilized form. In certain embodiments of the first, second, third or fourth subgroup above), the pharmaceutical composition is substantially free of water. For example, the pharmaceutical composition may contain less than 1.0% water, such as less than 0.8%, less than 0.7%, less than 0.6%, less than 0.5%, less than 0.4%, 0.3% by weight, based on the total weight of the pharmaceutical composition. It may contain less than 0.2%, or less than 0.1% water by weight.
[0086] Any embodiment described herein in the first, second, third, fourth, fifth, sixth or seventh aspect may also be applied to any of the embodiments in the eighth aspect. is understood.
[0087] In a ninth aspect, the invention provides a pharmaceutical composition according to any of the third, fourth, seventh and eighth aspects for use in therapy.
[0088] Any embodiment described herein under the first, second, third, fourth, fifth, sixth, seventh or eighth aspect also applies to any of the embodiments of the ninth aspect. It is understood that it can be done.
[0089] In a tenth aspect, the invention provides a pharmaceutical composition according to any of the third, fourth, seventh and eighth aspects for use in inducing an immune response.
[0090] Any embodiment described herein under the first, second, third, fourth, fifth, sixth, seventh, eighth or ninth aspect may be any embodiment of the tenth aspect. It is understood that it can also be applied to
[0091] The method claimed in the present invention allows stabilization of LNP compositions comprising mRNA and cationically ionizable lipids, where product activity and quality are maintained. In particular, product characteristics such as product particle size, ingredient integrity, activity and safety must be maintained for a shelf life of at least 12 months, preferably 24 months, and even better 36 months.
[0092] Further itemized embodiments are as follows: 1. A method of manufacturing a pharmaceutical composition, comprising: (I) preparing a formulation comprising lipid nanoparticles (LNPs), wherein the LNPs comprise a cationically ionizable lipid and mRNA, and one or more of the following are applied: (i) step (I) does not include the addition of NaCl and / or KCl; (ii) The pH of the formulation is the pK of the cationically ionizable lipid. a lower; (iii) the formulation is substantially free of citrate anions; (iv) the formulation is substantially free of inorganic phosphate anions; and (II) freezing the formulation to about -10°C or below, thereby obtaining the pharmaceutical composition in frozen form; including methods.
[0093] 2. The method of paragraph 1, further comprising the step (III) of lyophilizing the frozen formulation, thus obtaining the pharmaceutical composition in lyophilized form.
[0094] 3. The pH of the formulation is the pK of cationically ionizable lipids. a Lower, method of term 1 or 2.
[0095] 4. The method of item 1 or 2, wherein the formulation is substantially free of citrate anions.
[0096] 5. The method of item 1 or 2, wherein the preparation is substantially free of inorganic phosphate anions.
[0097] 6. The pH of the formulation is the pK of cationically ionizable lipids. a The method of item 1 or 2, wherein the concentration is lower and the formulation is substantially free of citrate anions.
[0098] 7. The pH of the formulation is the pK of cationically ionizable lipids. a The method of item 1 or 2, wherein the concentration is lower and the formulation is substantially free of inorganic phosphate anions.
[0099] 8. The method of item 1 or 2, wherein the preparation is substantially free of citrate anions and substantially free of inorganic phosphate anions.
[0100] 9. The pH of the formulation is the pK of cationically ionizable lipids. a 3. The method of item 1 or 2, wherein the formulation is substantially free of citrate anions and substantially free of inorganic phosphate anions.
[0101] 10. The method according to any of Items 1 to 9, wherein step (I) does not include the addition of NaCl.
[0102] 11. The method according to any of Items 1 to 9, wherein step (I) does not include the addition of KCl.
[0103] 12. The method of any of items 1 to 9, wherein step (I) does not include the addition of NaCl and KCl.
[0104] 13. The method of any of paragraphs 1 to 12, wherein the formulation comprises a buffer system and / or a cryoprotectant.
[0105] 14. The formulation contains a buffer system and the pH of the formulation is the pK of the cationically ionizable lipid. a Lower, any method from items 1 to 12.
[0106] 15. The formulation contains a cryoprotectant and the pH of the formulation is the pK of the cationically ionizable lipid. a Lower, any method from items 1 to 12.
[0107] 16. The pH of the formulation is the pK of cationically ionizable lipids. a 13. The method of any one of Items 1 to 12, wherein the formulation contains a buffer system and a cryoprotectant.
[0108] 17. The method according to any one of Items 1 to 12, wherein the formulation includes a buffer system and is substantially free of citrate anions.
[0109] 18. The method according to any one of Items 1 to 12, wherein the preparation contains a cryoprotectant and is substantially free of citrate anions.
[0110] 19. The method of any one of Items 1 to 12, wherein the formulation is substantially free of citrate anions and includes a buffer system and a cryoprotectant.
[0111] 20. The method according to any one of Items 1 to 12, wherein the preparation includes a buffer system and is substantially free of inorganic phosphate anions.
[0112] 21. The method according to any one of Items 1 to 12, wherein the preparation contains a cryoprotectant and is substantially free of inorganic phosphate anions.
[0113] 22. The method according to any one of Items 1 to 12, wherein the formulation is substantially free of inorganic phosphate anions and includes a buffer system and a cryoprotectant.
[0114] 23. The method according to any one of Items 1 to 12, wherein the formulation includes a buffer system and is substantially free of citrate anions and substantially free of inorganic phosphate anions.
[0115] 24. The method according to any one of Items 1 to 12, wherein the preparation contains a cryoprotectant, is substantially free of citrate anions, and is substantially free of inorganic phosphate anions.
[0116] 25. The method according to any one of Items 1 to 12, wherein the formulation is substantially free of citrate anions, substantially free of inorganic phosphate anions, and includes a buffer system and a cryoprotectant.
[0117] 26. If the formulation contains a buffer system and the pH of the formulation is the pK of the cationically ionizable lipid. a 13. The method according to any one of Items 1 to 12, wherein the formulation is substantially free of citrate anions and / or substantially free of inorganic phosphate anions.
[0118] 27. If the formulation contains a cryoprotectant and the pH of the formulation is the pK of the cationically ionizable lipid. a 13. The method according to any one of Items 1 to 12, wherein the formulation is substantially free of citrate anions and / or substantially free of inorganic phosphate anions.
[0119] 28. If the formulation contains a buffer system and a cryoprotectant and the pH of the formulation is equal to the pK of the cationically ionizable lipid. a 13. The method according to any one of Items 1 to 12, wherein the formulation is substantially free of citrate anions and / or substantially free of inorganic phosphate anions.
[0120] 29. A method according to any of paragraphs 1 to 28, wherein the pH of the formulation is at most 6.5, preferably at most 6.0.
[0121] 30. The method of any of paragraphs 13 to 29, wherein the buffer system includes water and a buffering substance.
[0122] 31. The method according to any of paragraphs 13 to 30, wherein the buffer system contains any one of HEPES, histidine, Tris, and acetic acid as a buffering substance.
[0123] 32. The method according to any one of Items 13 to 31, wherein the buffer system contains any one of HEPES, histidine, and Tris as a buffering substance.
[0124] 33. The method of any of paragraphs 13 to 32, wherein the buffer system contains HEPES as a buffering substance.
[0125] 34. The method of any of paragraphs 13 to 33, wherein the concentration of the buffer in the formulation is at most 50mM, preferably at most 40mM, more preferably at most 20mM.
[0126] 35. The method of any of paragraphs 13 to 34, wherein the cryoprotectant contains one or more carbohydrates.
[0127] 36. The method of any of paragraphs 13 to 35, wherein the cryoprotectant comprises sucrose, trehalose, glucose, or a combination thereof.
[0128] 37. The method according to any of Items 13 to 36, wherein the cryoprotectant contains sucrose and / or trehalose.
[0129] 38. The method of any of paragraphs 13 to 37, wherein the concentration of cryoprotectant in the formulation is at least 1% w / v.
[0130] 39. The method of any of paragraphs 13 to 38, wherein the buffer system comprises HEPES as a buffering substance and the cryoprotectant comprises sucrose and / or trehalose.
[0131] 40. The method of any of paragraphs 1 to 39, wherein the formulation further comprises a poloxamer.
[0132] 41. The method of paragraph 33 or 39, wherein the formulation does not contain a poloxamer.
[0133] 42. The method of any of paragraphs 1 to 41, wherein the cationically ionizable lipid comprises a head group containing at least one nitrogen atom that can be protonated under physiological conditions.
[0134] 43. Cationically ionizable lipids have formula (I): [ka] or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer structure thereof, where: L 1 or L 2 -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O) x -, -S-S-, -C(=O)S-, SC(=O)-, -NR a C(=O)-, -C(=O)NR a -,NR a C(=O)NR a -, -OC(=O)NR a -or-NR a C(=O)O-, and L 1 or L 2 The other is -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O) x -, -S-S-, -C(=O)S-, SC(=O)-, -NR a C(=O)-, -C(=O)NR a -,NR a C(=O)NR a -, -OC(=O)NR a -or-NR a C(=O)O- or a direct bond; G 1 and G 2 are each independently unsubstituted C 1 -C 12 alkylene or C 2 -C 12 is alkenylene; G 3 is C 1 -C 24 alkylene, C 2 -C 24 alkenylene, C 3 -C 8 Cycloalkylene, C 3 -C 8 Cycloalkenylene; R a is H or C 1 -C 12 is alkyl; R 1 and R 2 are each independently C 6 -C 24 alkyl or C 6 -C 24 is alkenyl; R 3 is H, OR 5 ,CN,-C(=O)OR 4 , -OC(=O)R 4 or -NR 5 C(=O)R 4 And; R 4 is C 1 -C 12 is alkyl; R 5 is H or C 1 -C 6 is alkyl; and x is 0, 1 or 2, Any method from items 1 to 42.
[0135] 44. The method of any one of Items 1 to 43, wherein the cationically ionizable lipid is selected from structures I-1 to I-36 shown herein.
[0136] 45. The method of any of paragraphs 1 to 42, wherein the cationically ionizable lipid is selected from structures A to F shown herein.
[0137] 46. Cationically ionizable lipids include N,N-dimethyl-2,3-dioleyloxypropylamine (DODMA), 1,2-dioleoyl-3-dimethylammonium-propane (DODAP), and heptatriaconta-6. ,9,28,31-tetraen-19-yl-4-(dimethylamino)butanoate (DLin-MC3-DMA) and 4-((di((9Z,12Z)-octadeca-9,12-diene-1- yl)amino)oxy)-N,N-dimethyl-4-oxobutan-1-amine (DPL-14).
[0138] 47. The method of any of paragraphs 1 to 46, wherein the LNP further comprises one or more additional lipids, preferably selected from the group consisting of polymer-conjugated lipids, neutral lipids, steroids and combinations thereof.
[0139] 48. The method of any of paragraphs 1-47, wherein the LNP comprises a cationically ionizable lipid, a polymer-conjugated lipid, a neutral lipid, and a steroid.
[0140] 49. The method of paragraph 47 or 48, wherein the polymer-conjugated lipid comprises a pegylated lipid.
[0141] 50. A pegylated lipid has the following structure: [ka] or a pharmaceutically acceptable salt, tautomer or stereoisomer structure thereof, where: R 12 and R13 are straight or branched, saturated or unsaturated alkyl chains each independently containing 10 to 30 carbon atoms, where the alkyl chain is optionally interrupted by one or more ester linkages; and w has an average value in the range of 30 to 60.
[0142] 51. The method of paragraph 47 or 48, wherein the polymer-conjugated lipid comprises a polysarcosine-lipid conjugate or a conjugate of polysarcosine and a lipid-like substance.
[0143] 52. Polysarcosine-lipid conjugates or conjugates of polysarcosine and lipid-like substances are polysarcosine-diacylglycerol conjugates, polysarcosine-dialkyloxypropyl conjugates, polysarcosine-phospholipid conjugates, polysarcosine-ceramide conjugates and mixtures thereof.
[0144] 53. The method according to any of paragraphs 47 to 52, wherein the neutral lipid is preferably a phospholipid selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidic acid, phosphatidylserine or sphingomyelin.
[0145] 54. Phospholipids include distearoyl phosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dimyristoyl phosphatidylcholine (DMPC), dipentadecanoylphosphatidylcholine, dilauroyl phosphatidylcholine, dipalmitoylphosphatidylcholine (DPPC), and dialachidoyl phosphatidylcholine (DAPC). ), dibehenoyl phosphatidylcholine (DBPC), ditricosanoyl phosphatidylcholine (DTPC), dilignocyloyl phosphatidylcholine (DLPC), palmitoyloleoyl-phosphatidylcholine (POPC), 1,2-di-O-octadecenyl-sn- Glycero-3-phosphocholine (18:0 Diether PC), 1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), dioleoylphosphatidylethanolamine (DOPE), distearoyl-phosphatidylethanolamine (DSPE), dipalmitoyl-phosphatidylethanolamine (DPPE), dimyristoyl-phosphatidylethanolamine (DMPE), dilauroyl-phosphatidylethanolamine (DLPE) ) and diphytanoyl-phosphatidylethanolamine (DPyPE).
[0146] 55. The method according to any of Items 47 to 54, wherein the steroid contains a sterol such as cholesterol.
[0147] 56. The method according to any of Items 1 to 55, wherein the formulation further comprises a chelating agent.
[0148] 57. The method of paragraph 56, wherein the concentration of the chelating agent in the formulation is at most 20mM, preferably at most 10mM, more preferably at most 5mM.
[0149] 58. The method of paragraph 56 or 57, wherein the chelating agent is EDTA.
[0150] 59. The method of any of paragraphs 1 to 55, wherein the formulation does not contain a chelating agent.
[0151] 60. The method according to any of Items 1 to 59, wherein the ratio of cationically ionizable lipid to mRNA is 2:1 to 12:1.
[0152] 61. The method according to any of Items 1 to 60, wherein the mRNA is encapsulated or bound to LNP.
[0153] 62. The method according to any of Items 1 to 61, wherein the mRNA contains a modified nucleoside instead of uridine.
[0154] 63. The method of paragraph 62, wherein the modified nucleoside is selected from pseudouridine (ψ), N1-methyl-pseudouridine (m1ψ) and 5-methyl-uridine (m5U).
[0155] 64. The method of any of paragraphs 1 to 63, wherein the mRNA includes a 5' cap.
[0156] 65. The method of any of paragraphs 1 to 64, wherein the mRNA includes a 5'UTR.
[0157] 66. The method according to any of paragraphs 1 to 65, wherein the mRNA includes a 3'UTR.
[0158] 67. The method according to any of paragraphs 1 to 66, wherein the mRNA contains a polyA sequence.
[0159] 68. The method of paragraph 67, wherein the polyA sequence comprises at least 100 nucleotides.
[0160] 69. The method of any of paragraphs 1 to 68, wherein the mRNA encodes one or more polypeptides.
[0161] 70. The method of paragraph 69, wherein the one or more polypeptides include an epitope for inducing an immune response to the antigen in a subject.
[0162] 71. The method of paragraph 69 or 70, wherein the mRNA encodes an amino acid sequence comprising the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof. .
[0163] 72. The formulation is frozen to a temperature in the range of about -30°C to about -10°C, such as about -25°C to about -15°C or about -25°C to about -20°C or to a temperature of about -20°C; Any method from items 1 to 71.
[0164] 73. The method of any of items 2 to 72, wherein the frozen formulation is freeze-dried until the pharmaceutical composition is substantially free of water contained in the frozen formulation.
[0165] 74. The method of paragraph 73, wherein the frozen formulation is lyophilized until the pharmaceutical composition contains less than 1.0% water by weight.
[0166] 75. Step (I) comprises (a) preparing an mRNA solution comprising water and a buffer system; (b) an ethanolic solution comprising a cationically ionizable lipid and, if present, one or more additional lipids; and (c) mixing the mRNA solution prepared under (a) with the ethanolic solution prepared under (b), thereby preparing a formulation containing LNPs. Either way.
[0167] 76. Step (I) comprises (a') the preparation of liposomes or colloidal preparations of a cationically ionizable lipid in an aqueous phase and, if present, one or more additional lipids; and (b') aqueous phase. and (c') mixing the liposome or colloidal preparation prepared under (a') with the mRNA solution prepared under (b'); Either way.
[0168] 77. The method of paragraph 75 or 76, wherein step (I) further comprises, after step (c) or (c'), one or more steps selected from dilution and filtration, such as tangential flow filtration.
[0169] 78. A method for storing a pharmaceutical composition, the method comprising: preparing the pharmaceutical composition by any of the methods described in Items 1 to 77; A method comprising storing at a temperature in the range of about -15°C or about -25°C to about -20°C or at a temperature of about -20°C.
[0170] 79. The method of paragraph 78, wherein the storage of the pharmaceutical composition is at least 3 months, preferably at least 12 months, more preferably at least 24 months, more preferably at least 36 months.
[0171] 80. A frozen pharmaceutical composition that can be prepared by the method of any of Items 1 to 79.
[0172] 81. Size of LNPs after thawing frozen pharmaceutical composition (Z 平均 ) is about 50 nm to about 500 nm.
[0173] 82. Size of LNPs after thawing frozen pharmaceutical composition (Z 平均 ) and / or the size distribution and / or polydispersity index (PDI) of the LNPs before freezing (Z 平均 ) and / or size distribution and / or PDI.
[0174] 83. A lyophilized pharmaceutical composition that can be prepared by the method of any of items 2 to 79.
[0175] 84. Size of LNPs after lyophilized pharmaceutical composition reconstitution (Z 平均 ) is about 50 nm to about 500 nm.
[0176] 85. Size of LNPs after lyophilized pharmaceutical composition reconstitution (Z 平均 ) and / or the size distribution and / or PDI of the LNPs before lyophilization (Z 平均) and / or size distribution and / or PDI.
[0177] 86. A method for preparing a ready-to-use pharmaceutical composition, the method comprising: preparing a frozen pharmaceutical composition prepared by any of the methods in paragraphs 1 to 79, thawing the frozen pharmaceutical composition, and then preparing a ready-to-use pharmaceutical composition. A method comprising obtaining a pharmaceutical composition.
[0178] 87. A method for preparing a ready-to-use pharmaceutical composition, comprising: preparing a lyophilized pharmaceutical composition prepared by any of the methods in paragraphs 2 to 79, reconstituting the frozen pharmaceutical composition, and then using it. A method comprising obtaining a prepared pharmaceutical composition.
[0179] 88. A ready-to-use pharmaceutical composition that can be prepared by the method of paragraph 86 or 87.
[0180] 89. A pharmaceutical composition comprising LNPs, wherein the LNPs comprise a cationically ionizable lipid and an mRNA, wherein one or more of the following applies: (i) the pharmaceutical composition comprises NaCl and KCl in a combined amount of less than 10% by weight based on the total amount of lipids and mRNA in the pharmaceutical composition; (ii) when in aqueous liquid form, the pH of the pharmaceutical composition is the pK of the cationically ionizable lipid; a lower; (iii) the pharmaceutical composition is substantially free of citrate anions; (iv) the pharmaceutical composition is substantially free of inorganic phosphate anions; A pharmaceutical composition in frozen or lyophilized form.
[0181] 90. The pharmaceutical composition of paragraph 89 comprising NaCl and KCl at a combined concentration of less than 5% by weight, preferably less than 1% by weight, based on the total weight of lipids and mRNA in the pharmaceutical composition.
[0182] 91. The pK of a cationically ionizable lipid when the pH of the formulation is in aqueous liquid form. a The pharmaceutical composition of paragraph 89 or 90, which is lower.
[0183] 92. The pharmaceutical composition of paragraph 89 or 90, wherein the pharmaceutical composition is substantially free of citrate anions.
[0184] 93. The pharmaceutical composition of paragraph 89 or 90, wherein the pharmaceutical composition is substantially free of inorganic phosphate anions.
[0185] 94. (1) When in aqueous liquid form, the pH of the pharmaceutical composition is the pK of the cationically ionizable lipid. a and the pharmaceutical composition is substantially free of citrate anions; (2) When in aqueous liquid form, the pH of the pharmaceutical composition is the pK of the cationically ionizable lipid. a and the pharmaceutical composition is substantially free of inorganic phosphate anions; (3) the pharmaceutical composition is substantially free of citrate anions and substantially free of inorganic phosphate anions; or (4) When in aqueous liquid form, the pH of the pharmaceutical composition is the pK of the cationically ionizable lipid. a and the pharmaceutical composition is substantially free of citrate anions and substantially free of inorganic phosphate anions. The pharmaceutical composition of item 89 or 90.
[0186] 95. (1) the pharmaceutical composition comprises a buffer system and / or a cryoprotectant; (2) When the pharmaceutical composition includes a buffer system and is in aqueous liquid form, the pH of the pharmaceutical composition is the p of the cationically ionizable lipid. a lower; (3) When the pharmaceutical composition includes a cryoprotectant and is in an aqueous liquid form, the pH of the pharmaceutical composition is the pK of the cationically ionizable lipid. a lower; (4) When in aqueous liquid form, the pH of the pharmaceutical composition is the pK of the cationically ionizable lipid. a lower and the pharmaceutical composition comprises a buffer system and a cryoprotectant; (5) the pharmaceutical composition comprises a buffer system and is substantially free of citrate anions; (6) the pharmaceutical composition comprises a cryoprotectant and is substantially free of citrate anions; (7) the pharmaceutical composition is substantially free of citrate anions and includes a buffer system and a cryoprotectant; (8) the pharmaceutical composition comprises a buffer system and is substantially free of inorganic phosphate anions; (9) the pharmaceutical composition comprises a cryoprotectant and is substantially free of inorganic phosphate anions; (10) the pharmaceutical composition is substantially free of inorganic phosphate anions and includes a buffer system and a cryoprotectant; (11) the pharmaceutical composition comprises a buffer system and is substantially free of citrate anions and substantially free of inorganic phosphate anions; (12) the pharmaceutical composition contains a cryoprotectant and is substantially free of citrate anions and substantially free of inorganic phosphate anions; (13) the pharmaceutical composition is substantially free of citrate anions and substantially free of inorganic phosphate anions and includes a buffer system and a cryoprotectant; (14) When the pharmaceutical composition includes a buffer system and is in an aqueous liquid form, the pH of the pharmaceutical composition is the pK of the cationically ionizable lipid. a and the pharmaceutical composition is substantially free of citrate anions and / or substantially free of inorganic phosphate anions; (15) When the pharmaceutical composition includes a cryoprotectant and is in aqueous liquid form, the pH of the pharmaceutical composition is the pK of the cationically ionizable lipid. a lower and the pharmaceutical composition is substantially free of citrate anions and / or substantially free of inorganic phosphate anions; or (16) When the pharmaceutical composition includes a buffer system and a cryoprotectant and is in aqueous liquid form, the pH of the pharmaceutical composition is the p of the cationically ionizable lipid. a and the pharmaceutical composition is substantially free of citrate anions and / or substantially free of inorganic phosphate anions. The pharmaceutical composition according to any of Items 89 to 94.
[0187] 96. A pharmaceutical composition according to any of paragraphs 89 to 95, wherein when in aqueous liquid form, the pH of the pharmaceutical composition is at most 6.5, preferably at most 6.0.
[0188] 97. The pharmaceutical composition of paragraph 95 or 96, wherein the buffer system comprises water and a buffering substance.
[0189] 98. The pharmaceutical composition according to any of items 95 to 97, wherein the buffer system contains any one of HEPES, histidine, Tris, and acetic acid as a buffering substance.
[0190] 99. The pharmaceutical composition according to any of items 95 to 98, wherein the buffer system contains any one of HEPES, histidine, and Tris as a buffering substance.
[0191] 100. The pharmaceutical composition according to any of paragraphs 95 to 99, wherein the buffer system contains HEPES as a buffering substance.
[0192] 101. Paragraphs 95 to 100, wherein the amount of buffer in the pharmaceutical composition is at most 4 mmol, preferably at most 3.6 mmol, more preferably at most 1.8 mmol, per g of total weight of lipid and mRNA in the pharmaceutical composition. Any pharmaceutical composition.
[0193] 102. The pharmaceutical composition according to any of Items 95 to 101, wherein the cryoprotectant contains one or more carbohydrates.
[0194] 103. The pharmaceutical composition of any of paragraphs 95 to 102, wherein the cryoprotectant comprises sucrose, trehalose, glucose, or a combination thereof.
[0195] 104. The pharmaceutical composition according to any one of Items 95 to 103, wherein the cryoprotectant contains sucrose and / or trehalose.
[0196] 105. The amount of cryoprotectant in a pharmaceutical composition may be determined by the amount of cryoprotectant (i) if the pharmaceutical composition is in frozen form, the total amount of the pharmaceutical composition free of any solvent contained in the pharmaceutical composition, or (ii) if the pharmaceutical composition is in frozen form. The pharmaceutical composition of any of paragraphs 95 to 104, which is at least 80% by weight, based on the total amount of the pharmaceutical composition, if in dry form.
[0197] 106. The pharmaceutical composition according to any of paragraphs 95 to 105, wherein the buffer system comprises HEPES as a buffering substance and the cryoprotectant comprises sucrose and / or trehalose.
[0198] 107. The pharmaceutical composition according to any one of Items 89 to 106, further comprising a poloxamer.
[0199] 108. The pharmaceutical composition of paragraph 100 or 106, wherein the formulation does not contain a poloxamer.
[0200] 109. The pharmaceutical composition of any of paragraphs 89 to 108, wherein the cationically ionizable lipid comprises a head group containing at least one nitrogen atom that can be protonated under physiological conditions.
[0201] 110. Cationically ionizable lipids have formula (I): [ka] or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer structure thereof, where: L 1 or L 2 -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O) x -, -S-S-, -C(=O)S-, SC(=O)-, -NR a C(=O)-, -C(=O)NR a -,NR a C(=O)NR a -, -OC(=O)NR a -or-NR a C(=O)O-, and L 1 or L 2 The other is -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O) x -, -S-S-, -C(=O)S-, SC(=O)-, -NR a C(=O)-, -C(=O)NR a -,NR a C(=O)NR a -, -OC(=O)NR a -or-NR a C(=O)O- or a direct bond; G 1 and G 2 are each independently unsubstituted C 1 -C 12 alkylene or C 2 -C 12 is alkenylene; G 3 is C 1 -C 24 alkylene, C 2 -C 24 alkenylene, C 3 -C 8 Cycloalkylene, C 3 -C 8 Cycloalkenylene; R a is H or C 1 -C 12 is alkyl; R 1 and R 2 are each independently C 6 -C 24 alkyl or C 6 -C 24 is alkenyl; R 3 is H, OR 5 ,CN,-C(=O)OR 4 , -OC(=O)R 4 or -NR 5 C(=O)R 4 And; R 4 is C 1 -C 12 is alkyl; R 5 is H or C 1 -C 6 is alkyl; and x is 0, 1 or 2, The pharmaceutical composition according to any of Items 89 to 109.
[0202] 111. The pharmaceutical composition according to any one of Items 89 to 110, wherein the cationically ionizable lipid is selected from structures I-1 to I-36 shown herein.
[0203] 112. The pharmaceutical composition of any of paragraphs 89 to 109, wherein the cationically ionizable lipid is selected from structures A to F shown herein.
[0204] 113. Cationically ionizable lipids include N,N-dimethyl-2,3-dioleyloxypropylamine (DODMA), 1,2-dioleoyl-3-dimethylammonium-propane (DODAP), and heptatriaconta-6. ,9,28,31-tetraen-19-yl-4-(dimethylamino)butanoate (DLin-MC3-DMA) and 4-((di((9Z,12Z)-octadeca-9,12-diene-1- 109. The pharmaceutical composition according to any one of Items 89 to 109, which is selected from the group consisting of yl)amino)oxy)-N,N-dimethyl-4-oxobutan-1-amine (DPL-14).
[0205] 114. The pharmaceutical composition according to any of paragraphs 89 to 113, wherein the LNP further comprises one or more additional lipids, preferably selected from the group consisting of polymer-conjugated lipids, neutral lipids, steroids and combinations thereof.
[0206] 115. The pharmaceutical composition of any of Items 89 to 114, wherein the LNP comprises a cationically ionizable lipid, a polymer conjugated lipid, a neutral lipid, and a steroid.
[0207] 116. The pharmaceutical composition of paragraph 114 or 115, wherein the polymer conjugate lipid comprises a pegylated lipid.
[0208] 117. A pegylated lipid has the following structure: [ka] or a pharmaceutically acceptable salt, tautomer or stereoisomer structure thereof, where: R 12 and R 13 are straight or branched, saturated or unsaturated alkyl chains each independently containing 10 to 30 carbon atoms, where the alkyl chain is optionally interrupted by one or more ester linkages; and w 116, wherein the pharmaceutical composition has an average value in the range of 30 to 60.
[0209] 118. The pharmaceutical composition of paragraph 114 or 115, wherein the polymer conjugate lipid comprises a polysarcosine-lipid conjugate or a conjugate of polysarcosine and a lipid-like substance.
[0210] 119. Polysarcosine-lipid conjugates or conjugates of polysarcosine and lipid-like substances are polysarcosine-diacylglycerol conjugates, polysarcosine-dialkyloxypropyl conjugates, polysarcosine-phospholipid conjugates, polysarcosine-ceramide conjugates and mixtures thereof.
[0211] 120. The pharmaceutical composition according to any of paragraphs 114 to 119, wherein the neutral lipid is preferably a phospholipid selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidic acid, phosphatidylserine or sphingomyelin.
[0212] 121. Phospholipids include distearoyl phosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dimyristoyl phosphatidylcholine (DMPC), dipentadecanoylphosphatidylcholine, dilauroyl phosphatidylcholine, dipalmitoylphosphatidylcholine (DPPC), and dialachidoyl phosphatidylcholine (DAPC). ), dibehenoyl phosphatidylcholine (DBPC), ditricosanoyl phosphatidylcholine (DTPC), dilignocyloyl phosphatidylcholine (DLPC), palmitoyloleoyl-phosphatidylcholine (POPC), 1,2-di-O-octadecenyl-sn- Glycero-3-phosphocholine (18:0 Diether PC), 1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), dioleoylphosphatidylethanolamine (DOPE), distearoyl-phosphatidylethanolamine (DSPE), dipalmitoyl-phosphatidylethanolamine (DPPE), dimyristoyl-phosphatidylethanolamine (DMPE), dilauroyl-phosphatidylethanolamine (DLPE) ) and diphytanoyl-phosphatidylethanolamine (DPyPE).
[0213] 122. The pharmaceutical composition according to any one of Items 114 to 121, wherein the steroid contains a sterol such as cholesterol.
[0214] 123. The pharmaceutical composition according to any one of Items 89 to 122, further comprising a chelating agent.
[0215] 124. The medicament of paragraph 123, wherein the amount of chelating agent in the pharmaceutical composition is at most 0.8 mmol, preferably at most 0.4 mmol, more preferably at most 0.2 mmol per g of total weight of lipid and mRNA in the pharmaceutical composition. Composition.
[0216] 125. The pharmaceutical composition of paragraph 123 or 124, wherein the chelating agent is EDTA.
[0217] 126. The pharmaceutical composition according to any one of Items 89 to 122, wherein the pharmaceutical composition does not contain a chelating agent.
[0218] 127. The pharmaceutical composition according to any one of Items 89 to 126, wherein the ratio of cationically ionizable lipid to mRNA is 2:1 to 12:1.
[0219] 128. The pharmaceutical composition according to any one of Items 89 to 127, wherein the mRNA is encapsulated or bound to LNP.
[0220] 129. The pharmaceutical composition according to any one of Items 89 to 128, wherein the mRNA contains a modified nucleoside instead of uridine.
[0221] 130. The pharmaceutical composition of paragraph 129, wherein the modified nucleoside is selected from pseudouridine (ψ), N1-methyl-pseudouridine (m1ψ) and 5-methyl-uridine (m5U).
[0222] 131. The pharmaceutical composition according to any of Items 89 to 130, wherein the mRNA includes a 5' cap.
[0223] 132. The pharmaceutical composition according to any of Items 89 to 131, wherein the mRNA includes a 5'UTR.
[0224] 133. The pharmaceutical composition according to any of Items 89 to 132, wherein the mRNA includes a 3'UTR.
[0225] 134. The pharmaceutical composition according to any one of Items 89 to 133, wherein the mRNA contains a polyA sequence.
[0226] 135. The pharmaceutical composition of paragraph 134, wherein the polyA sequence comprises at least 100 nucleotides.
[0227] 136. The pharmaceutical composition according to any one of Items 89 to 135, wherein the mRNA encodes one or more polypeptides.
[0228] 137. The pharmaceutical composition of paragraph 136, comprising one or more polypeptide epitopes for inducing an immune response to an antigen in a subject.
[0229] 138. A medicament according to paragraph 136 or 137, wherein the mRNA encodes an amino acid sequence comprising the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof. Composition.
[0230] 139. The frozen pharmaceutical composition is frozen and storable at a temperature in the range of about -30°C to about -10°C, such as about -25°C to about -15°C or at a temperature of about -20°C, or a lyophilized pharmaceutical composition. Clause 89, wherein the composition is storable at a temperature ranging from about -25°C to about room temperature, such as from about -15°C to about 8°C, from about -10°C to about 2°C, or from about -5°C to about 0°C. ~138 any of the pharmaceutical compositions.
[0231] 140. Size of LNPs (Z 平均 ) is about 50 nm to about 500 nm, the pharmaceutical composition according to any one of Items 89 to 139.
[0232] 141. (i) Size of LNPs after thawing the frozen pharmaceutical composition (Z 平均 ) and / or the size distribution and / or PDI of the LNPs before freezing (Z 平均 ) and / or equal to the size distribution and / or PDI or (ii) the size of the LNPs after lyophilized pharmaceutical composition reconstitution (Z 平均 ) and / or the size distribution and / or PDI of the LNPs before lyophilization (Z 平均 ) and / or size distribution and / or PDI.
[0233] 142. The pharmaceutical composition according to any of Items 80 to 85 and 88 to 141 for use in treatment.
[0234] 143. The pharmaceutical composition according to any of Items 80 to 85 and 88 to 141 for use in inducing an immune response.
[0235] Further aspects of the invention are disclosed herein. [Brief explanation of the drawing]
[0236]
Figure 1
[0237]
Figure 2
[0238] [Figure 3] Shows the results of (A) freezing of three lipoplex compositions at -20°C and (B) storage at various freeze / thaw cycles, where the compositions contain a poloxamer, but at the time of composition preparation. The buffer system used is different.
[0239] [Figure 4] Shows the results of (A) freezing an LNP composition containing four LNPs at -20°C and (B) storage at various freeze / thaw cycles, where the four compositions were Different cationically ionizable lipids were used (DODMA, MC3-DMA or DPL-14).
[0240] [Figure 5] Shows the results of (A) freezing at −20° C. of LNP compositions containing three types of LNPs and (B) storage at various freeze / thaw cycles, where the compositions differ in N / P ratio.
[0241] [Figure 6] Shows the results of (A) freezing of an LNP composition containing two types of LNPs at -20°C and (B) storage at various freeze / thaw cycles, where the composition are different.
[0242] [Figure 7] The results of storage of three LNP compositions LNPs at −20° C. are shown, where the compositions differ in the pH used during composition preparation.
[0243] [Figure 8] Figure 3 shows the results of storage of four LNP compositions LNPs at -20°C, where the compositions differ in the amount of EDTA present in the composition.
[0244] [Figure 9] Figure 2 shows the freeze-drying cycle applied to stabilize LNPs in dehydrated conditions.
[0245] [Figure 10] Long-term stability of lyophilized LNPs as a function of temperature: (A) 4 °C, (B) 25 °C, or (C) 40 °C.
[0246] [Figure 11] Figure 3 shows the influence of lyophilization on the properties of LNPs as a function of the buffer system used.
[0247] [Figure 12] Figure 2 shows the effect of freezing at -20 °C on the properties of lipoplexes dispersed in aqueous media containing varying amounts of sucrose.
[0248] [Figure 13] Figure 3 shows the change in particle size of C12 lipid nanoparticles with storage periods at 4°C, 25°C and 40°C in batch 1. The time point at 0 months refers to the size before freeze-drying.
[0249] [Figure 14] Figure 3 shows the change in RNA integrity of C12 lipid nanoparticles with storage period at 4 °C, 25 °C and 40 °C in batch 1.
[0250] [Figure 15] Figure 3 shows the change in particle size of C12 lipid nanoparticles (second batch) with storage periods at 4°C, 25°C and 40°C compared to frozen storage at -20°C.
[0251] [Figure 16] Figure 3 shows changes in RNA integrity of C12 lipid nanoparticles (second batch) with storage periods at 4°C, 25°C and 40°C compared to frozen storage at -20°C.
[0252] [Figure 17] Figure 3 shows the change in particle size of C12 lipid nanoparticles in various buffers with storage periods at 4°C, 25°C and 40°C compared to frozen storage at -20°C.
[0253] [Figure 18] Figure 3 shows changes in RNA integrity of C12 lipid nanoparticles in various buffers with storage periods at 4°C, 25°C and 40°C compared to frozen storage at -20°C.
[0254] [Figure 19] Figure 3 shows the change in particle size of C12 pSAR lipid nanoparticles with storage periods at 4°C, 25°C and 40°C compared to frozen storage at -20°C.
[0255] [Figure 20] Figure 3 shows changes in RNA integrity of C12 pSAR lipid nanoparticles with storage periods at 4°C, 25°C and 40°C compared to frozen storage at -20°C. [Details for carrying out the invention]
[0256] Detailed description of the invention Although the invention is described in further detail below, it is to be understood that this disclosure is not limited to the particular methods, protocols and reagents described herein, as they may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of the invention, which is limited only by the appended claims. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art.
[0257] Below, elements of the invention are described in further detail. Although these elements are listed in conjunction with particular embodiments, it is to be understood, however, that they may be combined in any way and in any number to produce additional embodiments. The various described examples and preferred embodiments are not to be construed as limiting the invention only to the specifically stated embodiments. This description is to be understood to support and encompass embodiments that combine any number of disclosed and / or preferred elements with the specified embodiments. Furthermore, all permutations and combinations of all elements described in this application should be construed as disclosed by the description of this application, unless the context indicates otherwise. For example, if in a preferred embodiment the formulation (or pharmaceutical composition) comprises a cryoprotectant and in another preferred embodiment the cationically ionizable lipid is DODMA, then in a further preferred embodiment the formulation (or pharmaceutical composition) The composition includes a cryoprotectant and the cationically ionizable lipid is DODMA.
[0258] Preferably, the terms used herein refer to "A multilingual glossary of biotechnological terms: (IUPAC Recommendations)", H.G.W. Leuenberger, B. Nagel, and H. Koelbl, Eds., Helvetica Chimica Acta, CH-4010 Basel, Switzerland , (1995).
[0259] The practice of the present invention will employ, unless otherwise indicated, conventional chemistry, biochemistry, cell biology, immunology and recombinant DNA techniques, as described in the art literature (e.g., Organikum, Deutscher Verlag der Wissenschaften, Berlin). 1990; Streitwieser / Heathcook, "Organische Chemie", VCH, 1990; Beyer / Walter, "Lehrbuch der Organischen Chemie", S. Hirzel Verlag Stuttgart, 1988; Carey / Sundberg, "Organische Chemie", VCH, 1995; March, " "Advanced Organic Chemistry", John Wiley & Sons, 1985; Roempp Chemie Lexikon, Falbe / Regitz (Hrsg.), Georg Thieme Verlag Stuttgart, New York, 1989; Molecular Cloning: A Laboratory Manual, 2nd Edition, J. Sambrook et al. eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor 1989).
[0260] Throughout this specification and the claims that follow, unless the context requires otherwise, the term "comprises" and variations thereof, such as "including" and "comprising," are used to refer to the members, integers or steps listed. or is understood to imply the inclusion of a member, integer or group of steps, but not the exclusion of other members, integers or steps or groups of members, integers or steps. The term "consisting essentially of" means the exclusion of other members, integers or steps of any essential value. The term "comprising" includes the term "consisting essentially of," which in turn includes the term "consisting of." Thus, in each case in this application, the term "comprising" may be replaced by the term "consisting essentially of" or "consisting of." Similarly, in each case in this application, the term "consisting essentially of" may be replaced by the term "consisting of."
[0261] As used in the description of the invention, particularly in the claims, references to the singular and the singular are to be construed as encompassing both the singular and the plural, unless the context clearly dictates otherwise. The recitation of ranges of values herein is intended merely to serve as a shorthand way of individually referring to each individual value falling within the range. Unless otherwise specified herein, each individual value is included herein as if individually set forth herein. All methods described herein may be performed in any suitable order, unless otherwise indicated herein or clearly contrary to context. Any and all examples or exemplary language (e.g., "etc.") provided herein are intended merely to better illustrate the invention and are not intended to limit the scope of the invention as otherwise claimed. Not imposed. No language in the invention should be construed as indicating any non-claimed element essential to the practice of the invention.
[0262] As used herein, "and / or" is construed as specific disclosure of each of the two specified properties or components, with or without the other. For example, "X and / or Y" shall be construed to disclose the specific disclosure of each of (i) X, (ii) Y and (iii) X and Y as each is individually indicated herein. .
[0263] In the present invention, the term "about" means an interval of precision that is understood by a person skilled in the art to still be able to ascertain the technical implications of the nature of the problem. This term refers to ±5%, ±4%, ±3%, ±2%, ±1%, ±0.9%, ±0.8%, ±0.7%, ±0.6%, ± Deviations of 0.5%, ±0.4%, ±0.3%, ±0.2%, ±0.1%, ±0.05% and e.g. ±0.01% are indicated. As will be recognized by those skilled in the art, the specific such deviations in numerical values for a given technical effect will depend on the nature of the technical effect. For example, natural or biotechnological influences may generally result in greater deviations than human or engineered technological influences.
[0264] The recitation of ranges of values herein is intended merely to serve as a shorthand way of individually referring to each individual value falling within the range. Unless otherwise specified herein, each individual value is included herein as if individually set forth herein.
[0265] Several documents are cited throughout this specification. Each of the documents cited herein (including all patents, patent applications, scientific articles, manufacturer's specifications, instructions, etc.), whether supra or infra, is incorporated herein by reference in its entirety. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.
[0266] definition In the following, definitions are provided that apply to all aspects of the invention. The following terms have the following meanings unless otherwise specified: Any undefined terms have their recognized meanings.
[0267] As used herein, terms such as "reducing" or "inhibiting" the level of, e.g., about 5% or more, about 10% or more, about 15% or more, about 20% or more, about 25% or more, about 30% or more means the ability to cause an overall phenomenon of about 40% or more, about 50% or more, or about 75% or more. The term "inhibition" or similar terms includes complete or essentially complete inhibition, ie, a reduction to zero or essentially zero.
[0268] Terms such as "increase" or "enhance" refer to at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 80% or at least about 100% in certain embodiments. Concerning an increase or enhancement of.
[0269] "Physiological pH" as used herein refers to a pH of about 7.5.
[0270] As used herein, "%w / v" is a weight / volume percent that is a concentration unit that measures the amount of solute in grams (g) expressed as a percent of the total volume of a solution in milliliters (mL). means.
[0271] As used herein, "wt%" refers to weight percent, which is a concentration unit measuring the amount of a substance in grams (g) expressed as a percentage of the total weight of the total composition in grams (g). .
[0272] Regarding the presence of divalent ions, particularly divalent cations, their concentration or effective concentration (in the presence of free ions) due to the presence of a chelating agent is in certain embodiments sufficiently low to prevent RNA degradation. In certain embodiments, the concentration or effective concentration of divalent ions is below the catalytic level for hydrolysis of phosphodiester bonds between RNA nucleotides. In certain embodiments, the concentration of free divalent ions is 20 μM or less. In certain embodiments, there are no or essentially no free divalent ions.
[0273] "Osmolality" refers to the concentration of a particular solute expressed as osmoles of solute / kilograms of solvent.
[0274] The term "freezing" refers to the solidification of a liquid, usually by removing heat.
[0275] The term "freeze-drying" or "freeze-drying" refers to freezing and then reducing the ambient pressure (e.g. less than 15 Pa, e.g. less than 10 Pa, less than 5 Pa or less than 1 Pa) to remove the freezing medium in a substance directly from the solid phase. Freeze-drying of a substance by sublimating it into a phase. Therefore, the terms "lyophilization" and "freeze-drying" are used interchangeably herein.
[0276] The term "reconstitution" relates to adding a solvent such as water to a dried product to return it to a liquid state, such as its original liquid state.
[0277] The term "recombinant" in the present invention means "produced through genetic engineering." In certain embodiments, "recombinant" in the present invention is not naturally occurring.
[0278] The term "naturally occurring" as used herein refers to the fact that an object can be found in nature. For example, a peptide or nucleic acid that occurs in organisms (including viruses), that can be isolated from a natural source, and that has not been intentionally modified by humans in a laboratory is naturally occurring. The term "naturally occurring" means "occurring in nature" and includes both known objects as well as objects that have not yet been discovered and / or isolated from nature, but will be discovered and / or isolated from natural sources in the future. Contains objects obtained.
[0279] As used herein, the terms "room temperature" and "ambient temperature" are used interchangeably herein and range from at least about 15°C, preferably from about 15°C to about 35°C, from about 15°C to about 30°C, from about 15°C to It refers to a temperature of about 25°C or about 17°C to about 22°C. Such temperatures include 15°C, 16°C, 17°C, 18°C, 19°C, 20°C, 21°C and 22°C.
[0280] The term EDTA refers to ethylenediaminetetraacetic acid disodium salt. All concentrations are given relative to EDTA disodium salt.
[0281] The term "alkyl" refers to a saturated straight or branched hydrocarbon monoradical. Preferably the alkyl group is C 1-12 Alkyl abbreviated as 1 to 12 (e.g. 1 to 10) carbon atoms, i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms (e.g. C 1-10 Alkyl (abbreviated as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms), more preferably 1 to 8 carbon atoms, e.g. Contains ~6 or 1-4 carbon atoms. Examples of alkyl groups are methyl, ethyl, propyl, iso-propyl (also called 2-propyl or 1-methylethyl), butyl, iso-butyl, tert-butyl, n-pentyl, iso-pentyl, sec- Pentyl, neo-pentyl, 1,2-dimethyl-propyl, iso-amyl, n-hexyl, iso-hexyl, sec-hexyl, n-heptyl, iso-heptyl, n-octyl, 2-ethyl-hexyl, n- Includes nonyl, n-decyl, n-undecyl, n-dodecyl, etc. "Substituted alkyl" refers to one or more hydrogen atoms of an alkylene group (e.g. 1 to the maximum number of hydrogen atoms bonded to an alkyl group, e.g. 1, 2, 3, 4, 5, 6, 7). , 8, 9 or up to 10, for example 1 to 5, 1 to 4 or 1 to 3 or 1 or 2) are substituted with substituents other than hydrogen ( When more than one hydrogen atom is substituted, the substituents may be the same or different). Preferably, the substituents other than hydrogen are first level substituents as specified herein. Examples of substituted alkyl include chloromethyl, dichloromethyl, fluoromethyl and difluoromethyl.
[0282] The term "alkylene" refers to a saturated straight or branched hydrocarbon diradical. Preferably, alkylene has 1 to 12 (e.g. 1 to 10) carbon atoms, i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 , 11 or 12 carbon atoms (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms), more preferably 1 to 12 carbon atoms Contains 8 carbon atoms, such as 1-6 or 1-4 carbon atoms. Examples of alkylene groups are methylene, ethylene (i.e. 1,1-ethylene, 1,2-ethylene), propylene (i.e. 1,1-propylene, 1,2-propylene (-CH(CH 3 )CH 2 -), 2,2-propylene(-C(CH 3 ) 2 -) and 1,3-propylene), butylene isomers (e.g. 1,1-butylene, 1,2-butylene, 2,2-butylene, 1,3-butylene, 2,3-butylene (cis or trans or mixtures thereof), 1,4-butylene, 1,1-iso-butylene, 1,2-iso-butylene and 1,3-iso-butylene), pentylene isomers (e.g. 1,1-pentylene, 1, 2-pentylene, 1,3-pentylene, 1,4-pentylene, 1,5-pentylene, 1,1-iso-pentylene, 1,1-sec-pentyl, 1,1-neo-pentylene), hexylene isomers (e.g. 1,1-hexylene, 1,2-hexylene, 1,3-hexylene, 1,4-hexylene, 1,5-hexylene, 1,6-hexylene and 1,1-isohexylene), heptylene isomers ( For example, 1,1-heptylene, 1,2-heptylene, 1,3-heptylene, 1,4-heptylene, 1,5-heptylene, 1,6-heptylene, 1,7-heptylene and 1,1-isoheptylene) , octylene isomers (e.g. 1,1-octylene, 1,2-octylene, 1,3-octylene, 1,4-octylene, 1,5-octylene, 1,6-octylene, 1,7-octylene, 1 , 8-octylene and 1,1-isooctylene). Straight chain alkylene moieties having at least 3 carbon atoms and a free valence at each end are also considered methylenes (eg, 1,4-butylene can also be referred to as tetramethylene). Generally, instead of using "ylene" at the end of an alkylene moiety as above, "diyl" may be used at the end (e.g., 1,2-butylene can also be referred to as butane-1,2-diyl). ). "Substituted alkylene" refers to one or more hydrogen atoms of an alkylene group (e.g. 1 to the maximum number of hydrogen atoms bonded to an alkylene group, e.g. 1, 2, 3, 4, 5, 6, 7). , 8, 9 or up to 10, for example 1 to 5, 1 to 4 or 1 to 3 or 1 or 2) are substituted with substituents other than hydrogen ( When more than one hydrogen atom is substituted, the substituents may be the same or different). Preferably, the substituents other than hydrogen are first level substituents as specified herein.
[0283] The term "alkenyl" refers to an unsaturated straight or branched hydrocarbon monoradical having at least one carbon-carbon double bond. Generally, the maximum number of carbon-carbon double bonds in an alkenyl group is determined by dividing the carbon atoms in the alkenyl group by 2, and if the alkenyl group has an odd number of carbon atoms, rounding the result of the division to the next lower integer. , equal to an integer. For example, for an alkenyl group with 9 carbon atoms, the maximum number of carbon-carbon double bonds is 4. Preferably, the alkenyl group has 1 to 6 (eg 1 to 4) carbon-carbon double bonds, ie 1, 2, 3, 4, 5 or 6 carbon-carbon double bonds. Preferably, the alkenyl group has 2 to 12 (eg 2 to 10) carbon atoms, i.e. 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms (e.g. 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms), more preferably 2 to 8 carbon atoms , having, for example, 2 to 6 carbon atoms or 2 to 4 carbon atoms. Thus, in a preferred embodiment, the alkenyl group is C 2-12Alkenyl abbreviated as having 2 to 12, (e.g. 2 to 10) carbon atoms and 1, 2, 3, 4, 5 or 6 (e.g. 1, 2, 3, 4 or 5) carbon-carbon double bonds, more preferably 2 to 8 carbon atoms and 1, 2, 3 or 4 carbon-carbon double bonds, such as 2 to 6 of carbon atoms and 1, 2 or 3 carbon-carbon double bonds or 2 to 4 carbon atoms and 1 or 2 carbon-carbon double bonds. Carbon-carbon double bonds can be in the cis (Z) or trans (E) configuration. Examples of alkenyl groups are vinyl, 1-propenyl, 2-propenyl (i.e. allyl), 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1 -hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-heptenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 5-heptenyl, 6-heptenyl, 1-octenyl, 2-octenyl , 3-octenyl, 4-octenyl, 5-octenyl, 6-octenyl, 7-octenyl, 1-nonenyl, 2-nonenyl, 3-nonenyl, 4-nonenyl, 5-nonenyl, 6-nonenyl, 7-nonenyl, 8 -nonenyl, 1-decenyl, 2-decenyl, 3-decenyl, 4-decenyl, 5-decenyl, 6-decenyl, 7-decenyl, 8-decenyl, 9-decenyl, 1-undecenyl, 2-undecenyl, 3-undecenyl , 4-undecenyl, 5-undecenyl, 6-undecenyl, 7-undecenyl, 8-undecenyl, 9-undecenyl, 10-undecenyl, 1-dodecenyl, 2-dodecenyl, 3-dodecenyl, 4-dodecenyl, 5-dodecenyl, 6 -Dodecenyl, 7-dodecenyl, 8-dodecenyl, 9-dodecenyl, 10-dodecenyl, 11-dodecenyl, etc. If the alkenyl group is attached to a nitrogen atom, the double bond cannot be alpha to the nitrogen atom. "Substituted alkenyl" refers to one or more hydrogen atoms of an alkenyl group (e.g. 1 to the maximum number of hydrogen atoms bonded to an alkenyl group, e.g. 1, 2, 3, 4, 5, 6, 7 , 8, 9 or up to 10, such as 1 to 5, 1 to 4 or 1 to 3 or 1 or 2) are substituted with substituents other than hydrogen (1 When more than 1 hydrogen atoms are substituted, the substituents may be the same or different). Preferably, the substituents other than hydrogen are first level substituents as specified herein.
[0284] The term "alkenylene" refers to an unsaturated straight or branched hydrocarbon diradical having at least one carbon-carbon double bond. In general, the maximum number of carbon-carbon double bonds in an alkenylene group is determined by dividing the carbon atoms in the alkenylene group by 2 and rounding the result of the division to the next lower integer if the alkenylene group has an odd number of carbon atoms. is equal to an integer. For example, for an alkenylene group with 9 carbon atoms, the maximum number of carbon-carbon double bonds is 4. Preferably, the alkenylene group has 1 to 6 (eg 1 to 4) carbon-carbon double bonds, ie 1, 2, 3, 4, 5 or 6 carbon-carbon double bonds. Preferably, the alkenylene group has 2 to 12 (eg 2 to 10) carbon atoms, i.e. 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms (e.g. 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms), more preferably 2 to 8 carbon atoms , containing, for example, 2 to 6 carbon atoms or 2 to 4 carbon atoms. Thus, in preferred embodiments, alkenylene groups have 2 to 12 (e.g. 2 to 10 carbon) atoms and 1, 2, 3, 4, 5 or 6 (e.g. 1, 2) atoms. , 3, 4 or 5) carbon-carbon double bonds, more preferably 2 to 8 carbon atoms and 1, 2, 3 or 4 carbon-carbon double bonds, For example, it contains 2 to 6 carbon atoms and 1, 2 or 3 carbon-carbon double bonds or 2 to 4 carbon atoms and 1 or 2 carbon-carbon double bonds. Carbon-carbon double bonds can be in the cis (Z) or trans (E) configuration. Examples of alkenylene groups are ethene-1,2-diyl, vinylidene (also called ethenylidene), 1-propene-1,2-diyl, 1-propene-1,3-diyl, 1-propene-2,3 -diyl, arylidene, 1-butene-1,2-diyl, 1-butene-1,3-diyl, 1-butene-1,4-diyl, 1-butene-2,3-diyl, 1-butene-2 ,4-diyl, 1-butene-3,4-diyl, 2-butene-1,2-diyl, 2-butene-1,3-diyl, 2-butene-1,4-diyl, 2-butene-2 ,3-diyl, 2-butene-2,4-diyl, 2-butene-3,4-diyl, etc. If the alkenylene group is attached to a nitrogen atom, the double bond cannot be alpha to the nitrogen atom. "Substituted alkenylene" refers to one or more hydrogen atoms of an alkenylene group (e.g. 1 to the maximum number of hydrogen atoms bonded to an alkenylene group, e.g. 1, 2, 3, 4, 5, 6, 7). , 8, 9 or up to 10, for example 1 to 5, 1 to 4 or 1 to 3 or 1 or 2) are substituted with substituents other than hydrogen ( When more than one hydrogen atom is substituted, the substituents may be the same or different). Preferably, the substituents other than hydrogen are first level substituents as specified herein.
[0285] The term "cycloalkylene" is a cyclic non-aromatic version of "alkylene" and is a geminal, vicinal or lone diradical. In certain embodiments, the cycloalkylene is (i) monocyclic or polycyclic (e.g., bi- or tricyclic) and / or (ii) 3- to 14-membered (i.e., 3-, 4-, 5-, 6-membered). , 7 members, 8 members, 9 members, 10 members, 11 members, 12 members, 13 members or 14 members, for example 3 to 12 members or 3 to 10 members). In certain embodiments, cycloalkylene is a mono-, di- or tricyclic 3- to 14-membered (i.e., 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 11-, 12-membered, member, 13 member or 14 member, for example 3 to 12 member or 3 to 10 member) cycloalkylene. Generally, instead of using ``ylene'' at the end of a cycloalkylene moiety as above, you may use ``diyl'' at the end (for example, 1,2-cyclopropylene is also called cyclopropane-1,2-diyl). ). Examples of cycloalkylene groups are cyclohexylene, cycloheptylene, cyclopropylene, cyclobutylene, cyclopentylene, cyclooctylene, bicyclo[3.2.1]octylene, bicyclo[3.2.2]nonylene and adamantanylene (e.g. tricyclo[ 3.3.1.1 3,7 ]decane-2,2-diyl). "Substituted cycloalkylene" means one or more hydrogen atoms of an alkylene group (e.g. 1 to the maximum number of hydrogen atoms bonded to a cycloalkylene group, e.g. 1, 2, 3, 4, 5, 6). , 7, 8, 9 or up to 10, such as 1 to 5, 1 to 4 or 1 to 3 or 1 or 2) are substituted with substituents other than hydrogen. (When more than one hydrogen atom is substituted, the substituents may be the same or different). Preferably, the substituents other than hydrogen are first level substituents as specified herein.
[0286] The term "cycloalkenylene" represents a cyclic non-aromatic version of "alkenylene" and is a geminal, vicinal or isolated diradical. In general, the maximum number of carbon-carbon double bonds in a cycloalkenylene group is determined by dividing the carbon atoms in the cycloalkenylene group by 2, and if the carbon atoms in the cycloalkenylene group are odd, dividing the result of the division by an integer below Equal to an integer, rounded to . For example, for a cycloalkenylene group having 9 carbon atoms, the maximum number of carbon-carbon double bonds is 4. Preferably, the cycloalkenylene group has 1 to 6 (eg 1 to 4), ie, 1, 2, 3, 4, 5 or 6 elementary-carbon double bonds. In certain embodiments, the cycloalkenylene is (i) monocyclic or polycyclic (e.g., bi- or tricyclic) and / or (ii) 3- to 14-membered (i.e., 3-, 4-, 5-, 6-membered). , 7 members, 8 members, 9 members, 10 members, 11 members, 12 members, 13 members or 14 members, for example 3 to 12 members or 3 to 10 members). In certain embodiments, cycloalkenylene is a mono-, di- or tricyclic 3- to 14-membered (i.e., 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 11-, 12-membered 13- or 14-membered, such as 3-12 or 3-10) cycloalkenylene. Examples of cycloalkenylene groups include cyclohexenylene, cycloheptenylene, cyclopropenylene, cyclobutenylene, cyclopentenylene and cyclooctenylene. "Substituted cycloalkenylene" means one or more hydrogen atoms of a cycloalkenylene group (e.g. 1 to the maximum number of hydrogen atoms bonded to a cycloalkenylene group, e.g. 1, 2, 3, 4, 5, 6 , 7, 8, 9 or up to 10, such as 1 to 5, 1 to 4 or 1 to 3 or 1 or 2) are substituted with substituents other than hydrogen. meaning (when more than one hydrogen atom is substituted, the substituents may be the same or different). Preferably, the substituents other than hydrogen are first level substituents as specified herein.
[0287] The term "aromatic" used in connection with hydrocarbons means that the entire molecule must be aromatic. For example, if a monocyclic aryl is hydrogenated (partially or fully), the resulting hydrogenated cyclic structure is classified as a cycloalkyl for purposes of this invention. Similarly, if a di- or polycyclic aryl (e.g. naphthyl) is hydrogenated, the resulting hydrogenated di- or polycyclic structure (e.g. 1,2-dihydronaphthyl) is a cycloalkyl (even if one of the rings is still aromatic, such as in 1,2-dihydronaphthyl).
[0288] Typical first level substituents are preferably C 1-3 Alkyl, phenyl, halogen, -CF 3 , -OH, -OCH 3 ,-SCH 3 , -NH 2-z (CH 3 ) z , -C(=O)OH and -C(=O)OCH 3where z is 0, 1 or 2 and C 1-3 Alkyl is methyl, ethyl, propyl or isopropyl. Particularly preferred first level substituents are methyl, ethyl, propyl, isopropyl, halogen (e.g. F, Cl or Br) and -CF 3 , for example halogens (e.g. F, Cl or Br) and -CF 3 selected from the group consisting of.
[0289] The expression "frozen pharmaceutical composition after thawing" as used herein in relation to a frozen pharmaceutical composition means that the frozen pharmaceutical composition is characterized (e.g., the size (Z 平均 ) and / or size distribution and / or PDI) must be thawed before they can be measured.
[0290] As used herein in relation to a lyophilized pharmaceutical composition, the expression "after reconstitution of the lyophilized pharmaceutical composition" means that the lyophilized pharmaceutical composition is characterized (e.g., the size (Z 平均 ) and / or size distribution and / or PDI) must be reconstituted (e.g. by addition of deionized water, such as water for injection) before they can be measured.
[0291] As used herein in reference to a frozen or lyophilized pharmaceutical composition, the expression "pH of the pharmaceutical composition when in aqueous liquid form" means that the frozen pharmaceutical composition is thawed before the pH of the pharmaceutical composition can be measured. This means that the pharmaceutical composition must be diluted and optionally diluted with water (or an aqueous medium) or the lyophilized pharmaceutical composition must be reconstituted (eg, by the addition of deionized water, such as water for injection).
[0292] The term "cryoprotectant" relates to a substance added to a formulation to protect the active ingredient during the freezing process.
[0293] According to the present invention, the term "peptide" includes oligos and polypeptides, including about 2 or more, about 3 or more, about 4 or more, about 6 or more, about 8 or more, about 10 or more, about 13 or more, which are linked to each other via peptide bonds. The above refers to a substance containing about 16 or more, about 20 or more, and up to about 50, about 100, or about 150 consecutive amino acids. Although the term "protein" refers to large peptides, particularly peptides having at least about 151 amino acids, the terms "peptide" and "protein" are generally used synonymously herein.
[0294] A "therapeutic protein" has a positive or beneficial effect on a condition or disease state of a subject when provided to the subject in a therapeutically effective amount. In certain embodiments, therapeutic proteins have curative or palliative properties and can be administered to ameliorate, palliate, alleviate, reverse, delay onset, or reduce the severity of one or more symptoms of a disease or disorder. Therapeutic proteins may have prophylactic properties and may be administered to delay disease onset or reduce the severity of such disease or condition. The term "therapeutic protein" includes the entire protein or peptide and may also refer to therapeutically active fragments thereof. Therapeutically active variants of the protein may also be included. Examples of therapeutically active proteins include, but are not limited to, vaccination antigens and immunostimulants such as cytokines.
[0295] According to the invention, once a nucleic acid, such as an mRNA encoding a peptide or protein, has been taken up or introduced into a cell, i.e. transfected or transduced, the cell is present in vitro or in a subject that contains the peptide or protein. Preferably, it can bring about the expression of. The cell may express the encoded peptide or protein intracellularly (eg, in the cytoplasm and / or nucleus), may secrete the encoded peptide or protein, or may express the encoded peptide or protein on its surface.
[0296] According to the present invention, terms such as "expressing nucleic acid" and "encoding nucleic acid" or similar terms are used interchangeably herein, and with respect to a particular peptide or polypeptide, the nucleic acid is present in a suitable environment, preferably If present in a cell, it means that it can be expressed to produce the peptide or polypeptide.
[0297] The term "portion" refers to a fraction. With respect to a particular structure, such as an amino acid sequence or a protein, the term "portion" may refer to a continuous or non-contiguous fraction of the structure.
[0298] The terms "portion" and "fragment" are used interchangeably herein and refer to a contiguous element. For example, a part of a structure, such as an amino acid sequence or a protein, refers to the contiguous elements of the structure. When used in the context of a composition, the term "portion" means a portion of the composition. For example, a portion of a composition can be any portion from 0.1% to 99.9% (e.g., 0.1%, 0.5%, 1%, 5%, 10%, 50%, 90% or 99%) of the composition. .
[0299] A "fragment" in reference to an amino acid sequence (peptide or protein) refers to a sequence representing a portion of the amino acid sequence, ie, an amino acid sequence truncated at the N-terminus and / or C-terminus. Fragments truncated at the C-terminus (N-terminal fragments) can be obtained, for example, by translation of a truncated open reading frame lacking the 3' end of the open reading frame. Fragments truncated at the N-terminus (C-terminal fragments) can be obtained, for example, by translation of a truncated open reading frame lacking the 5' end of the open reading frame, as long as the truncated open reading frame contains an initiation codon for initiating translation. It can be done. A fragment of an amino acid sequence comprises, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% of the amino acid residues from the amino acid sequence. A fragment of an amino acid sequence preferably comprises at least 6, especially at least 8, at least 12, at least 15, at least 20, at least 30, at least 50 or at least 100 contiguous amino acids from the amino acid sequence.
[0300] According to the invention, a part or fragment of a peptide or protein preferably has at least one of the functional properties of the peptide or protein from which it is brought. Such functional properties include pharmacological activity, interaction with other peptides or proteins, enzymatic activity, interaction with antibodies, and selective binding of nucleic acids. For example, a pharmacologically active fragment of a peptide or protein comprises at least one of the pharmacological activities of the peptide or protein from which the fragment was produced. A part or fragment of a peptide or protein preferably comprises a sequence of at least 6, especially at least 8, at least 10, at least 12, at least 15, at least 20, at least 30 or at least 50 consecutive amino acids of the peptide or protein. A part or fragment of a peptide or protein preferably comprises a sequence of at most 8, especially at most 10, at most 12, at most 15, at most 20, at most 30 or at most 55 consecutive amino acids of the peptide or protein.
[0301] "Variant" herein refers to an amino acid sequence that differs from a parent amino acid sequence by at least one amino acid modification. The parent amino acid sequence can be a naturally occurring or wild type (WT) amino acid sequence or a modified version of a wild type amino acid sequence. Preferably, the variant amino acid sequence has at least one amino acid modification compared to the parent amino acid sequence, such as 1 to about 20 amino acid modifications and preferably 1 to about 10 or 1 to about 5 amino acid modifications compared to the parent. have
[0302] "Wild type" or "WT" or "natural" herein means an amino acid sequence found in nature, including allelic variations. A wild-type amino acid sequence, peptide or protein has an amino acid sequence that has not been intentionally modified.
[0303] For the purposes of the present invention, "variants" of an amino acid sequence (peptide, protein or polypeptide) include amino acid insertion variants, amino acid addition variants, amino acid deletion variants and / or amino acid substitution variants. variants, splice variants, post-translational modifications, conformations, isoforms, allelic variants, species variants and species homologs, especially those that occur in nature. The term "variant" specifically includes fragments of amino acid sequences.
[0304] Amino acid insertion variants include insertions of single or more amino acids into a particular amino acid sequence. In the case of amino acid sequence variants with insertions, one or more amino acid residues are inserted at specific positions in the amino acid sequence, but random insertions with appropriate screening of the resulting products are also possible. Amino acid addition variants include amino and / or carboxy terminal fusions of one or more amino acids, such as 1, 2, 3, 5, 10, 20, 30, 50 or more amino acids. Amino acid deletion variants are characterized by the removal of one or more amino acids from the sequence, eg, 1, 2, 3, 5, 10, 20, 30, 50 or more amino acids. The deletion can be made at any position in the protein. Amino acid deletion variants containing deletions at the N-terminus and / or C-terminus of a protein are also referred to as N-terminal and / or C-terminal truncated variants. Amino acid substitution variants are characterized by at least one residue in the sequence that is removed and another residue inserted in its place. Preference is given to modification of positions in the amino acid sequence that are not conserved in homologous proteins or peptides and / or substitution of amino acids by others with similar properties. Preferably, amino acid changes in peptide and protein variants are conservative amino acid changes, ie, substitutions of similarly charged or uncharged amino acids. Conservative amino acid changes include substitutions of one of a family of amino acids that are related in their side chains. Naturally occurring amino acids are generally divided into four families: acidic (aspartic acid, glutamic acid), basic (lysine, arginine, histidine), and nonpolar (alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan). and uncharged polar (glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine) amino acids. Phenylalanine, tryptophan and tyrosine are sometimes classified together as aromatic amino acids. In certain embodiments, conservative amino acid substitutions include substitutions within the following groups: - glycine, alanine; - valine, isoleucine, leucine; - aspartic acid, glutamic acid; - asparagine, glutamine; - serine, threonine; - lysine, arginine; and - Phenylalanine, tyrosine.
[0305] Preferably, the degree of similarity, preferably identity, between an amino acid sequence and an amino acid sequence that is a variant of the certain amino acid sequence is at least about 60%, 70%, 80%, 81%, 82%, 83%, 84%. , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%. Similarity or identity is preferably at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, of the total length of the reference amino acid sequence. Indicated for amino acid regions that are at least about 80%, at least about 90% or about 100%. For example, when the reference amino acid sequence consists of 200 amino acids, the degree of similarity or identity is preferably at least about 20, at least about 40, at least about 60, at least about 80, at least about 100, at least about 120, at least about 140, at least About 160, at least about 180 or about 200 amino acids, in certain embodiments, are indicated for contiguous amino acids. In certain embodiments, similarity or identity is indicated for the entire length of the reference amino acid sequence. Alignments for determining sequence similarity, preferably sequence identity, are performed using tools known in the art, preferably using the best sequence alignment, e.g. using Align, with standard settings, preferably EMBOSS:: Can be implemented using needle, Matrix: Blosum62, Gap Open 10.0, Gap Extend 0.5.
[0306] "Sequence similarity" indicates the percentage of amino acids that are identical or represent conservative amino acid substitutions. "Sequence identity" between two amino acid sequences indicates the percentage of amino acids that are identical between these sequences. "Sequence identity" between two nucleic acid sequences refers to the percentage of nucleotides that are identical between these sequences.
[0307] The terms "% identical" and "% identity" or similar terms are specifically intended to refer to the percentage of nucleotides or amino acids that are identical in optimal alignment between the sequences being compared. The percentage is purely statistical, and the differences between the two sequences may, but are not necessarily, randomly distributed over the entire length of the sequences being compared. Comparison of two sequences is usually performed by comparing segments or "comparison regions" of the sequences to identify local regions of corresponding sequences after optimal alignment. Optimal alignments for comparison were performed manually or with the help of the local homology algorithm of Smith and Waterman, 1981, Ads App. Math. 2, 482, Neddleman and Wunsch, 1970, J. Mol. Biol. 48, 443 with the help of the local homology algorithm of Pearson and Lipman, 1988, Proc. Natl Acad. Sci. USA 88, 2444 or with the aid of a computer program that uses said algorithm. (GAP, BESTFIT, FASTA, BLAST P, BLAST N and TFASTA in Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Drive, Madison, Wis.). In certain embodiments, the percent identity of two sequences is determined on the United States National Center for Biotechnology Information (NCBI) website (e.g., blast.ncbi.nlm.nih.gov / Blast.cgi?PAGE_TYPE=BlastSearch&BLAST_SPEC=blast2seq&LINK_LOC=align2seq). Determine using available BLASTN or BLASTP algorithms. In one embodiment, the algorithm parameters used in the BLASTN algorithm on the NCBI website are: (i) Threshold set to 10; (ii) Term size set to 28; (iii) Query range set to 0. maximum match; (iv) match / mismatch score set to 1, -2; (v) gap cost set to linear; and (vi) low complexity region filter used. In one embodiment, the algorithm parameters used in the NCBI website's BLASTP algorithm are: (i) threshold set to 10; (ii) term size set to 3; (iii) query range set to 0. (iv) matrix set to BLOSUM62; (v) gap cost set to Existence: 11 Extension: 1; and (vi) conditional composition score matrix adjustment.
[0308] Percentage identity involves determining the number of identical positions to which the compared sequences correspond, dividing this number by the number of compared positions (eg, the number of positions in the reference sequence), and multiplying this result by 100.
[0309] In certain embodiments, similarity or identity is expressed over a region that is at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or about 100% of the total length of the reference sequence. It will be done. For example, if the reference nucleic acid sequence consists of 200 nucleotides, the degree of identity is at least about 100, at least about 120, at least about 140, at least about 160, at least about 180 or about 200 nucleotides, in some embodiments, consecutive nucleotides. is shown about. In certain embodiments, similarity or identity is expressed over the entire length of the reference sequence.
[0310] A homologous amino acid sequence according to the invention comprises at least 40%, in particular at least 50%, at least 60%, at least 70%, at least 80%, at least 90% and preferably at least 95%, at least 98 or at least 99% of the amino acid residues. Show identity.
[0311] Amino acid sequence variants described herein can be readily prepared by those skilled in the art, eg, by recombinant DNA engineering. Manipulation of DNA sequences to prepare peptides or proteins with substitutions, additions, insertions or deletions is detailed, for example, in Sambrook et al. (1989). Moreover, the peptide and amino acid variants described herein can be readily prepared with the aid of known peptide synthesis techniques, such as, for example, solid phase synthesis and similar methods.
[0312] In certain embodiments, the fragment or variant of an amino acid sequence (peptide or protein) is preferably a "functional fragment" or "functional variant." The term "functional fragment" or "functional variant" of an amino acid sequence refers to any fragment or variant that exhibits one or more functional properties that are identical or similar to the amino acid sequence from which it is derived, i.e., is functionally equivalent. be. With respect to antigens or antigenic sequences, one particular function is one or more immunogenic activities exhibited by the amino acid sequence from which the fragment or variant is derived. As used herein, the term "functional fragment" or "functional variant" specifically means that one or more amino acids have been changed as compared to the amino acid sequence of the parent molecule or sequence, and that one or more of the functions of the parent molecule or sequence are For example, refers to a variant molecule or sequence capable of eliciting an immune response. In certain embodiments, modifications to the amino acid sequence of a parent molecule or sequence do not significantly affect or alter the characteristics of the molecule or sequence. In different embodiments, the function of the functional fragment or functional variant may be reduced, but still significantly present, e.g., the immunogenicity of the functional variant is at least 50%, at least 60% that of the parent molecule or sequence. %, at least 70%, at least 80% or at least 90%. However, in other embodiments, the immunogenicity of a functional fragment or variant may be enhanced compared to the parent molecule or sequence.
[0313] A designated amino acid sequence (peptide, protein or polypeptide) "derived from" an amino acid sequence (peptide, protein or polypeptide) refers to the origin of the original amino acid sequence. Preferably, an amino acid sequence derived from a particular amino acid sequence has an amino acid sequence that is identical, essentially identical or homologous to the particular sequence or a fragment thereof. An amino acid sequence derived from a particular amino acid sequence can be a variant of the particular sequence or a fragment thereof. For example, those skilled in the art will appreciate that antigens suitable for use herein can be modified to differ in sequence from the naturally occurring or native sequence from which they are derived, but retain the desired activity of the native sequence.
[0314] "Isolated" means altered or removed from its natural state. For example, a nucleic acid or peptide that is naturally present in a living animal is not "isolated," but the same nucleic acid or peptide that is partially or completely isolated from concomitant materials in its natural state is "isolated." An isolated nucleic acid or protein can exist in substantially pure form or can exist in a non-natural environment, eg, in a host cell. In a preferred embodiment, the mRNA used in the invention is in substantially pure form. In certain embodiments, the solution (preferably an aqueous solution) of mRNA in substantially pure form is less than 0.2% w / v, such as less than 0.15% w / v, less than 0.10% w / v, less than 0.05% w / v. or containing NaCl and KCl in a combined concentration of less than 0.01 w / v.
[0315] The term "genetic modification" or simply "modification" includes transfecting a cell with a nucleic acid. The term "transfection" relates to the introduction of nucleic acids, especially RNA, into cells. For purposes of the present invention, the term "transfection" also includes the introduction of a nucleic acid into or uptake of a nucleic acid by such a cell, where the cell may be present in a subject, eg, a patient. Thus, according to the invention, cells for transfection with the nucleic acids described herein can be present in vitro or in vivo, eg, the cells can form part of an organ, tissue and / or organism of a patient. According to the invention, transfection can be transient or stable. For some applications of transfection, it may be sufficient that the transfected genetic material is expressed only transiently. RNA can be transfected into cells to transiently express the encoded protein. Because nucleic acids introduced during the transfection process are not normally integrated into the nuclear genome, foreign nucleic acids are diluted or degraded through mitosis. Cells capable of episomal amplification of nucleic acids exhibit greatly reduced dilution rates. If it is desired that the transfected nucleic acid actually persist in the genome of the cell and its daughter cells, stable transfection must be performed. Such stable transfection can be achieved using virus-based or transposon-based systems for transfection. Generally, a nucleic acid encoding an antigen is transiently transfected into cells. RNA can be transfected into cells to transiently express the encoded protein.
[0316] According to the invention, an analogue of a peptide or protein is a modified version of the peptide or protein from which it is derived and which has at least one of the functional properties of said peptide or protein. For example, a pharmacologically active analog of a peptide or protein has at least one of the pharmacological activities of the peptide or protein from which the analog is derived. Such modifications include any chemical modification, including single or multiple substitutions, deletions and / or additions of carbohydrates, lipids and / or any molecules associated with the protein or peptide, such as the protein or peptide. In certain embodiments, the protein or peptide "analog" may be glycosylated, acetylated, phosphorylated, amidated, palmitoylated, myristoylated, isoprenylated, lipidated, alkylated, derivatized, or introduced with protecting / blocking groups. , modified forms derived from proteolytic cleavage or conjugation to antibodies or other cellular ligands. The term "analog" extends to all functional chemical equivalents of the proteins and peptides.
[0317] "Activation" or "stimulation" as used herein refers to the state of immune effector cells, such as T cells, that are sufficiently stimulated to induce detectable cell proliferation. Activation may also be associated with initiation of signal transduction pathways, induction of cytokine production and detectable effector functions. The term "activated immune effector cell" refers, among other things, to an immune effector cell undergoing cell division.
[0318] The term "priming" refers to the process by which an immune effector cell, such as a T cell, first comes into contact with a specific antigen, causing differentiation into an effector cell, such as an effector T cell.
[0319] The term "clonal expansion" or "expansion" refers to the process by which a particular thing increases. In the present invention, the term is preferably used in the context of an immunological response, in which immune effector cells are stimulated by an antigen to proliferate and specific immune effector cells recognized by the antigen are amplified. Preferably, clonal expansion leads to differentiation of immune effector cells.
[0320] An "antigen" according to the present invention refers to any substance that causes an immune response and / or to which an immune response or immune system is directed, such as a cellular response. This also includes situations in which an antigen is processed into antigenic peptides, particularly when presented in the context of MHC molecules, and an immune response or immune mechanism is directed towards one or more antigenic peptides. In particular, "antigen" relates to any substance, preferably a peptide or protein, that reacts specifically with antibodies or T lymphocytes (T cells). According to the present invention, the term "antigen" includes any molecule that contains at least one epitope, such as a T cell epitope. Preferably, the antigen in the present invention is a molecule that, optionally after treatment, induces an immune response that is preferably antigen (including antigen-expressing cells) specific. In certain embodiments, the antigen is a disease-associated antigen, such as a tumor, viral or bacterial antigen, or an epitope derived from such an antigen.
[0321] According to the invention, any suitable antigen that is a candidate for an immune response may be used, where the immune response can be both a humoral and a cellular immune response. In certain embodiments of the invention, the antigen is presented by cells, preferably antigen presenting cells, preferably in the context of MHC molecules, which results in an immune response against the antigen. Antigens are preferably products directed against or derived from naturally occurring antigens. Such naturally occurring antigens may include or be derived from allergens, viruses, bacteria, fungi, parasites and other infectious agents and pathogens or the antigen may be a tumor antigen. According to the invention, an antigen may correspond to a naturally occurring product, for example a viral protein or a part thereof.
[0322] The term "disease associated antigen" is used in its broadest sense to refer to any antigen associated with a disease. Disease-associated antigens are molecules that contain epitopes that stimulate the host's immune system to mount a cellular antigen-specific and / or humoral antibody response against the disease. Disease-associated antigens include pathogen-associated antigens, ie, antigens associated with infection by microorganisms, typically associated with cancer, typically tumors, such as microbial antigens (eg, bacterial or viral antigens) or tumor antigens.
[0323] In a preferred embodiment, the antigen is a tumor antigen, ie one that appears intracellularly or as a surface antigen on the part of the tumor cell, especially primarily on the tumor cell. In other embodiments, the antigen is a pathogen-associated antigen, ie, an antigen from a pathogen, eg, a virus, a bacterium, a unicellular organism, or a parasite, eg, a viral antigen, such as a viral ribonucleoprotein or coat protein. In particular, the antigen is targeted to cells of the immune system, preferably CD4, in particular through modulation of T cell receptor activity. + and CD8 + It should be presented by MHC molecules that regulate lymphocyte activation.
[0324] The term "tumor antigen" refers to a component of a cancer cell that may be derived from the cytoplasm, cell surface, or cell nucleus. In particular, it refers to antigens produced intracellularly or as surface antigens of tumor cells. For example, tumor antigens include carcinoembryonic antigen, α1-fetoprotein, isoferritin and fetal sulfoglycoprotein, α2-H-ferroprotein and γ-fetoprotein, and various viral tumor antigens. According to the invention, tumor antigens preferably include any antigen that is characteristic of a tumor or cancer and of tumor or cancer cells in terms of type and / or level of expression.
[0325] The term "viral antigen" refers to any viral element that has antigenic properties, ie, is capable of inducing an immune response in an individual. Viral antigens can be viral ribonucleoproteins or envelope proteins.
[0326] The term "bacterial antigen" refers to any bacterial element that has antigenic properties, ie, is capable of inducing an immune response in an individual. Bacterial antigens may be derived from bacterial cell walls or cytoplasmic membranes.
[0327] The term "epitope" refers to an antigenic determinant of a molecule in an antigen, i.e., a molecule recognized by the immune system, e.g., recognized by an antibody T or B cell, especially when presented in the context of an MHC molecule. A part or fragment. Epitopes of a protein preferably include continuous or discontinuous portions of the protein, preferably about 5 to about 100, preferably about 5 to about 50, more preferably about 8 to about 0, most preferably about 10 ~25 amino acids in length, for example, the epitope is preferably 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 amino acids in length. could be. It is particularly preferred in the present invention that the epitope is a T cell epitope.
[0328] Terms such as "epitope", "fragment of an antigen", "immunogenic peptide" and "antigenic peptide" are used interchangeably herein, preferably an antigen or a cell expressing or containing and preferably presenting the antigen. Preferably, it relates to incomplete expression of an antigen capable of eliciting an immune response against. Preferably, the term relates to an immunogenic portion of an antigen. Preferably, it is that portion of an antigen that is recognized (ie, specifically bound) by a T cell receptor, especially if presented in the context of an MHC molecule. Certain preferred immunogenic moieties bind to MHC class I or class II molecules. The term "epitope" refers to a portion or fragment of a molecule, such as an antigen, that is recognized by the immune system. For example, epitopes can be recognized by T cells, B cells or antibodies. Epitopes of an antigen may include contiguous or non-contiguous portions of the antigen and are about 5 to about 100, such as about 5 to about 50, more preferably about 8 to about 30, most preferably about 8 to about 25 amino acids in length. For example, the epitope may preferably be 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 amino acids long. . In certain embodiments, the epitope is about 10 to about 25 amino acids long. The term "epitope" includes T cell epitopes.
[0329] The term "T cell epitope" refers to a portion or fragment of a protein that is recognized by a T cell when presented in the context of an MHC molecule. The term "major histocompatibility complex" and the abbreviation "MHC" refer to a gene complex that includes MHC class I and MHC class II molecules and is present in all vertebrates. MHC proteins or molecules are important for signal transduction between lymphocytes and antigen-presenting or diseased cells in immune responses, where MHC proteins or molecules bind to peptide epitopes and are recognized by T cell receptors on T cells. Present the epitope as shown. Proteins encoded by MHC are expressed on the cell surface and present self-antigens (peptide fragments from the cell itself) and non-self-antigens (eg, fragments of invading microorganisms) to T cells. For class I MHC / peptide complexes, the binding peptide is typically about 8 to about 10 amino acids long, although longer or shorter peptides may be effective. For class II MHC / peptide complexes, the binding peptide is typically about 10 to about 25 amino acids in length, particularly about 13 to about 18 amino acids in length, although longer or shorter peptides may be effective.
[0330] Peptide and protein antigens can be from 2 to 100 amino acids, including, for example, 5 amino acids, 10 amino acids, 15 amino acids, 20 amino acids, 25 amino acids, 30 amino acids, 35 amino acids, 40 amino acids, 45 amino acids or 50 amino acids in length. In certain embodiments, a peptide can be more than 50 amino acids. In certain embodiments, a peptide can be more than 100 amino acids.
[0331] A peptide or protein antigen can be any peptide or protein that can induce or increase the ability of the immune system to produce antibodies against the peptide or protein and a T cell response.
[0332] In certain embodiments, the vaccine antigen, ie, the antigen whose inoculation into a subject induces an immune response, is recognized by immune effector cells. Preferably, the vaccine antigen, if recognized by the immune effector cells, can induce stimulation, priming and / or expansion of immune effector cells carrying antigen receptors that recognize the vaccine antigen under appropriate co-stimulatory signals. . In an embodiment of the invention, the vaccine antigen is preferably presented on or present on the surface of a cell, preferably an antigen presenting cell. In certain embodiments, the antigen is presented by a diseased cell (eg, a tumor cell or an infected cell). In certain embodiments, the antigen receptor is a TCR that binds to an epitope of an antigen presented in the context of MHC. In certain embodiments, binding of a TCR results in stimulation, priming and / or expansion of a T cell when expressed and / or presented by a T cell to an antigen presented by a cell, such as an antigen presenting cell. bring about. In certain embodiments, binding of the TCR results in cytolysis and / or apoptosis of the diseased cell when expressed by and / or presented by the T cell in response to an antigen presented to the diseased cell; The T cells preferably release cytotoxic factors such as perforin and granzymes.
[0333] In certain embodiments, the antigen receptor is an antibody or a B cell receptor that binds to an epitope of the antigen. In certain embodiments, the antibody or B cell receptor binds to a natural epitope of the antigen.
[0334] The term "cell surface expressed" or "cell surface bound" means that a molecule, such as an antigen, is associated with and located at the plasma membrane of a cell, where at least a portion of the molecule is located outside the cell's extracellular region. It faces the space and is accessible from outside the cell, for example by an antibody located outside the cell. In this context, the portion is preferably at least 4, preferably at least 8, preferably at least 12, more preferably at least 20 amino acids. Coupling may be direct or indirect. For example, the binding may be through one or more transmembrane domains, one or more lipid anchors, or through interaction with some other protein, lipid, saccharide, or other structure that may be found in the outer leaflet of the plasma membrane of the cell. obtain. For example, a molecule that binds to the cell surface may be a transmembrane protein that has an extracellular portion or may be a protein that binds to the cell surface by interaction with another protein that is a transmembrane protein.
[0335] "Cell surface" or "surface of a cell" is used according to its ordinary meaning in the art, and thus includes the outside of the cell that is accessible for binding by proteins and other molecules. An antigen is expressed on the cell surface if it is located on the surface of the cell and is accessible for binding by, for example, an antigen-specific antibody added to the cell.
[0336] In the present invention, the term "extracellular portion" or "exodomain" refers to the extracellular space of a cell and is preferably accessible from outside the cell by a binding molecule such as an antibody located outside the cell. A part of a certain molecule, such as a protein. Preferably, the term refers to one or more extracellular loops or domains or fragments thereof.
[0337] The terms "T cell" and "T lymphocyte" are used interchangeably herein and refer to T helper cells (CD4 + Cytotoxic T cells (CTL, CD8 + T cells). The term "antigen-specific T cell" or similar terms refers to an antigen that, when presented on the surface of an antigen-presenting cell or a diseased cell, such as a cancer cell, recognizes and preferably targets an antigen, particularly in the context of an MHC molecule. Concerning T cells that exert T cell effector functions. A T cell is considered specific for an antigen if the cell kills target cells that express the antigen. T cell specificity can be assessed using any of a variety of standard techniques, for example within a chromium release assay or a proliferation assay. Alternatively, the synthesis of lymphokines (eg, interferon-γ) can be measured. In certain embodiments of the invention, the RNA (particularly the mRNA) encodes at least one epitope.
[0338] The term "target" means an agent, such as a cell or tissue, that is a target for an immune response, such as a cellular immune response. Targets include cells that present antigens or antigenic epitopes, ie, peptide fragments derived from the antigen. In certain embodiments, the target cell is a cell that expresses the antigen, preferably presenting the antigen in conjunction with class I MHC.
[0339] "Antigen processing" is the fragmentation of the antigen (e.g., the breakdown of a protein into peptides) and the fragmentation of one or more of these fragments (e.g., the breakdown of a protein into peptides) for presentation by a cell, preferably an antigen-presenting cell, for specific T cells. (e.g., by binding) to MHC molecules (e.g., by binding).
[0340] "Antigen-responsive CTL" refers to CD8 cells that are responsive to antigens or peptides derived from the antigen and are presented together with class I MHC on the surface of antigen-presenting cells. + means T cell.
[0341] According to the present invention, CTL responsiveness is associated with sustained calcium flux, cell division, cytokine production such as IFN-γ and TNF-α, upregulation of activation markers such as CD44 and CD69, and tumor antigen expression in specific cells of target cells. May include lytic killing. CTL responsiveness may also be determined using artificial reporters that accurately indicate CTL responsiveness.
[0342] The terms "immune response" and "immune response" are used interchangeably herein in their conventional sense and refer to an integrated bodily response to an antigen, preferably a cellular immune response, a humoral immune response, or both. . According to the present invention, the term "immune response" or "immune response against" an agent such as an antigen, cell or tissue relates to an immune response such as a cellular response directed against the agent. The immune response includes the production of antibodies against one or more antigens and antigen-specific T lymphocytes, preferably CD4, which can be detected in vitro with various proliferation or cytokine production tests. + and CD8 + T lymphocytes, more preferably CD8 + The response may include one or more reactions selected from the group consisting of expansion of T lymphocytes.
[0343] The terms "inducing an immune response" and "evoking an immune response" and similar terms in the present invention refer to the induction of an immune response, preferably a cellular immune response, a humoral immune response, or both. The immune response may be preventive / inhibitory / prophylactic and / or therapeutic. The immune response may be against some immunogen or antigen or antigenic peptide, preferably against a tumor-associated antigen or a pathogen-associated antigen, such as an antigen of a virus (e.g. influenza virus (A, B or C), CMV or RSV). ). "Induction" in this context can mean that prior to induction there was no immune response to the particular antigen or pathogen, and that prior to induction there was a level of immune response to the particular antigen or pathogen; It can also mean enhanced after said immune response. Therefore, "induction of an immune response" in this context also includes "enhancement of an immune response." Preferably, after the induction of an immune response in an individual, the individual is protected from the development of a disease, such as an infectious disease or a cancerous disease, or has a disease condition reduced due to the induction of the immune response.
[0344] The term "cellular immune response", "cellular response", "cell-mediated immunity" or similar terms refers to a cell to a cell characterized by expressing an antigen and / or presenting an antigen with class I or class II MHC. Means to include a response. The cellular response involves cells called T cells or T lymphocytes that act as "helpers" or "killers." Helper T cells (CD4 + Killer cells (also known as T cells) play a more central role in regulating immune responses, and killer cells (cytotoxic T cells, cytolytic T cells, CD8 + T cells or CTLs) kill cells such as diseased cells.
[0345] The term "humoral immune response" refers to the process in a living organism in which antibodies are produced in response to factors and organisms that are ultimately neutralized and / or eliminated. The specificity of the antibody response is mediated by T and / or B cells through membrane-associated receptors that bind monospecific antigens. After binding to the appropriate antigen and receiving various other activation signals, B lymphocytes divide and produce memory B cells and antibody-secreting plasma cell clones, each identical to that recognized by its antigen receptor. produce antibodies that recognize antigenic epitopes of Memory B lymphocytes remain dormant until they are subsequently activated by a specific antigen. These lymphocytes provide the cellular basis of memory and the consequent increase in antibody responses when re-exposed to specific antigens.
[0346] The term "antibody" as used herein refers to an immunoglobulin molecule that can specifically bind to an epitope of an antigen. In particular, the term "antibody" refers to a glycoprotein that includes at least two heavy (H) chains and two light (L) chains interconnected by disulfide bonds. The term "antibody" includes monoclonal antibodies, recombinant antibodies, human antibodies, humanized antibodies, chimeric antibodies and any combinations of the foregoing. Each heavy chain consists of a heavy chain variable region (VH) and a heavy chain constant region (CH). Each light chain consists of a light chain variable region (VL) and a light chain constant region (CL). Variable and constant regions are also referred to herein as variable and constant domains, respectively. The VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), separated by more conserved regions, termed framework regions (FR). Each VH and VL consists of three CDRs and four FRs, arranged in the following order from the amino-terminus to the carboxy-terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The CDRs of VH are referred to as HCDR1, HCDR2 and HCDR3, and the CDRs of VL are referred to as LCDR1, LCDR2 and LCDR3. The variable regions of heavy and light chains contain binding domains that interact with antigen. The constant regions of antibodies include the heavy chain constant region (CH) and the light chain constant region (CL), where the CH can be further subdivided into the constant domain CH1, the hinge region and the constant domains CH2 and CH3 (from the amino terminus Arranged in the following order in the carboxy-terminal direction: CH1, CH2, CH3). The constant regions of antibodies can mediate the binding of immunoglobulins to host tissues or factors, including various cells of the immune system (eg, effector cells) and the first component of the classical complement system (C1q). The antibody may be an intact immunoglobulin of natural or recombinant origin and may be an immunoactive portion of an intact immunoglobulin. Antibodies are typically tetramers of immunoglobulin molecules. Antibodies include, for example, polyclonal antibodies, monoclonal antibodies, Fv, Fab and F(ab) 2 and can exist in a variety of forms, including single chain antibodies and humanized antibodies.
[0347] The term "immunoglobulin" relates to proteins of the immunoglobulin superfamily, preferably antibodies or antigen receptors such as the B cell receptor (BCR). Immunoglobulins are characterized by structural domains that have a characteristic immunoglobulin (Ig) fold, ie, immunoglobulin domains. The term includes membrane-bound immunoglobulins and soluble immunoglobulins. Membrane-bound immunoglobulin also generally refers to surface or membrane immunoglobulins that are part of the BCR. Soluble immunoglobulin generally refers to antibodies. Immunoglobulins generally contain several chains, typically two identical heavy chains and two identical light chains, linked by disulfide bonds. These chains are mainly V L (variable light chain) domain, C L (constant light chain) domain, V H (variable heavy chain) domain and C H (constant heavy chain) domain C H 1.C H 2,C H 3 and C H Consists of 4 immunoglobulin domains. There are five types of mammalian immunoglobulin heavy chains, namely α, δ, ε, γ and μ, which are responsible for different classes of antibodies, namely IgA, IgD, IgE, IgG and IgM. Contrary to the heavy chains of soluble immunoglobulins, the heavy chains of membrane or surface immunoglobulins contain a transmembrane domain and a short cytoplasmic domain at the carboxy terminus. In mammals, there are two types of light chains: lambda and kappa. Immunoglobulin chains include variable regions and constant regions. The constant region is essentially conserved in the various isotypes of immunoglobulins, where the variable portion is highly variable and is responsible for antigen recognition.
[0348] The terms "vaccination" and "immunization" are the process of treating an individual for therapeutic or prophylactic reasons with one or more immunogens or antigens or derivatives thereof, as described herein, specifically encoding one or more immunogens or antigens or derivatives thereof. It relates to administering to an individual in the form of RNA (particularly mRNA) to stimulate an immune response against said one or more immunogens or antigens or cells characterized by the presentation of said one or more immunogens or antigens.
[0349] "Cells characterized by the presentation of antigens" or "antigen-presenting cells" or "MHC molecules that present antigens on the surface of antigen-presenting cells" or similar expressions refer to MHC molecules, preferably MHC class I and / or MHC It refers to diseased cells, especially cells such as tumor cells or infected cells or antigen-presenting cells, which present antigens or antigenic peptides, either directly or upon subsequent processing, in the context of class II molecules, most preferably MHC class I molecules.
[0350] In the present invention, the term "transcription" relates to the process by which the genetic code of a DNA sequence is transcribed into RNA (particularly mRNA). Subsequently, RNA (particularly mRNA) can be translated into peptides or proteins.
[0351] In the context of RNA, the terms "expression" or "translation" refer to the process by the cell's ribosomes in which an mRNA strand directs the assembly of amino acid sequences to form a peptide or protein.
[0352] As used herein, the term "any" or "optionally" means that the subsequently described event, situation, or condition may or may not occur; Including cases where this occurs and cases where it does not occur.
[0353] Prodrugs of certain compounds described herein are compounds that, when administered to an individual, undergo a chemical transformation under physiological conditions to provide the specified compound. Additionally, prodrugs can be converted to specific compounds by chemical or biochemical methods in an ex vivo environment. For example, a prodrug may slowly convert to a specific compound, eg, when placed in a transdermal patch reservoir with the appropriate enzyme or chemical reagent. Examples of prodrugs are in vivo hydrolysable esters (using alcohol or carboxy groups contained in certain compounds) or amides (using amino or carboxy groups contained in certain compounds). Specifically, any amino group contained in a particular compound that carries at least one hydrogen atom can be converted into a prodrug form. Typical N-prodrug forms include carbamates, Mannich bases, enamines and enaminones.
[0354] "Isomers" are compounds that have the same molecular formula but differ in structure ("structural isomers") or in the geometric (spatial) position of functional groups and / or atoms ("stereoisomers"). "Enantiomers" are pairs of stereoisomers that are non-superimposable mirror images of each other. A "racemic mixture" or "racemate" contains a pair of enantiomers in equal amounts and is indicated by the prefix (±). "Diastereomers" are pairs of stereoisomers that are not superimposable or mirror images of each other. "Tautomers" are structural isomers of the same chemical that, even when pure, spontaneously and reversibly interconvert with each other by movement of individual atoms or groups of atoms; i.e., tautomers The sexual forms are in dynamic chemical equilibrium with each other. An example of a tautomer is the keto-enol-tautomer. "Conformers" are stereoisomers that can formally be interconverted only by rotation around a single bond, such as - in particular - the chair, half-chair, wing and twisted-bone forms of cyclohexane. This results in various three-dimensional forms of (hetero)cyclic rings.
[0355] The term "average diameter" is measured by dynamic light scattering (DLS) and refers to the length dimension, the so-called Z 平均 and the mean hydrodynamic diameter of the particles whose data were analyzed using the so-called cumulant algorithm, which results in a polydispersity index (PDI) that is dimensionless (Koppel, D., J. Chem. Phys. 57, 1972 , pp 4814-4820, ISO 13321). Here, "average diameter", "diameter" or "size" for particles is Z 平均 used synonymously with this value.
[0356] The "polydispersity index" is preferably calculated on the basis of dynamic light scattering measurements by so-called cumulant analysis, as described in the definition of "average diameter". Under certain essential conditions, it can be interpreted as a measurement of the size distribution of an ensemble of nanoparticles.
[0357] The “radius of rotation” of the particle with respect to the axis of rotation (here R g ) is the radial distance from the point of the axis of rotation at which the moment of inertia about an axis is the same as the actual distribution of mass if the entire mass of the particle is assumed to be concentrated. Mathematically, R g is the root mean square distance of a component of a particle from its center of mass or some axis. For example, a fixed distance s from the center of mass i A mass m consisting of n mass elements located at i For macromolecules (i=1, 2, 3,..., n), R g is s for all mass elements i 2 is the square root of the mass average of and can be calculated as:
number
[0358] The radius of gyration can be determined or calculated experimentally, for example using light scattering methods. In particular, small scattering vectors
number
number
[0359] The "D10 value" is the diameter at which 10% of the particles have a diameter smaller than this value, especially with respect to the quantitative size distribution of the particles. The D10 value is intended to describe the proportion of the smallest particles within a particle population (eg within a particle peak obtained with a flow field separation method).
[0360] A "D50 value" is the diameter at which 50% of the particles have a diameter smaller than this value, particularly with respect to the quantitative size distribution of the particles. The D50 value is intended to describe the average particle size within a particle population (eg within a particle peak obtained by flow field separation method).
[0361] A "D90 value" is the diameter at which 90% of the particles have a diameter smaller than this value, especially with respect to the quantitative size distribution of the particles. "D95", "D99" and "D100" values have corresponding meanings. The D90, D95, D99 and D100 values are intended to describe the proportion of large particles within a particle population (eg within a particle peak obtained with a flow field separation method).
[0362] The "hydrodynamic radius" (sometimes referred to as the "Stokes radius" or "Stokes-Einstein radius") of a particle is the radius of an imaginary hard sphere that diffuses at the same velocity as the particle. Hydrodynamic radius is related to particle mobility, taking into account not only size but also solvent effects. For example, particles that are less electrically charged and more hydrated may have a larger hydrodynamic radius than particles that are more electrically charged and less hydrated. This is because small particles attract a large number of water molecules as they move through the solution. Although the actual dimensions of particles in a solvent cannot be measured directly, the hydrodynamic radius can be defined by the Stokes-Einstein equation:
number
[0363] As used herein, the term "agglomeration" refers to agglomerates of particles, where the particles are identical or very similar and interact with each other in a non-covalent manner (e.g., ionic interactions, H-bridge interactions, dipole interactions). bond through interactions and / or van der Waals interactions).
[0364] As used herein, the expression "light scattering" refers to a physical process in which light is forced to deviate from a straight trajectory in one or more paths due to local inhomogeneities in the medium through which it passes.
[0365] The term "UV" means ultraviolet, and refers to a band of the electromagnetic spectrum with wavelengths from 10 nm to 400 nm, ie, shorter than visible light but longer than X-rays.
[0366] As used herein, the expression "multi-angle light scattering" or "MALS" relates to a technique that measures the scattering of light by a sample into multiple angles. "Multi-angle" in this respect means that the scattered light is measured by different, distinct, e.g. This means that it can be detected at an angle of . In one preferred embodiment, the light source used in MALS is a laser source (MALLS: Multi-Angle Laser Light Scattering). Based on the MALS signal of a composition containing particles and using an appropriate formulation (e.g. Zimm plot, Berry plot or Debye plot), the radius of gyration (R g ), hence the size can be determined. Preferably, the Zimm plot is a graphical representation using the following formula:
number
number
number
[0367] As used herein, the expression "dynamic light scattering" or "DLS" refers to a technique that determines the size and size distribution profile of particles, particularly with respect to the hydrodynamic radius of the particles. A monochromatic light source, usually a laser, is directed through a polarizer and onto the sample. The scattered light then passes through a second polarizer, where it is detected and the resulting image is projected onto a screen. Particles in solution are struck by light and diffract light in all directions. The diffracted light from the particles is interfered either constructively (light region) or destructively (dark region). This process is repeated at short intervals, and the resulting set of speckle patterns is analyzed using an autocorrelator that compares the light intensity of each spot over time.
[0368] As used herein, the expression "static light scattering" or "SLS" refers to a technique for determining the size and size distribution profile of particles, particularly with respect to the radius of gyration of the particles and / or the molar mass of the particles. High-intensity monochromatic light, usually a laser, is fired into a solution containing particles. Measure the scattered intensity at one or many angles using one or many detectors. Angular dependence is necessary for accurate measurement of both molar mass and size of the radius of the entire macromolecule. Therefore, simultaneous measurements at several angles relative to the direction of the incident light, known as multi-angle light scattering (MALS) or multi-angle laser light scattering (MALLS), are generally considered as the standard practice for static light scattering. .
[0369] The term "nucleic acid" includes deoxyribonucleic acid (DNA), ribonucleic acid (RNA), combinations thereof and modified forms thereof. The term includes genomic DNA, cDNA, mRNA, recombinantly produced and chemically synthesized molecules. Nucleic acids can exist as single-stranded or double-stranded and linear or covalently closed molecules. Nucleic acids can be isolated. The term "isolated nucleic acid" means, according to the invention, that the nucleic acid (i) has been amplified in vitro, e.g. by polymerase chain reaction (PCR) for DNA or by in vitro transcription (e.g. using RNA polymerase) for RNA. (ii) recombinantly produced by cloning, (iii) purified, eg, by cleavage and separation by gel electrophoresis, or (iv) synthesized, eg, by chemical synthesis.
[0370] The term "nucleoside" (abbreviated herein as "N") relates to compounds that can be considered nucleotides lacking a phosphate group. A nucleoside is a nucleobase attached to a sugar (eg, ribose or deoxyribose), whereas a nucleotide consists of a nucleoside and one or more phosphate groups. Examples of nucleosides include cytidine, uridine, pseudouridine, adenosine and guanosine.
[0371] The five standard nucleosides that normally make up naturally occurring nucleic acids are uridine, adenosine, thymidine, cytidine, and guanosine. The five nucleosides are commonly abbreviated to their one-letter codes U, A, T, C and G, respectively. However, thymidine is more commonly written as "dT" (the "d" stands for "deoxy") because it contains a 2'-deoxyribofuranose moiety rather than the ribofuranose ring found in uridine. . This is because thymidine is found in deoxyribonucleic acid (DNA) and not in ribonucleic acid (RNA). Conversely, uridine is found in RNA and not DNA. The remaining three nucleosides can be found in both RNA and DNA. In RNA they are represented as A, C and G, while in DNA they are represented as dA, dC and dG.
[0372] The modified purine (A or G) or pyrimidine (C, T or U) base moiety preferably contains one or more alkyl groups, more preferably one or more C 1-4 Modified with an alkyl group, even more preferably one or more methyl groups. A specific example of a modified purine or pyrimidine base moiety is N 7 -alkyl-guanine, N 6 -alkyl-adenine, 5-alkyl-cytosine, 5-alkyl-uracil and N(1)-alkyl-uracil, e.g. N 7 -C 1-4 Alkyl-guanine, N 6 -C 1-4 Alkyl-adenine, 5-C 1-4 Alkyl-cytosine, 5-C 1-4 Alkyl-uracil and N(1)-C 1-4 Alkyl-uracil, preferably N 7 -Methyl-guanine, N 6 -Methyl-adenine, 5-methyl-cytosine, 5-methyl-uracil and N(1)-methyl-uracil.
[0373] As used herein, the term "DNA" refers to nucleic acid molecules containing deoxyribonucleotide residues. In a preferred embodiment, the DNA contains all or mostly deoxyribonucleotide residues. As used herein, "deoxyribonucleotide" refers to a nucleotide lacking a hydroxyl group at the 2' position of the β-D-ribofuranosyl group. DNA may include double-stranded DNA, single-stranded DNA, isolated DNA, such as partially purified DNA, essentially pure DNA, synthetic DNA, recombinantly produced DNA as well as naturally occurring DNA. It includes, but is not limited to, modified DNA that differs by addition, deletion, substitution, and / or change of the above nucleotides. Such changes may refer to the addition of internal DNA nucleotides or non-nucleotide material to the ends of the DNA. It is also contemplated herein that the nucleotides in the DNA may be non-standard nucleotides such as chemically synthesized nucleotides or ribonucleotides. For the purposes of this invention, these modified DNAs are considered analogs of naturally occurring DNA. A molecule has a deoxyribonucleotide residue content of more than 50% (e.g., at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%) based on the total number of nucleotide residues in the molecule. , at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%) then it is "predominantly deoxyribonucleotide residues". The total number of nucleotide residues in a molecule is the sum of all nucleotide residues, whether the nucleotide residues are standard (ie, naturally occurring) nucleotide residues or analogs thereof.
[0374] The DNA may be recombinant DNA and may be obtained by cloning nucleic acids, especially cDNA. cDNA can be obtained by reverse transcription of RNA.
[0375] The term "RNA" relates to nucleic acid molecules that contain ribonucleotide residues. In a preferred embodiment, the RNA comprises all or mostly ribonucleotide residues. As used herein, "ribonucleotide" refers to a nucleotide having a hydroxyl group at the 2' position of the β-D-ribofuranosyl group. RNA includes double-stranded RNA, single-stranded RNA, isolated RNA, such as partially purified RNA, essentially pure RNA, synthetic RNA, recombinantly produced RNA as well as naturally occurring RNA. It includes, but is not limited to, modified RNA that differs by addition, deletion, substitution, and / or change of the above nucleotides. Such changes can refer to the addition of internal RNA nucleotides or non-nucleotide material to the RNA terminus. It is also contemplated herein that the nucleotides in the RNA can be chemically synthesized nucleotides or non-standard nucleotides such as deoxynucleotides. For the purposes of the present invention, these altered / modified nucleotides may be referred to as analogs of naturally occurring nucleotides, and the corresponding RNA containing such altered / modified nucleotides (i.e. altered / modified RNA) may be referred to as analogs of naturally occurring nucleotides. It may be called an analog of RNA. The molecule has more than 50% ribonucleotide residues (e.g., at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, based on the total number of nucleotide residues in the molecule). "predominantly ribonucleotide residues" if (at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%). The total number of nucleotide residues in a molecule is the sum of all nucleotide residues, whether the nucleotide residues are standard (ie, naturally occurring) nucleotide residues or analogs thereof.
[0376] "RNA" refers to mRNA, tRNA, ribosomal RNA (rRNA), small nuclear RNA (snRNA), self-amplifying RNA (saRNA), single-stranded RNA (ssRNA), dsRNA, inhibitory RNA (e.g. antisense ssRNA, small molecule interfering RNA (siRNA) or microRNA (miRNA)), activating RNA (eg, small activating RNA) and immunostimulatory RNA (isRNA).
[0377] The term "in vitro transcription" or "IVT" as used herein means that transcription (ie, production of RNA) is performed in a cell-free manner. That is, IVT does not use live / cultured cells, but rather uses the transcriptional machinery extracted from the cells, such as cell lysates or isolated components thereof containing RNA polymerase (preferably T7, T3 or SP6 polymerase).
[0378] mRNA According to the present invention, the term "mRNA" means "messenger RNA" and relates to a "transcript" that can be produced using a DNA template and that can code for a peptide or protein. Typically, mRNA includes a 5'-UTR, a peptide / protein coding region and a 3'-UTR. In the present invention, mRNA is preferably produced by in vitro transcription (IVT) from a DNA template. As mentioned above, in vitro transcription methods are known to those skilled in the art, and a variety of in vitro transcription kits are commercially available.
[0379] Although mRNA is single-stranded, it may contain self-complementary sequences, and portions of the mRNA can fold and pair with themselves to form a double helix.
[0380] According to the invention, "dsRNA" means double-stranded RNA, which is RNA with two partially or completely complementary strands.
[0381] In a preferred embodiment of the invention, mRNA refers to an RNA transcript encoding a peptide or protein.
[0382] In certain embodiments, the mRNA encoding the peptide or protein preferably has at least 45 nucleotides (e.g., at least 60, at least 90, at least 100, at least 200, at least 300, at least 400, at least 500, at least 600, at least 700, at least 800 , at least 900, at least 1,000, at least 1,500, at least 2,000, at least 2,500, at least 3,000, at least 3,500, at least 4,000, at least 4,500, at least 5,000, at least 6,000, at least 7,000, at least 8,000, at least 9,000 nucleotides), preferably up to 15,000, For example, it has a length of up to 14,000, up to 13,000, up to 12,000 nucleotides, up to 11,000 nucleotides or up to 10,000 nucleotides.
[0383] As established in the art, mRNA generally includes a 5' untranslated region (5'-UTR), a peptide coding region and a 3' untranslated region (3'-UTR). In certain embodiments, mRNA is produced by in vitro transcription or chemical synthesis. In certain embodiments, mRNA is produced by in vitro transcription using a DNA template. In vitro transcription methods are known to those skilled in the art; for example, Molecular Cloning: A Laboratory Manual, 2 nd See Edition, J. Sambrook et al. eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor 1989. Additionally, versatile in vitro transcription kits are available, for example from Thermo Fisher Scientific (e.g. TranscriptAid TM T7 kit, MEGAscript® T7 kit, MAXIscript®), New England BioLabs Inc. (e.g. HiScribe TM T7 kit, HiScribe TM T7 ARCA mRNA kit), Promega (e.g. RiboMAX TM , HeLaScribe®, Riboprobe® systems), Jena Bioscience (e.g. SP6 or T7 transcription kits) and Epicentre (e.g. AmpliScribe TM ) is commercially available from. Synthesizing (preferably in vitro transcription) correspondingly modified nucleotides such as modified naturally occurring nucleotides, non-naturally occurring nucleotides and / or modified non-naturally occurring nucleotides to provide modified mRNA Modifications can be carried out and / or added to the mRNA after transcription.
[0384] In certain embodiments, the mRNA is in vitro transcribed mRNA (IVT-RNA), which can be obtained by in vitro transcription of a suitable DNA template. The promoter for controlling transcription can be any promoter of any RNA polymerase. Particular examples of RNA polymerases are T7, T3 and SP6 RNA polymerases. Preferably, in vitro transcription is controlled by the T7 or SP6 promoter. A DNA template for in vitro transcription can be obtained by cloning a nucleic acid, in particular a cDNA, and introducing it into a suitable vector for in vitro transcription. cDNA can be obtained by reverse transcription of RNA.
[0385] In certain embodiments of the invention, the mRNA is a "replicon mRNA" or simply a "replicon", in particular a "self-replicating mRNA" or a "self-amplifying mRNA". In certain particularly preferred embodiments, the replicon or self-replicating mRNA is derived from or contains elements derived from a ssRNA virus, particularly a positive-strand sRNA virus such as an alphavirus. Alphaviruses are typical representatives of positive-strand RNA viruses. Alphaviruses multiply in the cytoplasm of infected cells (for a review of the alphavirus life cycle, see Jose et al., Future Microbiol., 2009, vol. 4, pp. 837-856). The total genome length of many alphaviruses typically ranges from 11,000 to 12,000 nucleotides, and the genomic RNA typically includes a 5' cap and a 3' poly(A) tail. The alphavirus genome encodes non-structural proteins (involved in transcription, modification and replication of viral RNA and protein modification) and structural proteins (forming virus particles). There are typically two open reading frames (ORFs) in a genome. The four non-structural proteins (nsP1-nsP4) are encoded together by the first ORF, which typically starts near the 5' end of the genome, while the alphavirus structural proteins are found downstream of the first ORF. It is co-encoded by a second ORF that extends near the 3' end of the genome. Typically, the first ORF is larger than the second ORF, approximately in a 2:1 ratio. In alphavirus-infected cells, only nucleic acid sequences encoding non-structural proteins are translated from genomic RNA, whereas genetic information encoding structural proteins is transferred to eukaryotic messenger RNA (mRNA; Gould et al., 2010, Antiviral Res ., vol. 87 pp. 111-124). After infection, ie early in the viral life cycle, (+) strand genomic RNA acts directly like messenger RNA for the translation of the open reading frame encoding the nonstructural polyprotein (nsP1234). Alphavirus-derived vectors have been proposed for the delivery of foreign genetic information to target cells or organisms. A simple approach replaces open reading frames encoding alphavirus structural proteins with open reading frames encoding proteins of interest. Alphavirus-based trans-replication systems utilize alphavirus nucleotide sequence elements in two separate nucleic acid molecules: one nucleic acid molecule encodes a viral replicase and the other nucleic acid molecule is replicated in trans by the replicase. (hence the name trans-replication system). Trans-replication requires the presence of both of these nucleic acid molecules in a given host cell. Nucleic acid molecules that can be replicated in trans by a replicase must contain certain alphavirus sequence elements to enable recognition by the alphavirus replicase and RNA synthesis.
[0386] In certain embodiments of the invention, the mRNA comprises one or more modifications, eg, for increased stability and / or increased translation efficiency and / or decreased immunogenicity and / or decreased cytotoxicity. For example, for increased mRNA expression, modifications may be made within the coding region, ie, the sequence encoding the expressed peptide or protein, preferably without altering the sequence of the expressed peptide or protein. Such modifications are described, for example, in WO2007 / 036366 and PCT / EP2019 / 056502 and include: 5' cap structures; elongation or shortening of the naturally occurring poly(A) tail; Modifications to the 5'- and / or 3'-untranslated regions (UTRs), such as the introduction of UTRs that are unrelated to the coding region; substitution of one or more naturally occurring nucleotides with synthetic nucleotides; and codon optimization (e.g. (altering, preferably increasing) the GC content of the RNA). The term "modification" in the context of a modified mRNA according to the invention relates to any modification of an mRNA that is preferably not naturally present in said mRNA.
[0387] In certain embodiments, the mRNA includes a 5' cap structure. In certain embodiments, the mRNA does not have an uncapped 5'-triphosphate. In certain embodiments, the mRNA may include a conventional 5' cap and / or a 5' cap analog. The term "conventional 5' cap" refers to the cap structure found at the 5' end of an mRNA molecule, generally consisting of guanosine 5'-triphosphate (Gppp), which binds the mRNA via its triphosphate moiety. (ie, the guanosine is attached to the rest of the mRNA via a 5'→5' triphosphate bond). Guanosine is N 7 can be methylated at position (cap structure m 7 Gppp). The term “5’ cap analogue” is based on the conventional 5’ cap, but to avoid incorporation of the 5’ cap analog in the reverse orientation, m 7 Refers to a 5' cap that is modified at the 2' or 3' position of a guanosine structure (such 5' cap analogs are also referred to as anti-reverse cap analogs (ARCA)). Particularly preferred 5' cap analogs are phosphorothioate-modified 5' cap analogs with β-phosphate (e.g. m 2 7,2’O G(5')ppSp(5')G (referred to as beta-S-ARCA or β-S-ARCA) with one or more substitutions on the bridging and non-bridging oxygens in the phosphate bridge. As described herein, the provision of a 5' cap structure to an mRNA can be performed using a DNA template in the presence of a corresponding 5' cap compound, and the 5' cap structure is co-transcriptionally incorporated into the produced mRNA strand. This can be achieved by in vitro transcription, or the mRNA can be produced by, for example, in vitro transcription and the 5' cap structure can be attached to the mRNA after transcription using a capping enzyme, such as the capping enzyme of vaccinia virus.
[0388] In certain embodiments, the mRNA is m 2 7,2’O G(5’)ppSp(5’)G (especially its D1 diastereomer), m 2 7,3’O G(5’)ppp(5’)G and m 2 7,3’-O Gppp(m 1 2’-O )ApG.
[0389] In certain embodiments, the mRNA comprises Cap0, Cap1 or Cap2, preferably Cap1 or Cap2. According to the invention, the term "cap 0" is replaced by the structure "m 7 GpppN', where N is any nucleoside with an OH moiety in the 2' position. According to the invention, the term "cap 1" is replaced by the structure "m 7 GpppNm”, where Nm is OCH at the 2’ position 3 Any nucleoside that has a moiety. According to the invention, the term "cap 2" is replaced by the structure "m 7 GpppNmNm”, where each Nm is independently OCH at the 2’ position 3 Any nucleoside that has a moiety.
[0390] The D1 diastereomer of beta-S-ARCA (β-S-ARCA) has the following structure: [ka]
[0391] "D1 diastereomer of Beta-S-ARCA" or "Beta-S-ARCA(D1)" is compared with D2 diastereomer of Beta-S-ARCA (Beta-S-ARCA(D2)) on HPLC column It is the diastereomer of beta-S-ARCA that is eluted first and therefore has a short retention time. HPLC is preferably analytical HPLC. In one embodiment, a Supelcosil LC-18-T RP column, preferably in the format 5 μm, 4.6×250 mm, is used for the separation, whereby a flow rate of 1.3 ml / min can be applied. In certain embodiments, a methanol in ammonium acetate gradient within 15 minutes is used, such as a 0-25% linear gradient of methanol in 0.05M ammonium acetate, pH=5.9. UV detection (VWD) can be performed at 260 nm and fluorescence detection (FLD) can be performed with excitation at 280 nm and detection at 337 nm.
[0392] 5’ cap analog m which is a component of cap 1 2 7,3’-O Gppp(m 1 2’-O )ApG(m 2 7,3’O G(5’)ppp(5’)m 2’-O ApG) has the following structure: [ka]
[0393] An example of cap0 mRNA containing β-S-ARCA and mRNA has the following structure: [ka]
[0394] m 2 7,3’O An example of a cap 0 mRNA containing G(5')ppp(5')G and mRNA has the following structure: [ka]
[0395] m 2 7,3’-O Gppp(m 1 2’-O ) An example of a cap1 mRNA containing ApG and mRNA has the following structure: [ka]
[0396] As used herein, the term "poly A tail" or "poly A sequence" refers to an uninterrupted or interrupted sequence of adenylate residues, typically located at the 3' end of an mRNA molecule. Poly A tails or poly A sequences are known to those skilled in the art and can be attached to the 3'-UTR in the mRNAs described herein. The uninterrupted polyA tail is characterized by consecutive adenylate residues. A naturally uninterrupted polyA tail is typical. The mRNA disclosed herein has a polyA tail attached to the free 3' end of the mRNA by a post-transcriptional template-independent RNA polymerase or a polyA tail encoded by DNA and transcribed by a template-dependent RNA polymerase. It is possible.
[0397] A polyA tail of approximately 120 A nucleotides has been shown to have a beneficial effect on the level of mRNA in transfected eukaryotic cells and on the level of protein translated from the open reading frame present upstream (5') of the polyA tail. (Holtkamp et al., 2006, Blood, vol. 108, pp. 4009-4017).
[0398] PolyA tails can be of any length. In certain embodiments, the polyA tail comprises at least 20, at least 30, at least 40, at least 80 or at least 100 and at most 500, at most 400, at most 300, at most 200 or at most 150 A nucleotides, in particular about 120 A nucleotides. consisting essentially of or consisting of. In this context, "consisting essentially of" means the majority of the nucleotides in the polyA tail, typically at least 75%, at least 80%, at least 85%, at least 90%, depending on the number of nucleotides in the polyA tail, At least 95%, at least 96%, at least 97%, at least 98% or at least 99% are A nucleotides, but the remaining nucleotides are other than A nucleotides, such as U nucleotides (uridylic acid), G nucleotides (guanylic acid) or C nucleotide (cytidylic acid). In this context, "consisting of" means that all nucleotides of the polyA tail, ie, 100% by number of nucleotides in the polyA tail, are A nucleotides. The term "A nucleotide" or "A" refers to adenylic acid.
[0399] In certain embodiments, the polyA tail is attached during RNA transcription, eg, during the preparation of in vitro transcribed RNA, based on a DNA template containing repeating dT nucleotides (deoxythymidylic acid) on the strand complementary to the coding strand. The DNA sequence (coding strand) encoding the poly(A) tail is called the poly(A) cassette.
[0400] In certain embodiments, the poly(A) cassette present in the coding strand of DNA consists essentially of dA nucleotides, but is interrupted by random sequences of four nucleotides (dA, dC, dG and dT). Such random sequences can be 5-50, 10-30 or 10-20 nucleotides long. Such a cassette is disclosed in WO2016 / 005324A1, which is incorporated herein by reference. Any poly(A) cassette disclosed in WO2016 / 005324A1 can be used in the present invention. Consisting essentially of dA nucleotides, but interrupted by equal random sequences with an equal distribution of 4 nucleotides (dA, dC, dG, dT), e.g. A poly(A) cassette is included that exhibits constant propagation of plasmid DNA, yet at the RNA level is associated with beneficial properties that favor RNA stability and translation efficiency. As a result, in certain embodiments, the polyA tail comprised in the mRNA molecules described herein consists essentially of A nucleotides, but is interrupted by a random sequence of four nucleotides (A, C, G, U). be done. Such random sequences can be 5-50, 10-30 or 10-20 nucleotides long.
[0401] In certain embodiments, no nucleotides other than A nucleotides flank the poly A tail at the 3' end, ie, the poly A tail is not masked or continued at the 3' end with nucleotides other than A.
[0402] In certain embodiments, the mRNA used in the invention comprises a 5'-UTR and / or a 3'-UTR. The term "untranslated region" or "UTR" refers to a region in a DNA molecule that is transcribed but not translated into an amino acid sequence or a corresponding region in an RNA molecule, such as an mRNA molecule. An untranslated region (UTR) may be present 5' (upstream) of an open reading frame (5'-UTR) and / or 3' (downstream) of an open reading frame (3'-UTR). The 5'-UTR, if present, is located at the 5' end, upstream of the start codon of the protein coding region. The 5'-UTR is downstream of, eg, directly adjacent to, the 5' cap (if present). The 3'-UTR, if present, is located at the 3' end downstream of the stop codon of the protein coding region, but the term "3'-UTR" preferably does not include polyA sequences. Thus, the 3'-UTR is upstream of the polyA sequence (if present), eg, directly adjacent to the polyA sequence. Incorporation of the 3'-UTR into the 3'-untranslated region of an RNA (preferably mRNA) molecule can enhance translation efficiency. A synergistic effect may be achieved by the incorporation of two or more such 3'-UTRs (these are preferably arranged in a head-to-tail orientation; see, for example, Holtkamp et al., Blood 108, 4009-4017 (2006 )reference). The 3'-UTR can be autologous or heterologous to the introduced RNA (preferably mRNA). In certain embodiments, the 3'-UTR is linked to a globin gene or mRNA, such as the gene or mRNA of alpha2-globin, alpha1-globin or beta-globin, preferably beta-globin, more preferably human beta-globin. Originates from For example, the RNA (preferably mRNA) may contain one or more, preferably two copies of a globin gene, such as alpha2-globin, alpha1-globin, beta-globin, preferably beta-globin, more preferably human beta-globin. It can be modified by replacing or inserting an existing 3'-UTR with a 3'-UTR.
[0403] The mRNA may have modified ribonucleotides for increased stability and / or decreased immunogenicity and / or decreased cytotoxicity. For example, in certain embodiments, uridine in the mRNAs described herein is replaced (partially or completely, preferably completely) with a modified nucleoside. In certain embodiments, the modified nucleoside is a modified uridine.
[0404] In certain embodiments, the modified uridine that replaces uridine is selected from the group consisting of pseudouridine (ψ), N1-methyl-pseudouridine (m1ψ), 5-methyl-uridine (m5U), and combinations thereof.
[0405] In certain embodiments, the modified nucleosides that replace uridine (partially or completely, preferably completely) in the mRNA are 3-methyl-uridine (m3U), 5-methoxy-uridine (mo5U), 5-aza-uridine , 6-aza-uridine, 2-thio-5-aza-uridine, 2-thio-uridine (s2U), 4-thio-uridine (s4U), 4-thio-pseudouridine, 2-thio-pseudouridine, 5 -Hydroxy-uridine (ho5U), 5-aminoallyl-uridine, 5-halo-uridine (e.g. 5-iodo-uridine or 5-bromo-uridine), uridine 5-oxyacetic acid (cmo5U), uridine 5-oxyacetic acid methyl Ester (mcmo5U), 5-carboxymethyl-uridine (cm5U), 1-carboxymethyl-pseudouridine, 5-carboxyhydroxymethyl-uridine (chm5U), 5-carboxyhydroxymethyl-uridine methyl ester (mchm5U), 5-methoxy Carbonylmethyl-uridine (mcm5U), 5-methoxycarbonylmethyl-2-thio-uridine (mcm5s2U), 5-aminomethyl-2-thio-uridine (nm5s2U), 5-methylaminomethyl-uridine (mnm5U), 1- Ethyl-pseudouridine, 5-methylaminomethyl-2-thio-uridine (mnm5s2U), 5-methylaminomethyl-2-seleno-uridine (mnm5se2U), 5-carbamoylmethyl-uridine (ncm5U), 5-carboxymethylamino Methyl-uridine (cmnm5U), 5-carboxymethylaminomethyl-2-thio-uridine (cmnm5s2U), 5-propynyl-uridine, 1-propynyl-pseudouridine, 5-taurinomethyl-uridine (τm5U), 1-taurinomethyl-pseudouridine Uridine, 5-taurinomethyl-2-thio-uridine (τm5s2U), 1-taurinomethyl-4-thio-pseudouridine), 5-methyl-2-thio-uridine (m5s2U), 1-methyl-4-thio-pseudouridine (m1s4ψ), 4-thio-1-methyl-pseudouridine, 3-methyl-pseudouridine (m3ψ), 2-thio-1-methyl-pseudouridine, 1-methyl-1-deaza-pseudouridine, 2-thio -1-Methyl-1-deaza-pseudouridine, dihydrouridine (D), dihydropseudouridine, 5,6-dihydrouridine, 5-methyl-dihydrouridine (m5D), 2-thio-dihydrouridine, 2-thio- Dihydropseudouridine, 2-methoxy-uridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine, 4-methoxy-2-thio-pseudouridine, N1-methyl-pseudouridine, 3-(3- Amino-3-carboxypropyl)uridine (acp3U), 1-methyl-3-(3-amino-3-carboxypropyl)pseudouridine (acp3ψ), 5-(isopentenylaminomethyl)uridine (inm5U), 5-( isopentenylaminomethyl)-2-thio-uridine (inm5s2U), α-thio-uridine, 2'-O-methyl-uridine (Um), 5,2'-O-dimethyl-uridine (m5Um), 2'- O-methyl-pseudouridine (ψm), 2-thio-2'-O-methyl-uridine (s2Um), 5-methoxycarbonylmethyl-2'-O-methyl-uridine (mcm5Um), 5-carbamoylmethyl-2 '-O-methyl-uridine (ncm5Um), 5-carboxymethylaminomethyl-2'-O-methyl-uridine (cmnm5Um), 3,2'-O-dimethyl-uridine (m3Um), 5-(isopentenylamino Methyl)-2'-O-methyl-uridine (inm5Um), 1-thio-uridine, deoxythymidine, 2'-F-ara-uridine, 2'-F-uridine, 2'-OH-ara-uridine, 5 It can be any one or more of -(2-carbomethoxyvinyl)uridine, 5-[3-(1-E-propenylamino)uridine or any other modified uridine known in the art.
[0406] RNA (preferably mRNA) that has been modified by pseudouridine (partially or completely, preferably completely replacing uridine) is referred to herein as "Ψ-modified", whereas the term "m1Ψ-modified" refers to It means that the RNA (preferably the mRNA) contains N(1)-methylpseudouridine (partially or completely, preferably completely replacing uridine). Furthermore, the term "m5U-modified" means that the RNA (preferably the mRNA) comprises 5-methyluridine (partially or completely, preferably completely replacing uridine). Such Ψ- or m1Ψ- or m5U-modified RNAs are generally less immunogenic compared to unmodified forms and are therefore preferred in applications where induction of an immune response is to be avoided or minimized.
[0407] The codons of the mRNA used in the present invention can be modified, for example, by increasing the GC content of the RNA and / or by increasing the synonymous frequency of codons that are rare in the cell (or subject) in which the peptide or protein of interest is to be expressed. It can be further optimized to replace codons that are codons. In certain embodiments, the amino acid sequence encoded by the mRNA used in the invention may be encoded by a coding sequence that has codon optimization and / or increased G / C content compared to the wild-type coding sequence. This also includes embodiments in which one or more sequence regions of the coding sequence have been codon-optimized and / or have increased G / C content compared to the corresponding sequence region of the wild-type coding sequence. In certain embodiments, codon optimization and / or G / C content increase preferably does not change the sequence of the encoded amino acid sequence.
[0408] The term "codon optimization" refers to altering the codons of a coding region of a nucleic acid molecule to reflect the typical codon usage of the host organism, preferably without altering the amino acid sequence encoded by the nucleic acid molecule. In the present invention, the coding region is preferably codon-optimized for optimal expression in the subject to be treated using the mRNA described herein. Codon optimization is based on the knowledge that translation efficiency is also determined by differences in the frequency of tRNA presence in cells. Therefore, the sequence of the mRNA can be modified such that codons that occur frequently in tRNAs are inserted in place of "rare codons."
[0409] In certain embodiments, the guanosine / cytosine (G / C) content of the coding region of the mRNA described herein is increased compared to the G / C content of the corresponding coding sequence of the wild-type RNA, wherein The encoded amino acid sequence is preferably unmodified compared to the amino acid sequence encoded by wild-type RNA. This modification of the mRNA sequence is based on the fact that the sequence of any RNA region to be translated is important for efficient translation of that mRNA. Sequences with increased G (guanosine) / C (cytosine) content are more stable than sequences with increased A (adenosine) / U (uracil) content. For several codons coding for one and the same amino acid (so-called degeneracy of the genetic code), the most favorable codon for stability can be determined (so-called alternative codon usage). Depending on the amino acids encoded by the mRNA, there are various possibilities for modification of the mRNA sequence compared to the wild type sequence. In particular, replacing codons containing A and / or U nucleotides by other codons that code for the same amino acids but do not contain A and / or U or have a low content of A and / or U nucleotides. It can be modified by
[0410] In various embodiments, the G / C content of the coding region of the mRNA described herein is at least 10%, at least 20%, at least 30%, at least It can be increased by 40%, at least 50%, at least 55% or more.
[0411] the above modifications, i.e. incorporation of a 5' cap structure, incorporation of a polyA sequence, unmasking of a polyA sequence, modification of the 5'- and / or 3'-UTR (e.g. incorporation of one or more 3'-UTRs); Replacement of one or more naturally occurring nucleotides with synthetic nucleotides (e.g. 5-methylcytidine for cytidine and / or pseudouridine (Ψ) or N(1)-methylpseudouridine (m1Ψ) for uridine or The combination of 5-methyluridine (m5U)) and codon optimization has a synergistic effect on increasing RNA (preferably mRNA) stability and translation efficiency. Therefore, in a preferred embodiment, the mRNA used in the present invention is modified as described above, namely (i) incorporation of a 5' cap structure, (ii) incorporation of polyA sequence, unmasking of polyA sequence; (iii) 5 '- and / or 3'-UTR alterations (e.g. incorporation of one or more 3'-UTRs); (iv) replacement of one or more naturally occurring nucleotides with synthetic nucleotides (e.g. 5- for cytidine); at least 2, at least 3 of pseudouridine (Ψ) or N(1)-methylpseudouridine (m1Ψ) or 5-methyluridine (m5U)) and (v) codon optimization for methylcytidine and / or uridine , including combinations of at least 4 or all 5.
[0412] Certain embodiments of the invention relate to targeted delivery of the mRNA disclosed herein to certain cells or tissues. In certain embodiments, the invention involves targeting the lymphatic system, particularly secondary lymphoid organs, more specifically the spleen. Targeting the lymphatic system, particularly secondary lymphoid organs, more specifically the spleen, is particularly preferred when the mRNA administered is an mRNA encoding an antigen or epitope for the induction of an immune response. In certain embodiments, the target cells are spleen cells. In certain embodiments, the target cells are antigen presenting cells, such as professional antigen presenting cells in the spleen. In certain embodiments, the target cells are splenic dendritic cells. The "lymphatic system" is part of the circulatory system, including the network of lymph vessels that transport lymph, and is an important part of the immune system. The lymphatic system consists of lymphoid organs, a ductal network of lymph vessels, and circulating lymph. Primary or central lymphoid organs produce lymphocytes from immature progenitor cells. The thymus and bone marrow constitute the primary lymphoid organs. Secondary or peripheral lymphoid organs, including the lymph nodes and spleen, maintain mature naive lymphocytes and mount adaptive immune responses.
[0413] Lipid-based mRNA delivery systems have inherent preference for the liver. Hepatic accumulation is caused by discontinuities in the hepatic vasculature or lipid metabolism (liposomes and lipid or cholesterol conjugates). In certain embodiments, the target organ is the liver and the target tissue is liver tissue. Delivery to such a target tissue may be particularly advantageous if the presence of the mRNA or encoded peptide or protein in this organ or tissue is desired and / or the expression of large quantities of the encoded peptide or protein is desired and / or particularly significant. Preferred if systemic presence of the encoded peptide or protein in amounts is desired or necessary.
[0414] In certain embodiments, after administration of the mRNA particles described herein, at least a portion of the mRNA is delivered to the target cell or target organ. In certain embodiments, at least a portion of the mRNA is delivered to the cytosol of the target cell. In certain embodiments, the mRNA is an mRNA that encodes a peptide or protein, and the mRNA is translated by the target cell to produce the peptide or protein. In certain embodiments, the target cells are cells in the liver. In certain embodiments, the target cell is a muscle cell. In certain embodiments, the target cells are endothelial cells. In certain embodiments, the target cells are tumor cells or cells of the tumor microenvironment. In certain embodiments, the target cells are blood cells. In certain embodiments, the target cells are lymph node cells. In certain embodiments, the target cells are lung cells. In certain embodiments, the target cells are blood cells. In certain embodiments, the target cells are skin cells. In certain embodiments, the target cells are spleen cells. In certain embodiments, the target cells are antigen presenting cells, such as professional antigen presenting cells in the spleen. In certain embodiments, the target cells are splenic dendritic cells. In certain embodiments, the target cell is a T cell. In certain embodiments, the target cell is a B cell. In certain embodiments, the target cells are NK cells. In certain embodiments, the target cells are monocytes. Thus, the RNA particles described herein can be used to deliver mRNA to such target cells. Accordingly, the present invention also relates to a method of delivering mRNA to target cells in a subject, the method comprising administering to the subject an mRNA particle as described herein. In certain embodiments, mRNA is delivered to the cytosol of target cells. In certain embodiments, the mRNA is an mRNA that encodes a peptide or protein, and the RNA is translated by the target cell to produce the peptide or protein.
[0415] "Encodes" refers to genes that have defined nucleotide sequences (i.e., rRNA, tRNA, and mRNA) or defined amino acid sequences that serve as templates for the synthesis of other polymers and macromolecules in biological processes; Refers to the inherent properties of a specific sequence of nucleotides in a polynucleotide such as cDNA or mRNA, and the biological properties resulting therefrom. Thus, a gene encodes a protein if transcription and translation of the mRNA corresponding to the gene produces the protein in a cell or other biological system. The nucleotide sequence is identical to the mRNA sequence, and both the coding strand, usually provided in a sequence listing, and the non-coding strand, used as a template for transcription of the gene or cDNA, are proteins or other products of that gene or cDNA. can be said to be coded.
[0416] In certain embodiments, the mRNA for use in the invention comprises a nucleic acid sequence encoding one or more polypeptides, such as peptides or proteins, preferably pharmaceutically active peptides or proteins.
[0417] In a preferred embodiment, the mRNA used in the invention comprises a nucleic acid sequence encoding a peptide or protein, preferably a pharmaceutically active peptide or protein, and in particular is capable of expressing said peptide or protein when introduced into a cell or subject. can. Therefore, the mRNA used in the present invention preferably comprises a coding region (open reading frame (ORF)) encoding a peptide or protein, preferably encoding a pharmaceutically active peptide or protein. In this regard, an "open reading frame" or "ORF" is a continuous stretch of codons that begins with a start codon and ends with a stop codon. mRNA encoding such a pharmaceutically active peptide or protein is referred to herein as "pharmaceutically active mRNA."
[0418] According to the present invention, the term "pharmaceutically active peptide or protein" means a peptide or protein that can be used for the treatment of an individual for whom expression of the peptide or protein is beneficial, e.g. beneficial in alleviating the symptoms of a disease or disorder. means. Preferably, the pharmaceutically active peptide or protein has curative or palliative properties and can be administered to ameliorate, palliate, alleviate, reverse, delay the onset of, or reduce the severity of or more symptoms of a disease or disorder. . Preferably, the pharmaceutically active peptide or protein has a positive or beneficial effect on a condition or disease state when administered to an individual in a therapeutically effective amount. Pharmaceutically active peptides or proteins may have prophylactic properties and may be used for delaying the onset of a disease or disorder or reducing the severity of such a disease or disorder. The term "pharmaceutically active peptide or protein" includes the entire protein or polypeptide and may also refer to pharmaceutically active fragments thereof. Pharmaceutically active analogs of peptides or proteins may also be included.
[0419] Examples of pharmaceutically active peptides and proteins include cytokines, hormones, adhesion molecules, immunoglobulins, immunologically active compounds, growth factors, protease inhibitors, enzymes, receptors, apoptosis regulators, transcription factors, Including, but not limited to, tumor suppressor proteins, structural proteins, reprogramming factors, genome engineering proteins and blood proteins.
[0420] The term "cytokine" refers to a protein that has a molecular weight of about 5-20 kDa and participates in cell signaling (eg, paracrine, endocrine and / or autocrine signaling). In particular, when released, cytokines exert effects on the behavior of cells surrounding the site of release. Examples of cytokines include lymphokines, interleukins, chemokines, interferons and tumor necrosis factor (TNF). According to the invention, cytokines do not include hormones or growth factors. Cytokines differ from hormones in that (i) their effective concentrations are usually much more variable than hormones, and (ii) they are generally produced by a wide range of cells (nearly all nucleated cells can produce cytokines). Interferons are usually characterized by antiviral, antiproliferative and immunomodulatory activities. Interferons are proteins that modify and control gene transcription within cells by binding to interferon receptors on the surface of regulated cells, thus inhibiting viral replication within cells. Interferons can be classified into two types. IFN-gamma is the only type II interferon; all others are type I interferons. Specific examples of cytokines are erythropoietin (EPO), colony stimulating factor (CSF), granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), tumor necrosis factor (TNF), Bone morphogenetic protein (BMP), interferon alpha (IFNα), interferon beta (IFNβ), interferon gamma (INFγ), interleukin 2 (IL-2), interleukin 4 (IL-4), interleukin 10 (IL-10) ), interleukin 11 (IL-11), interleukin 12 (IL-12) and interleukin 21 (IL-21).
[0421] In certain embodiments, the pharmaceutically active peptide or protein comprises a recruitment protein. In this embodiment, the invention provides a method of treating a subject with a disorder requiring protein supplementation (e.g., a protein deficiency disorder), comprising administering to the subject an RNA described herein that encodes a supplemental protein. Provides a method including: The term "protein supplementation" refers to the introduction of proteins (including functional variants thereof) into a subject deficient in such proteins. The term also refers to the introduction of proteins into subjects who otherwise need or would benefit from the provision of proteins, eg, suffering from protein deficiency. The term "disorder characterized by protein deficiency" refers to any disorder in which the pathology is characterized by the absence or insufficient amount of the protein. The term encompasses protein folding disorders, ie, conformational hindrances, that result in biologically inactive protein products. Protein deficiency may be associated with infection, immunosuppression, organ failure, glandular problems, radiation sickness, nutritional deficiencies, poisoning or other environmental or external insults.
[0422] The term "hormone" refers to a class of signaling molecules produced by glands, where signaling typically involves the following steps: (i) synthesis of hormones in specific tissues; (ii) storage and secretion (iii) transport of the hormone to its target; (iv) binding of the hormone by receptors; (v) relay and amplification of the signal; and (vi) degradation of the hormone. Hormones differ from cytokines in that (1) hormones usually have less variable working concentrations and (2) are generally produced by specific types of cells. In certain embodiments, "hormone" includes insulin, vasopressin, prolactin, adrenocorticotropic hormone (ACTH), thyroid hormone, growth hormone (e.g., human growth hormone or bovine somatotropin), oxytocin, atrial natriuretic peptide (ANP), Peptide or protein hormones such as glucagon, somatostatin, cholecystokinin, gastrin and leptin.
[0423] The term "adhesion molecule" relates to proteins located on the surface of cells and involved in the association of cells with other cells or with the extracellular matrix (ECM). Adhesion molecules are typically transmembrane receptors and can be classified as calcium-independent (eg, integrins, immunoglobulin superfamily, lymphocyte homing receptors) and calcium-dependent (cadherins and selectins). Examples of adhesion molecules are integrins, lymphocyte homing receptors, selectins (eg, P-selectin) and addressins.
[0424] Integrins are also involved in signal transduction. In particular, upon ligand binding, integrins modulate cell signaling pathways, such as those of transmembrane protein kinases, such as receptor tyrosine kinases (RTKs). Such regulation may lead to cell proliferation, division, survival or differentiation or apoptosis. A specific example of an integrin is α 1 β 1 ,α 2 β 1 ,α 3 β 1 ,α 4 β 1 ,α 5 β 1 ,α 6 β 1 ,α 7 β 1 ,α L β 2 ,α M β 2 ,α IIb β 3 ,α V β 1 ,α V β 3 ,α V β 5 ,α V β 6 ,α V β 8 and α 6 β 4 including.
[0425] The term "immunoglobulin" or "immunoglobulin superfamily" refers to molecules involved in cell recognition, binding and / or adhesion processes. Molecules belonging to this superfamily share properties in that they contain regions known as immunoglobulin domains or folds. Members of the immunoglobulin superfamily include antibodies (e.g., IgG), T-cell receptors (TCR), major histocompatibility complex (MHC) molecules, co-receptors (e.g., CD4, CD8, CD19), and antigen receptors. Includes accessory molecules (eg, CD-3γ, CD3-δ, CD-3ε, CD79a, CD79b), costimulatory or inhibitory molecules (eg, CD28, CD80, CD86), and others.
[0426] The term "immunologically active compound" preferably refers to a compound that modifies the immune response by inducing and / or suppressing the maturation of immune cells, inducing and / or suppressing cytokine biosynthesis, and / or by stimulating antibody production by B cells. Relates to any compound that modifies humoral immunity. Immunologically active compounds have potent immunostimulatory activity, including but not limited to antiviral and antitumor activity, and can also downregulate other aspects of the immune response, such as in a wide range of TH2-mediated diseases. The immune response that is useful in the treatment of TH2 can be shifted away from the TH2 immune response. Immunologically active compounds can be useful as vaccine adjuvants. Examples of immunologically active compounds are interleukins, colony stimulating factor (CSF), granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), erythropoietin, tumor necrosis. including factors (TNF), interferons, integrins, addressins, selectins, homing receptors and antigens, especially tumor-associated antigens, pathogen-associated antigens (eg bacterial, parasitic or viral antigens), allergens and self-antigens. Preferred immunologically active compounds are vaccine antigens, ie, antigens whose inoculation into a subject induces an immune response.
[0427] The term "autoantigen" or "self-antigen" refers to a substance that originates within a subject's body (i.e., an autoantigen may also be referred to as a "self-antigen") and produces an abnormally active immune response against normal parts of this body. refers to an antigen that causes Such vigorous immune responses to self-antigens can be the cause of "autoimmune diseases."
[0428] The term "allergen" refers to an abnormality that originates outside a subject's body (i.e., an allergen may also be referred to as a "foreign antigen") and causes the subject's immune system to fight off a perceived threat that is not otherwise harmful to the subject. An antigen that produces an active immune response to a specific antigen. "Allergy" is a disease caused by such an active immune response to allergens. Allergens are antigens that can stimulate a type-I hypersensitivity response in atopic individuals, usually through an immunoglobulin E (IgE) response. Specific examples of allergens include allergens derived from peanut proteins (eg, Ara h 2.02), ovalbumin, grass pollen proteins (eg, Phl p 5), and dust mite proteins (eg, Der p 2).
[0429] The term "growth factor" refers to molecules that can stimulate cell growth, proliferation, healing and / or cell differentiation. Typically, growth factors act as signaling molecules between cells. The term "growth factor" includes specific cytokines and hormones that bind to specific receptors on the surface of target cells. Examples of growth factors are bone morphogenetic proteins (BMPs), fibroblast growth factors (FGFs), vascular endothelial growth factors (VEGFs), e.g. VEGFA, epidermal growth factors (EGFs), insulin-like growth factors, ephrins, macrophages. colony stimulating factor, granulocyte colony stimulating factor, granulocyte macrophage colony stimulating factor, neuregulin, neurotrophic factors (e.g. brain derived neurotrophic factor (BDNF), nerve growth factor (NGF)), placental growth factor (PGF), Platelet-derived growth factor (PDGF), renalase (RNLS) (anti-apoptotic survival factor), T cell growth factor (TCGF), thrombopoietin (TPO), transforming growth factor (transforming growth factor alpha (TGF-α), transforming growth factor beta (TGF-β)) and tumor necrosis factor-alpha (TNF-α). In certain embodiments, a "growth factor" is a peptide or protein growth factor.
[0430] The term "protease inhibitor" refers to molecules, especially peptides or proteins, that inhibit the function of proteases. Protease inhibitors can be classified by the protease inhibited (eg, asparagine protease inhibitors) or by the mechanism of action (eg, suicide inhibitors such as serpins). Examples of protease inhibitors include serpins such as alpha 1 antitrypsin, aprotinin and bestatin.
[0431] The term "enzyme" refers to a macromolecular biological catalyst that accelerates chemical reactions. Like all catalysts, enzymes are not consumed in the reactions they catalyze and do not alter the equilibrium of the reactions. Unlike many other catalysts, enzymes are much more specific. In certain embodiments, the enzyme is essential to the subject's homeostasis, eg, any dysfunction of the enzyme (particularly reduced activity, which may be due to either mutation, deletion, or decreased production) results in disease. Examples of enzymes include herpes simplex virus type 1 thymidine kinase (HSV1-TK), hexosaminidase, phenylalanine hydroxylase, pseudocholinesterase and lactase.
[0432] The term "receptor" refers to a protein molecule that accepts signals from outside the cell, especially chemical signals called ligands. Binding of a signal (eg, a ligand) to a receptor causes some type of response in the cell, such as intracellular activation of a kinase. Receptors include transmembrane receptors (e.g. ionotropic receptors, G protein-coupled (metabotropic) receptors and enzyme-coupled receptors) and intracellular receptors (e.g. cytoplasmic and nuclear receptors). )including. Examples of receptors include steroid hormone receptors, growth factor receptors, and peptide receptors (ie, receptors where the ligand is a peptide), such as P-selectin glycoprotein ligand-1 (PSGL-1). The term "growth factor receptor" refers to a receptor that binds growth factors.
[0433] The term "apoptosis regulator" refers to a molecule, especially a peptide or protein, that modulates, ie activates or inhibits, apoptosis. Apoptosis regulators can be divided into two broad classes: those that control mitochondrial function and those that regulate caspases. The first class includes proteins that preserve mitochondrial integrity (e.g., BCL-2, BCL-xL) by preventing loss of mitochondrial membrane potential and / or release of pro-apoptotic proteins such as cytochrome C into the cytosol. . This first class also contains a pro-apoptotic protein that promotes the release of cytochrome C. (for example, BAX, BAK, BIM). The second class includes proteins such as inhibitors of apoptosis proteins (eg, XIAP) or FLIP that block activation of caspases.
[0434] The term "transcription factor" specifically relates to proteins that control the rate of transcription of genetic information from DNA to messenger RNA by binding to specific DNA sequences. Transcription factors may control cell division, cell proliferation, and cell death throughout life; cell migration and organization during embryonic development; and / or responses to signals from outside the cell, such as hormones. Transcription factors typically contain at least one DNA binding domain that binds to specific DNA sequences that flank the genes controlled by the transcription factor. Specific examples of transcription factors include MECP2, FOXP2, FOXP3, the STAT protein family and the HOX protein family.
[0435] The term "tumor suppressor protein" refers to a molecule, particularly a peptide or protein, that protects cells from a process that leads to cancer. Tumor suppressor proteins (usually encoded by the corresponding tumor suppressor genes) exert attenuating or oppressive effects on cell cycle control and / or promote apoptosis. Their function may be one or more of the following: suppression of inheritance essential for continuation of the cell cycle; coupling of the cell cycle to DNA damage (as long as damaged DNA is present in the cell, cell division will not occur); If damaged DNA cannot be repaired, initiation of apoptosis; suppression of metastasis (eg, preventing tumor cells from dispersing, blocking loss of contact inhibition, inhibiting metastasis); and DNA repair. Examples of tumor suppressor proteins are p53, phosphatase and tensin homolog (PTEN), SWI / SNF (SWItch / nonfermentable sucrose), von Hippel-Lindau tumor suppressor (pVHL), and adenomatoid polypoid polypoid (APC). , CD95, tumorigenicity suppressor 5 (ST5), tumorigenicity suppressor 5 (ST5), tumorigenicity suppressor 14 (ST14) and Yippee-like 3 (YPEL3).
[0436] The term "structural protein" refers to proteins that contribute to the stiffness and rigidity of otherwise liquid biological components. Structural proteins are mostly fibrous (eg collagen and elastin) but can also be globular (eg actin and tubulin). Typically, globular proteins are soluble as monomers, but polymerize to form long, fibers that can form, for example, the cytoskeleton. Other structural proteins are motor proteins (such as myosin, kinesin and dynein) and surfactant proteins that can produce mechanical forces. Examples of structural proteins include collagen, surfactant protein A, surfactant protein B, surfactant protein C, surfactant protein D, elastin, tubulin, actin and myosin.
[0437] The term "reprogramming factor" or "reprogramming transcription factor" when expressed in a somatic cell, optionally together with further factors such as further reprogramming factors, renders the somatic cell endowed with stem cell characteristics, in particular It relates to molecules, especially peptides or proteins, that reprogram or dedifferentiate cells into pluripotent cells. Specific examples of reprogramming factors include OCT4, SOX2, c-MYC, KLF4, LIN28 and nano-G.
[0438] The term "genome engineering protein" relates to a protein that can be inserted, deleted or replaced with DNA in the genome of a subject. Specific examples of genome-engineered proteins include meganucleases, zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and clustered regularly arranged short palindromic repeats-CRISPR-associated protein 9 (CRISPR-Cas9). )including.
[0439] The term "blood protein" relates to peptides or proteins present in the plasma of a subject, especially the plasma of healthy subjects. Blood proteins are involved in transport (e.g. albumin, transferrin), enzymatic activity (e.g. thrombin or ceruloplasmin), coagulation (e.g. fibrinogen), defense against pathogens (e.g. complement components and immunoglobulins), protease inhibitors (e.g. , alpha 1 antitrypsin). Examples of blood proteins are thrombin, serum albumin, factor VII, factor VIII, insulin, factor IX, factor X, tissue plasminogen activator, protein C, von Willebrand factor, antithrombin III. , glucocerebrosidase, erythropoietin, granulocyte colony stimulating factor (G-CSF), modified factor VIII and anticoagulants.
[0440] Thus, in certain embodiments, the pharmaceutically active peptide or protein is preferably selected from the group consisting of (i) erythropoietin (EPO), interleukin 4 (IL-2) and interleukin 10 (IL-11). (ii) adhesion molecules, especially integrins; (iii) immunoglobulins, especially antibodies; (iv) immunologically active compounds, especially antigens; (v) hormones, especially vasopressin, insulin. or growth hormone; (vi) growth factors, especially VEGFA; (vii) protease inhibitors, especially alpha 1 antitrypsin; (viii) preferably herpes simplex virus type 1 thymidine kinase (HSV1-TK), hexosaminidase, phenylalanine an enzyme selected from the group consisting of hydroxylases, pseudocholinesterases, pancreatic enzymes and lactases; (ix) receptors, especially growth factor receptors; (x) apoptosis regulators, especially BAX; (xi) transcription factors, especially FOXP3 (xii) tumor suppressor proteins, especially p53; (xiii) structural proteins, especially surfactant protein B; (xiv) e.g. (xv) genome-engineered proteins, especially clustered regularly arranged short palindromic repeats-CRISPR-associated protein 9 (CRISPR-Cas9); and (xvi) blood proteins, especially fibrinogen. be.
[0441] In certain embodiments, the pharmaceutically active peptide or protein comprises one or more antigens or one or more epitopes, i.e., administration of the peptide or protein to a subject is therapeutic or partially or fully protective. inducing an immune response against the one or more antigens or one or more epitopes in a possible subject.
[0442] In certain embodiments, the mRNA encodes at least one epitope.
[0443] In certain embodiments, the epitope is derived from a tumor antigen. A tumor antigen can be a "standard" antigen commonly known to be expressed in a variety of cancers. Tumor antigens are "neo-antigens" that are specific to an individual's tumor and have not been previously recognized by the immune system. Neo-antigens or neo-epitopes can result from one or more cancer-specific mutations in the cancer cell's genome that lead to amino acid changes. Examples of tumor antigens are p53, ART-4, BAGE, beta-catenin / m, Bcr-abL CAMEL, CAP-1, CASP-8, CDC27 / m, CDK4 / m, CEA, cell surface proteins of the claudin family. , such as CLAUD ΓΝ-6, claudin-18.2 and claudin-12, c-MYC, CT, Cyp-B, DAM, ELF2M, ETV6-AML1, G250, GAGE, GnT-V, Gap 100, HAGE, HER- 2 / neu, HPV-E7, HPV-E6, HAST-2, hTERT (or hTRT), LAGE, LDLR / FUT, MAGE-A, preferably MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A5, MAGE-A6, MAGE-A7, MAGE-A8, MAGE-A9, MAGE-A10, MAGE-A11 or MAGE-A12, MAGE-B, MAGE-C, MART-1 / Melan-A, MC1R, myosin / m, MUC1, MUM-1, MUM-2, MUM-3, NA88-A, NF1, NY-ESO-1, NY-BR-1, pl90 minor BCR-abL, Pml / RARa, PRAME, proteinase 3 , PSA, PSM, RAGE, RU1 or RU2, SAGE, SART-1 or SART-3, SCGB3A2, SCP1, SCP2, SCP3, SSX, Survivin, TEL / AML1, TPI / m, TRP-1, TRP-2, TRP Including, but not limited to -2 / INT2, TPTE, WT and WT-1.
[0444] Cancer mutations vary from individual to individual. Cancer mutations that encode novel epitopes (neo-epitopes) therefore represent attractive targets for vaccine composition and immunotherapy development. The effectiveness of tumor immunotherapy depends on the selection of cancer-specific antigens and epitopes that can induce a strong immune response within the host. RNA can be used to deliver patient-specific tumor epitopes to patients. Dendritic cells (DCs) present in the spleen represent antigen-presenting cells of particular interest for RNA expression of immunogenic epitopes or antigens, such as tumor epitopes. The use of multiple epitopes has been shown to enhance the therapeutic efficacy of tumor vaccine compositions. Rapid sequencing of the tumor mutanome provides multiple epitopes for personalized vaccines, for example, which can be encoded by the mRNA described herein as a single polypeptide, with the epitopes optionally separated by a linker. It is possible. In certain embodiments of the invention, the mRNA has at least one epitope, at least two epitopes, at least three epitopes, at least four epitopes, at least five epitopes, at least six epitopes, at least seven at least 8 epitopes, at least 9 epitopes or at least 10 epitopes. Exemplary embodiments include mRNAs encoding at least 5 epitopes (referred to as "pentatopes") and mRNAs encoding at least 10 epitopes (referred to as "decatopes").
[0445] In certain embodiments, the epitope is derived from a pathogen-associated antigen, particularly a viral antigen. In certain embodiments, the epitope is derived from the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof. Thus, in certain embodiments, the mRNA used in the invention is an amino acid sequence comprising the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof. code.
[0446] In certain embodiments of the invention, the antigen (e.g. a tumor antigen or vaccine antigen) is preferably administered as a single-stranded, 5'-capped mRNA that is translated into each protein once the RNA has entered the cells of the subject to which it is administered. be done. Preferably, the RNA contains structural elements that are optimized for maximum effectiveness of the RNA in terms of stability and translation efficiency (5'cap, 5'UTR, 3'UTR, poly(A) sequences).
[0447] In certain embodiments, beta-S-ARCA(D1) is utilized as a specific capping structure at the 5' end of the mRNA. In some embodiments, m 2 7,3’-O Gppp(m 1 2’-O )ApG is used as a specific capping structure at the 5' end of mRNA. In certain embodiments, the 5'-UTR sequence is derived from human alpha-globin mRNA, optionally with an optimized 'Kozak sequence' for increased translation efficiency. In certain embodiments, a combination of two sequence elements (FI elements) from an "amino-terminal enhancer of split gene" (AES) mRNA (referred to as F) and a mitochondrial-encoded 12S ribosomal RNA (referred to as I), and poly(A) sequences to ensure high maximal protein levels and long-term persistence of mRNA. In certain embodiments, two repeat 3'-UTRs from human beta-globin mRNA are placed between the coding sequence and the poly(A) sequence to ensure high maximal protein levels and long-term persistence of the mRNA. In one embodiment, a poly(A) sequence of dimensions 110 nucleotides long consisting of a stretch of 30 adenosine residues is used, followed by a 10 nucleotide linker sequence and another 70 adenosine residues. This poly(A) sequence was designed for RNA stability and translation efficiency enhancement.
[0448] In certain embodiments, mRNA encoding an antigen (eg, a tumor antigen or a vaccine antigen) is expressed in cells of the subject being treated to provide the antigen. In certain embodiments, the mRNA is transiently expressed in the subject's cells. In certain embodiments, the mRNA is transcribed in vitro. In certain embodiments, the expression of the antigen is on the cell surface. In certain embodiments, the antigen is expressed and presented in the context of MHC. In certain embodiments, the expression of the antigen is in the extracellular space, ie, the antigen is secreted.
[0449] The antigen molecule or its advanced product, eg, a fragment thereof, may be bound to an antigen receptor, such as a BCR or TCR, or an antibody carried by an immune effector cell.
[0450] Peptide and protein antigens provided to a subject according to the invention by administration of mRNA encoding the peptide and protein antigens, where the antigen is a vaccine antigen, are preferably administered to the subject to whom the peptide or protein antigens are provided. resulting in the induction of an immune response, eg, a humoral and / or cellular immune response. The immune response is preferably directed against a target antigen. Thus, the vaccine antigen may include the target antigen, a variant thereof or a fragment thereof. In certain embodiments, such fragments or variants are immunologically equivalent to the target antigen. In the present invention, the term "fragment of an antigen" or "variant of an antigen" refers to a factor that results in the induction of an immune response targeting an antigen, ie a target antigen. Thus, the vaccine antigen may correspond to or include a target antigen, may correspond to or include a fragment of a target antigen, or may correspond to or include an antigen that is homologous to the target antigen or a fragment thereof. Thus, according to the invention, a vaccine antigen may comprise an immunogenic fragment of a target antigen or an amino acid sequence homologous to an immunogenic fragment of a target antigen. "Immunogenic fragment of an antigen" according to the present invention preferably relates to a fragment of an antigen capable of inducing an immune response against a target antigen. Vaccine antigens can be recombinant antigens.
[0451] The term "immunologically equivalent" means that immunologically equivalent molecules, such as immunologically equivalent amino acid sequences, exhibit the same or essentially the same immunological properties and / or, e.g. Regarding the type of effect, it means exerting the same or essentially the same immunological effect. In the present invention, the term "immunologically equivalent" is preferably used in reference to the immunological effects or properties of the antigen or antigenic variant used for immunization. For example, an amino acid sequence is immunologically equivalent to a reference amino acid sequence if the amino acid sequence, when exposed to a subject's immune system, induces an immune response that has the specificity of reacting with the reference amino acid sequence. .
[0452] In certain embodiments, the mRNA used in the invention is non-immunogenic. RNA encoding an immunostimulatory agent can be administered according to the invention to provide an adjuvant effect. RNA encoding an immunostimulatory agent can be standard RNA or non-immunogenic RNA.
[0453] As used herein, the term "non-immunogenic RNA" (e.g., "non-immunogenic mRNA") refers to non-immunogenic RNA that does not induce a response by the immune system or that, upon administration to a mammal, is a non-immunogenic RNA. RNA that induces a weaker response than that induced by the same RNA that differs only in that it has not been subjected to any modifications or treatments that make it more sensitive, ie, than that induced by standard RNA (stdRNA). In certain preferred embodiments, non-immunogenic RNA, also referred to herein as modified RNA (modRNA), includes the incorporation of modified nucleosides and double-stranded RNA (dsRNA) that suppress RNA-mediated activation of innate immune receptors into RNA. Removal renders it non-immunogenic.
[0454] To render non-immunogenic RNA (particularly mRNA) non-immunogenic through the incorporation of modified nucleosides, any modified nucleoside can be used as long as it reduces or suppresses the immunogenicity of the RNA. Particularly preferred are modified nucleosides that inhibit RNA-mediated activation of innate immune receptors. In certain embodiments, the modified nucleoside includes the replacement of one or more uridines with a nucleoside that includes a modified nucleobase. In certain embodiments, the modified nucleobase is a modified uracil. In certain embodiments, the nucleoside comprising a modified nucleobase is 3-methyl-uridine (m 3 U), 5-methoxy-uridine (mo 5 U), 5-aza-uridine, 6-aza-uridine, 2-thio-5-aza-uridine, 2-thio-uridine (s 2 U), 4-thio-uridine(s 4 U), 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxy-uridine (ho 5 U), 5-aminoallyl-uridine, 5-halo-uridine (e.g. 5-iodo-uridine or 5-bromo-uridine), uridine 5-oxyacetic acid (cmo 5 U), uridine 5-oxyacetic acid methyl ester (mcmo 5 U), 5-carboxymethyl-uridine (cm5U), 1-carboxymethyl-pseudouridine, 5-carboxyhydroxymethyl-uridine (chm 5 U), 5-carboxyhydroxymethyl-uridine methyl ester (mchm 5 U), 5-methoxycarbonylmethyl-uridine (mcm5U), 5-methoxycarbonylmethyl-2-thio-uridine (mcm 5 s 2 U), 5-aminomethyl-2-thio-uridine (nm 5 s 2 U), 5-methylaminomethyl-uridine (mnm 5 U), 1-ethyl-pseudouridine, 5-methylaminomethyl-2-thio-uridine (mnm 5 s 2 U), 5-methylaminomethyl-2-seleno-uridine (mnm 5 se 2 U), 5-carbamoylmethyl-uridine (ncm5U), 5-carboxymethylaminomethyl-uridine (cmnm 5 U), 5-carboxymethylaminomethyl-2-thio-uridine (cmnm 5 s 2 U), 5-propynyl-uridine, 1-propynyl-pseudouridine, 5-taurinomethyl-uridine (τm 5 U), 1-taurinomethyl-pseudouridine, 5-taurinomethyl-2-thio-uridine (τm5s2U), 1-taurinomethyl-4-thio-pseudouridine), 5-methyl-2-thio-uridine (m 5 s 2 U), 1-methyl-4-thio-pseudouridine (m 1 s 4 ψ), 4-thio-1-methyl-pseudouridine, 3-methyl-pseudouridine (m 3 ψ), 2-thio-1-methyl-pseudouridine, 1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-1-deaza-pseudouridine, dihydrouridine (D), dihydropseudouridine, 5,6-dihydrouridine, 5-methyl-dihydrouridine (m 5 D), 2-thio-dihydrouridine, 2-thio-dihydropseudouridine, 2-methoxy-uridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine, 4-methoxy-2-thio-pseudo Uridine, N1-methyl-pseudouridine, 3-(3-amino-3-carboxypropyl)uridine (acp 3 U), 1-methyl-3-(3-amino-3-carboxypropyl)pseudouridine (acp3ψ), 5-(isopentenylaminomethyl)uridine (inm 5 U), 5-(isopentenylaminomethyl)-2-thio-uridine (inm 5 s 2 U), α-thio-uridine, 2’-O-methyl-uridine (Um), 5,2’-O-dimethyl-uridine (m 5 Um), 2’-O-methyl-pseudouridine (ψm), 2-thio-2’-O-methyl-uridine (s 2 Um), 5-methoxycarbonylmethyl-2'-O-methyl-uridine (mcm5Um), 5-carbamoylmethyl-2'-O-methyl-uridine (ncm5Um), 5-carboxymethylaminomethyl-2'-O- Methyl-uridine (cmnm 5 Um), 3,2’-O-dimethyl-uridine (m 3 Um), 5-(isopentenylaminomethyl)-2’-O-methyl-uridine (inm 5 Um), 1-thio-uridine, deoxythymidine, 2'-F-ara-uridine, 2'-F-uridine, 2'-OH-ara-uridine, 5-(2-carbomethoxyvinyl)uridine and 5- [selected from the group consisting of 3-(1-E-propenylamino)uridine; In certain particularly preferred embodiments, the nucleoside comprising a modified nucleobase is pseudouridine (ψ), N1-methyl-pseudouridine (m1ψ) or 5-methyl-uridine (m5U), especially N1-methyl-pseudouridine.
[0455] In certain embodiments, the replacement of one or more uridines with a nucleoside comprising a modified nucleobase comprises at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 10%, at least 25% of the uridines. , at least 50%, at least 75%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% substitution.
[0456] During the synthesis of mRNA by in vitro transcription (IVT) using T7 RNA polymerase, aberrant products containing significant amounts of double-stranded RNA (dsRNA) are produced due to the atypical activity of the enzyme. dsRNA induces inflammatory cytokines and activates effector enzymes, leading to inhibition of protein synthesis. dsRNA can be removed from RNA, such as IVT RNA, by ion-pair reverse phase HPLC using, for example, non-porous or porous C-18 polystyrene-divinylbenzene (PS-DVB) matrices. Alternatively, an enzyme-based method using E. coli RNaseIII, which specifically hydrolyzes dsRNA but not ssRNA, thus eliminating dsRNA contaminants from IVT RNA preparations, can be used. Additionally, dsRNA can be separated from ssRNA using cellulosic materials. In certain embodiments, the RNA preparation is contacted with a cellulosic material and the ssRNA is separated from the cellulosic material under conditions that allow binding of the dsRNA to the cellulosic material and do not allow binding of the ssRNA to the cellulosic material. Suitable methods for providing ssRNA are disclosed, for example, in WO2017 / 182524.
[0457] "Remove" or "removal," as the term is used herein, means that the characteristics of a population of a first substance, such as a non-immunogenic RNA, are reversed from a population of an adjacent second substance, such as a dsRNA. Here, a group of first substances does not necessarily lack the second substance, and a group of second substances does not necessarily lack the first substance. However, the first population of substances characterized by the second population of substances has a measurably lower content of the second substance compared to an unseparated mixture of the first and second substances.
[0458] In certain embodiments, the removal of dsRNA (particularly mRNA) from non-immunogenic RNA is less than 10%, less than 5%, less than 4%, less than 3%, less than 2% of the RNA in the non-immunogenic RNA composition. , including removal of dsRNA where less than 1%, less than 0.5%, less than 0.3% or less than 0.1% is dsRNA. In certain embodiments, the non-immunogenic RNA (particularly mRNA) is free or substantially free of dsRNA. In certain embodiments, the non-immunogenic RNA (particularly mRNA) composition comprises a purified preparation of single-stranded nucleoside-modified RNA. For example, in some embodiments, a purified preparation of single-stranded nucleoside-modified RNA (particularly mRNA) is substantially free of double-stranded RNA (dsRNA). In certain embodiments, the purified preparation is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5% or at least 99.9% single-stranded nucleoside modified RNA.
[0459] In certain embodiments, non-immunogenic RNA (particularly mRNA) is more efficiently translated in a cell than standard RNA of the same sequence. In certain embodiments, translation is enhanced 2-fold compared to the unmodified counterpart. In certain embodiments, translation is enhanced by a factor of 3. In certain embodiments, translation is enhanced by a factor of 4. In certain embodiments, translation is enhanced by a factor of 5. In certain embodiments, translation is enhanced 6-fold. In certain embodiments, translation is enhanced by a factor of 7. In certain embodiments, translation is enhanced by 8-fold. In certain embodiments, translation is enhanced by a factor of 9. In certain embodiments, translation is enhanced by a factor of 10. In certain embodiments, translation is enhanced by 15 times. In certain embodiments, translation is enhanced 20-fold. In certain embodiments, translation is enhanced 50-fold. In certain embodiments, translation is enhanced 100-fold. In certain embodiments, translation is enhanced 200-fold. In some embodiments, translation is enhanced 500-fold. In some embodiments, translation is enhanced 1000-fold. In some embodiments, translation is enhanced 2000 times. In some embodiments, the multiple is 10-1000 times. In certain embodiments, the multiple is 10-100 times. In some embodiments, the multiple is 10-200 times. In some embodiments, the multiple is 10-300 times. In some embodiments, the multiple is 10-500 times. In some embodiments, the multiple is 20-1000 times. In some embodiments, the multiple is 30-1000 times. In some embodiments, the multiple is 50-1000 times. In some embodiments, the multiple is 100-1000 times. In some embodiments, the multiple is 200-1000 times. In certain embodiments, translation is enhanced by some other substantial amount or range of amounts.
[0460] In certain embodiments, non-immunogenic RNA (particularly mRNA) exhibits significantly lower natural immunogenicity than standard RNA of the same sequence. In certain embodiments, non-immunogenic RNA (particularly mRNA) exhibits a 2-fold lower innate immune response than its unmodified counterpart. In certain embodiments, natural immunogenicity is reduced by 3-fold. In certain embodiments, natural immunogenicity is reduced by 4-fold. In certain embodiments, natural immunogenicity is reduced by 5-fold. In certain embodiments, natural immunogenicity is reduced by 6-fold. In certain embodiments, natural immunogenicity is reduced by 7-fold. In certain embodiments, natural immunogenicity is reduced by 8-fold. In certain embodiments, natural immunogenicity is reduced by 9-fold. In certain embodiments, natural immunogenicity is reduced 10-fold. In certain embodiments, natural immunogenicity is reduced by 15-fold. In certain embodiments, natural immunogenicity is reduced 20-fold. In certain embodiments, natural immunogenicity is reduced by 50-fold. In certain embodiments, natural immunogenicity is reduced by 100-fold. In certain embodiments, natural immunogenicity is reduced 200-fold. In certain embodiments, natural immunogenicity is reduced by 500-fold. In certain embodiments, natural immunogenicity is reduced 1000-fold. In certain embodiments, natural immunogenicity is reduced 2000-fold.
[0461] The term "indicating significantly less natural immunogenicity" refers to a detectable reduction in natural immunogenicity. In certain embodiments, the term refers to a reduction such that an effective amount of non-immunogenic RNA (particularly mRNA) can be administered without eliciting a detectable innate immune response. In certain embodiments, the term refers to repeated administration of non-immunogenic RNA (particularly mRNA) without inducing an innate immune response sufficient to cause a detectable decrease in the production of the protein encoded by the non-immunogenic RNA. This refers to a decrease that can be achieved. In certain embodiments, the reduction is such that the non-immunogenic RNA (particularly the mRNA) can be administered repeatedly without inducing an innate immune response sufficient to eliminate detectable production of the protein encoded by the non-immunogenic RNA. It is something.
[0462] "Immunogenicity" is the ability of a foreign substance, such as RNA, to elicit an immune response within the human or other animal body. The innate immune system is a component of the immune system that is relatively non-specific and immediate. It is one of the two main components of the vertebrate immune system, along with the adaptive immune system.
[0463] "Endogenous" as used herein refers to any substance derived from or produced in an organism, cell, tissue or system.
[0464] The term "exogenous" as used herein refers to any substance that is introduced or produced from outside an organism, cell, tissue or system.
[0465] The term "expression" as used herein is defined as the transcription and / or translation of a particular nucleotide sequence.
[0466] As used herein, the terms "bond," "fusion," or "fusion" are used interchangeably. These terms refer to the bringing together of two or more elements or components or domains.
[0467] particle Various types of RNA-containing particles have been previously described as suitable for the delivery of RNA in particulate form (see, eg, Kaczmarek, J. C. et al., 2017, Genome Medicine 9, 60). For non-viral RNA delivery vehicles, nanoparticle encapsulation of RNA physically protects the RNA from degradation and, depending on the specific chemistry, may aid cellular uptake and endosomal escape.
[0468] Electrostatic interactions between positively charged molecules such as polymers and lipids and negatively charged nucleic acids are involved in particle formation. This results in complexity and spontaneous formation of nucleic acid particles.
[0469] In the present invention, the term "particle" relates to structured objects formed by molecules or molecular complexes, in particular particle-forming compounds. Preferably, the particles have an envelope (e.g. one or more layers or thin layers) consisting of one or more types of amphiphiles (e.g. amphiphilic lipids, amphiphilic polymers and / or amphipathic proteins / polypeptides). layer). In this context, the expression "amphiphile" means a substance that has both hydrophilic and lipophilic properties. The envelope may also contain additional substances that need not be amphiphilic (eg, additional lipids and / or additional polymers). Thus, the particles may be of monolayer or multilayer structure, where the material consisting of one or more layers or thin layers comprises one or more types of amphiphiles (in particular amphiphilic lipids, amphipathic selected from the group consisting of polymers and / or amphiphilic proteins / polypeptides) optionally in combination with additional substances that do not need to be amphipathic (e.g. additional lipids and / or additional polymers). include. In certain embodiments, the term "particle" refers to micro- or nano-sized structures, such as micro- or nano-sized miniature structures. In this context, the term "microsized" means that all three external dimensions of the particle are on the microscale, ie from 1 to 5 μm. According to the present invention, the term "particle" includes lipoplex particles (LPX), lipid nanoparticles (LNP), polyplex particles, lipopolyplex particles, virus-like particles (VLPs) and mixtures thereof (e.g. LPX and VLPs). mixtures or mixtures of two or more particle types, such as mixtures of LNPs and VLPs).
[0470] "Nucleic acid particles" can be used to deliver nucleic acids to target sites of interest (eg, cells, tissues, organs, etc.). Nucleic acid particles may be formed from at least one cationic or cationically ionizable lipid or lipid-like substance, at least one cationic polymer such as protamine or a mixture thereof and a nucleic acid. Nucleic acid particles include lipid nanoparticle (LNP)-based and lipoplex (LPX)-based formulations.
[0471] Without intending to be bound by any theory, it is believed that cationic or cationically ionizable lipids or lipid-like substances and / or cationic polymers combine with nucleic acids to form aggregates that are colloidally stable. It is thought that this causes particles.
[0472] In certain embodiments, the particles described herein include at least one lipid or lipid-like substance other than a cationically ionizable lipid.
[0473] In certain embodiments, a nucleic acid particle (particularly an mRNA particle, such as an mRNA LNP) comprises more than one type of nucleic acid molecule, wherein basic structural elements such as molar mass or molecular structure, capping, coding region or other characteristics The molecular parameters of the nucleic acid molecules, such as those related to each other, may be similar or different from each other.
[0474] As used herein, "nanoparticle" refers to a particle comprising a nucleic acid (particularly mRNA) as described herein and at least one cationic lipid, where all three external dimensions of the particle are nanoscale; That is, at least about 1 nm and less than about 1000 nm (preferably 10-990 nm, for example 15-900 nm, 20-800 nm, 30-700 nm, 40-600 nm or 50-500 nm). Preferably, the longest and shortest axes are not significantly different. Preferably, the size of the particle is its diameter.
[0475] The nucleic acid particles described herein (particularly mRNA particles, such as mRNA LNPs) exhibit a polydispersity index (PDI) of less than about 0.5, less than about 0.4, less than about 0.3, less than about 0.2, less than about 0.1, or less than about 0.05. . By way of example, the nucleic acid particles may exhibit a polydispersity index ranging from about 0.01 to about 0.4 or from about 0.1 to about 0.3.
[0476] In the present invention, the term "lipoplex particle" refers to a particle comprising an amphipathic lipid, in particular a cationic amphipathic lipid, and a nucleic acid (in particular mRNA) as described herein. Electrostatic interactions between positively charged liposomes (derived from one or more amphiphilic lipids, especially cationic amphiphilic lipids) and negatively charged nucleic acids (especially mRNA) lead to complexation and spontaneous formation of nucleic acid lipoplex particles. bring. Positively charged liposomes can generally be synthesized using cationic amphiphilic lipids such as DOTMA and additional lipids such as DOPE. In certain embodiments, the nucleic acid (particularly mRNA) lipoplex particles are nanoparticles.
[0477] The term "lipid nanoparticle" relates to nanosized lipid-containing particles.
[0478] In the present invention, the term "polyplex particle" refers to a particle comprising an amphiphilic polymer, especially a cationic amphiphilic polymer, and a nucleic acid (especially mRNA) as described herein. Electrostatic interactions between positively charged cationic amphiphilic polymers and negatively charged nucleic acids (particularly mRNA) lead to complexity and spontaneous formation of nucleic acid polyplex particles. Positively charged amphiphilic polymers suitable for preparing polyplex particles include protamine, polyethyleneimine, poly-L-lysine, poly-L-arginine and histones. In certain embodiments, the nucleic acid (particularly mRNA) polyplex particles are nanoparticles.
[0479] The term "lipopolyplex particles" refers to the amphiphilic lipids described herein (especially cationic amphiphilic lipids), the amphiphilic polymers described herein (especially cationic amphiphilic polymers) and the nucleic acids described herein. (especially mRNA). In certain embodiments, the nucleic acid (particularly mRNA) lipopolyplex particles are nanoparticles.
[0480] The term "virus-like particle" (herein abbreviated as VLP) refers to a molecule that mimics a virus, but does not contain any genetic material and is therefore non-infectious. Preferably, the VLP comprises a nucleic acid (preferably RNA) as described herein, which nucleic acid (preferably RNA) is heterologous to the virus from which the VLP is derived. VLPs can be synthesized through individual expression of viral structural proteins, after which they can self-assemble into virus-like structures. In certain embodiments, a combination of structural capsid proteins from different viruses may be used to create recombinant VLPs. VLPs include hepatitis B virus (HBV) (small HBV-derived surface antigen (HBsAg)), Parvoviridae (e.g., adeno-associated virus), Papillomaviridae (e.g., HPV), Retroviridae (e.g., HIV), It can be produced from members of a wide variety of virus families, including the Flaviviridae (eg, hepatitis C virus) and bacteriophages (eg, Qβ, AP205).
[0481] The term "nucleic acid-containing particles" refers to particles as described herein to which nucleic acids (particularly mRNA) are bound. In this regard, the nucleic acid (especially mRNA) can be attached to the outer surface of the particle (surface nucleic acid (especially surface mRNA)) and / or included in the particle (encapsulated nucleic acid (especially encapsulated mRNA)).
[0482] In certain embodiments, the particles utilized in the methods and uses of the invention are in the range of about 10 to about 2000 nm, such as at least about 15 nm (preferably at least about 20 nm, at least about 25 nm, at least about 30 nm, at least about 35 nm, at least about 40nm, at least about 45nm, at least about 50nm, at least about 55nm, at least about 60nm, at least about 65nm, at least about 70nm, at least about 75nm, at least about 80nm, at least about 85nm, at least about 90nm, at least about 95nm or at least about 100nm) and / or up to 1900nm (preferably up to about 1900nm, up to about 1800nm, up to about 1700nm, up to about 1600nm, up to about 1500nm, up to about 1400nm, up to about 1300nm, up to about 1200nm, up to about 1100nm, up to about 1000nm, up to about 950 nm, up to about 900 nm, up to about 850 nm, up to about 800 nm, up to about 750 nm, up to about 700 nm, up to about 650 nm, up to about 600 nm, up to about 550 nm, or up to about 500 nm), preferably about 20 to about 1500 nm, e.g. Range of about 30 to about 1200nm, about 40 to about 1100nm, about 50 to about 1000nm, about 60 to about 900nm, about 70 to about 800nm, about 80 to 700nm, about 90 to 600nm or about 50 to 500nm or about 100 to 500nm , for example a size in the range of 10-1000nm, 15-500nm, 20-450nm, 25-400nm, 30-350nm, 40-300nm, 50-250nm, 60-200nm or 70-150nm (preferably diameter, i.e. radius of gyration) (R g ) value or twice the radius, such as twice the hydrodynamic radius).
[0483] For RNA lipid particles (particularly mRNA particles such as mRNA LNPs), the N / P ratio indicates the ratio of the number of nitrogen groups in the lipid to the number of phosphate groups in the RNA. It correlates with the charge ratio because the nitrogen atom (depending on pH) is usually positively charged and the phosphate group is negatively charged. The N / P ratio is pH dependent when charge balance exists. Lipid formulations are often formed with N / P ratios greater than 4 and up to 12, as positively charged nanoparticles are believed to favor transfection. In this case, the RNA would be completely bound to the nanoparticles.
[0484] The nucleic acid particles described herein (particularly mRNA particles such as mRNA LNPs) obtain colloids from at least one cationic or cationically ionizable lipid and / or at least one cationic polymer to form a colloid. They can be manufactured in a wide variety of ways, including mixing with nucleic acids to obtain nucleic acid particles.
[0485] The term "colloid" as used herein relates to a type of homogeneous mixture in which dispersed particles do not settle. The insoluble particles in the mixture are microscopic, with a particle size of 1-1000 nanometers. The mixture may be referred to as a colloid or a colloidal suspension. The term "colloid" refers only to particles in a mixture and may not be an entire suspension.
[0486] For the preparation of colloids containing at least one cationic or cationically ionizabl...
Claims
1. 1. A method of making a pharmaceutical composition comprising: (I) preparing a formulation comprising a lipid nanoparticle (LNP), wherein the LNP comprises a cationically ionizable lipid and mRNA, the pH of the formulation is up to 6.5, and step (I) does not include the addition of NaCl; and (II) freezing the formulation at or below about −10° C., thereby obtaining the pharmaceutical composition in frozen form. A method comprising:
2. 2. The method of claim 1, further comprising the step (III) of lyophilizing the frozen formulation, thus obtaining the pharmaceutical composition in lyophilized form.
3. (1) The pH of the formulation is up to 6.0; (2) the pH of the formulation is lower than the pKa of the cationically ionizable lipid; (3) the formulation is substantially free of citrate anion; (4) The formulation is substantially free of inorganic phosphate anions; (5) step (I) does not include the addition of NaCl; (6) the formulation further comprises a poloxamer; and / or (7) The formulation comprises a buffer system and / or a cryoprotectant. The method of claim 1 or 2. (i) the buffer system comprises water and a buffering substance; (ii) the buffer system comprises any one of HEPES, histidine, Tris and acetate as a buffering substance; (iii) the buffer system comprises HEPES as a buffering substance; (iv) the concentration of the buffer in the formulation is at most 50 mM, or at most 40 mM, or at most 20 mM; (v) the cryoprotectant comprises one or more carbohydrates; (vi) the cryoprotectant comprises sucrose, trehalose, glucose, or a combination thereof; (vii) the cryoprotectant comprises sucrose and / or trehalose; (viii) the concentration of the cryoprotectant in the formulation is at least 1% w / v; and / or (ix) the buffer system comprises HEPES as a buffering substance and the cryoprotectant comprises sucrose and / or trehalose; The method of claim 3.
5. The cationically ionizable lipid is (i) comprises a head group that includes at least one nitrogen atom that can be protonated under physiological conditions; (ii) Formula (I): 【Chemistry 1】 or a pharma- ceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein: one of L 1 and L 2 is -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O) x -, -S-S-, -C(=O)S-, SC(=O)-, -NR a C(=O)-, -C(=O)NR a -, NR a C(=O)NR a -, -OC(=O)NR a - or -NR a C(=O)O-; and the other of L 1 and L 2 is -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O) x -, -S-S-, -C(=O)S-, SC(=O)-, -NR a C(=O)-, -C(=O)NR a -, NR a C(=O)NR a -, -OC(=O)NR a - or -NR a C(=O)O- or a direct bond; G 1 and G 2 are each independently unsubstituted C 1 -C 12 alkylene or C 2 -C 12 alkenylene; G 3 is C 1 -C 24 alkylene, C 2 -C 24 alkenylene, C 3 -C 8 cycloalkylene, C 3 -C 8 cycloalkenylene; R a is H or C 1 -C 12 alkyl; R 1 and R 2 are each independently C 6 -C 24 alkyl or C 6 -C 24 alkenyl; R 3 is H, OR 5 , CN, -C(=O)OR 4 , -OC(=O)R 4 or -NR 5 C(=O)R 4 ; R 4 is C 1 -C 12 alkyl; R 5 is H or C 1 -C 6 alkyl; and x is 0, 1 or 2; or (iii) selected from the following structures A to F: 【Table 1】 or (iv) N,N-dimethyl-2,3-dioleyloxypropylamine (DODMA), 1,2-dioleoyl-3-dimethylammonium-propane (DODAP), heptatriaconta-6,9,28,31-tetraen-19-yl-4-(dimethylamino)butanoate (DLin-MC3-DMA) and 4-((di((9Z,12Z)-octadeca-9,12-dien-1-yl)amino)oxy)-N,N-dimethyl-4-oxobutan-1-amine (DPL-14). The method according to any one of claims 1 to 4.
6. The LNP further comprises one or more additional lipids selected from the group consisting of polymer-conjugated lipids, neutral lipids, steroids, and combinations thereof; or The LNPs comprise a cationically ionizable lipid, a polymer-conjugated lipid, a neutral lipid, and a steroid; The method according to any one of claims 1 to 5. (a) the polymer-conjugated lipid comprises a pegylated lipid, or the polymer-conjugated lipid comprises a pegylated lipid, and the pegylated lipid has the following structure: 【Chemistry 2】 or a pharma- ceutically acceptable salt, tautomer or stereoisomer thereof, wherein R 12 and R 13 are each independently a linear or branched, saturated or unsaturated alkyl chain containing from 10 to 30 carbon atoms, where the alkyl chain is optionally interrupted by one or more ester bonds; and w has an average value in the range of from 30 to 60; or the polymer-conjugated lipid comprises a polysarcosine-lipid conjugate or a conjugate of polysarcosine and a lipid-like substance, or the polymer-conjugated lipid comprises a polysarcosine-lipid conjugate or a conjugate of polysarcosine and a lipid-like substance, wherein the polysarcosine-lipid conjugate or the conjugate of polysarcosine and a lipid-like substance is a member selected from the group consisting of polysarcosine-diacylglycerol conjugates, polysarcosine-dialkyloxypropyl conjugates, polysarcosine-phospholipid conjugates, polysarcosine-ceramide conjugates, and mixtures thereof; (b) the neutral lipid is a phospholipid or is selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidic acid, phosphatidylserine or sphingomyelin or is selected from the group consisting of distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dimyristoylphosphatidylcholine (DMPC), dipentadecanoylphosphatidylcholine, di Lauroyl phosphatidylcholine, dipalmitoyl phosphatidylcholine (DPPC), diarachidoyl phosphatidylcholine (DAPC), dibehenoyl phosphatidylcholine (DBPC), ditricosanoyl phosphatidylcholine (DTPC), dilignoceroyl phosphatidylcholine (DLPC), palmitoyloleoyl-phosphatidylcholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 Diether PC), 1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), dioleoylphosphatidylethanolamine (DOPE), distearoyl-phosphatidylethanolamine (DSPE), dipalmitoyl-phosphatidylethanolamine (DPPE), dimyristoyl-phosphatidylethanolamine (DMPE), dilauroyl-phosphatidylethanolamine (DLPE) and diphytanoyl-phosphatidylethanolamine (DPyPE); and / or (c) the steroid comprises a sterol or comprises cholesterol; The method of claim 6. (i) a ratio of cationically ionizable lipid to mRNA of from 2:1 to 12:1; (ii) the mRNA is encapsulated or associated with the LNP; (iii) the mRNA contains modified nucleosides instead of uridine; (iv) the mRNA contains a modified nucleoside instead of uridine, wherein the modified nucleoside is selected from pseudouridine (ψ), N1-methyl-pseudouridine (mψ), and 5-methyl-uridine (m5U); (v) the mRNA comprises a 5' cap, a 5' UTR, a 3' UTR and / or a poly A sequence; (vi) the mRNA encodes one or more polypeptides; The method of any one of claims 1 to 7.
9. 9. The method of claim 8, wherein the one or more polypeptides comprise an epitope for inducing an immune response to an antigen in a subject or the mRNA encodes an amino acid sequence comprising the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof.
10. 10. The method of any of claims 1 to 9, wherein the formulation is frozen at a temperature in the range of about -30°C to about -10°C, at a temperature in the range of about -25°C to about -15°C, at a temperature in the range of about -25°C to about -20°C, or at a temperature of about -20°C.
11. The method of any one of claims 2 to 10, wherein the frozen formulation is freeze-dried until the pharmaceutical composition is substantially free of water contained in the frozen formulation or contains less than 1.0% by weight of water.
12. step (I) comprises: (a) preparing an mRNA solution comprising water and a buffer system; (b) preparing an ethanolic solution comprising a cationically ionizable lipid and, if present, one or more additional lipids; and (c) mixing the mRNA solution prepared under (a) with the ethanolic solution prepared under (b), thereby preparing a formulation comprising LNPs; or step (I) comprises: (a') preparing a liposome or colloid preparation of a cationically ionizable lipid and, if present, one or more additional lipids in an aqueous phase; and (b') preparing an mRNA solution comprising water and a buffer system; and (c') mixing the liposome or colloid preparation prepared under (a') with the mRNA solution prepared under (b'), The method of any one of claims 1 to 11.
13. 13. A method for storing a pharmaceutical composition, comprising preparing a pharmaceutical composition by the method of any of claims 1 to 12, and storing the pharmaceutical composition at a temperature in the range of about -30°C to about -10°C, or at a temperature in the range of about -25°C to about -15°C, or at a temperature in the range of about -25°C to about -20°C, or at a temperature of about -20°C.
14. Prepared by the process of any one of claims 1 to 13; or It can be prepared by the method according to any one of claims 2 to 13, Lyophilized pharmaceutical composition.
15. 1. A method for preparing a ready-to-use pharmaceutical composition comprising: (a) providing a frozen pharmaceutical composition prepared by the method of any one of claims 1 to 13, and thawing the frozen pharmaceutical composition, thereby obtaining a ready-to-use pharmaceutical composition; or (b) providing a lyophilized pharmaceutical composition prepared by the method of any one of claims 2 to 13, and reconstituting the frozen pharmaceutical composition, thereby obtaining a ready-to-use pharmaceutical composition. method.
16. A ready-to-use pharmaceutical composition which can be prepared by the method of claim 15.
17. A pharmaceutical composition comprising LNPs, wherein the LNPs comprise cationically ionizable lipids and mRNA, wherein: the pharmaceutical composition comprises NaCl and KCl in a combined amount of less than 10% by weight, based on the total amount of lipid and mRNA in the pharmaceutical composition, and when in aqueous liquid form, the pH of the pharmaceutical composition is up to 6.5; In frozen or freeze-dried form, Pharmaceutical compositions.
18. (1) The pharmaceutical composition comprises NaCl and KCl in a combined concentration of less than 5% by weight or less than 1% by weight, based on the total weight of lipid and mRNA in the pharmaceutical composition; (2) When in aqueous liquid form, the pH of the pharmaceutical composition is up to 6.0; (3) the pH of the formulation, when in aqueous liquid form, is lower than the pK a of the cationically ionizable lipid; (4) the pharmaceutical composition is substantially free of citrate anion; (5) the pharmaceutical composition is substantially free of inorganic phosphate anions; (6) The pharmaceutical composition comprises a buffer system and / or a cryoprotectant; (7) The pharmaceutical composition comprises a buffer system, the buffer system comprising water and a buffering substance; (8) The pharmaceutical composition comprises a buffer system, the buffer system comprising any one of HEPES, histidine, Tris, and acetic acid as a buffering substance; (9) The pharmaceutical composition comprises a buffer system, the buffer system comprising HEPES as a buffering substance; (10) The pharmaceutical composition comprises a buffer system, and the amount of buffer in the pharmaceutical composition is up to 4 mmol, or up to 3.6 mmol, or up to 1.8 mmol per gram of the total weight of lipid and mRNA in the pharmaceutical composition; (11) The pharmaceutical composition comprises a cryoprotectant, the cryoprotectant comprising one or more carbohydrates; (12) The pharmaceutical composition comprises a cryoprotectant, the cryoprotectant comprising sucrose, trehalose, glucose, or a combination thereof; (13) The pharmaceutical composition comprises a cryoprotectant, the cryoprotectant comprising sucrose and / or trehalose; (14) The pharmaceutical composition comprises a cryoprotectant, and the amount of the cryoprotectant in the pharmaceutical composition is at least 80% by weight, based on (i) the total amount of the pharmaceutical composition free of any solvent contained in the pharmaceutical composition, if the pharmaceutical composition is in frozen form, or (ii) the total amount of the pharmaceutical composition, if the pharmaceutical composition is in lyophilized form; (15) The pharmaceutical composition comprises a buffer system and a cryoprotectant, the buffer system comprising HEPES as a buffering substance, and the cryoprotectant comprising sucrose and / or trehalose; (16) The pharmaceutical composition further comprises a poloxamer; (17) The cationically ionizable lipid comprises a head group that includes at least one nitrogen atom that can be protonated under physiological conditions; (18) The cationically ionizable lipid has the formula (I): 【Chemistry 3】 or a pharma- ceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein: one of L 1 and L 2 is -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O) x -, -S-S-, -C(=O)S-, SC(=O)-, -NR a C(=O)-, -C(=O)NR a -, NR a C(=O)NR a -, -OC(=O)NR a - or -NR a C(=O)O-; and the other of L 1 and L 2 is -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O) x -, -S-S-, -C(=O)S-, SC(=O)-, -NR a C(=O)-, -C(=O)NR a -, NR a C(=O)NR a -, -OC(=O)NR a - or -NR a C(=O)O- or a direct bond; G 1 and G 2 are each independently unsubstituted C 1 -C 12 alkylene or C 2 -C 12 alkenylene; G 3 is C 1 -C 24 alkylene, C 2 -C 24 alkenylene, C 3 -C 8 cycloalkylene, C 3 -C 8 cycloalkenylene; R a is H or C 1 -C 12 alkyl; R 1 and R 2 are each independently C 6 -C 24 alkyl or C 6 -C 24 alkenyl; R 3 is H, OR 5 , CN, -C(=O)OR 4 , -OC(=O)R 4 or -NR 5 C(=O)R 4 ; R 4 is C 1 -C 12 alkyl; R 5 is H or C 1 -C 6 alkyl; and x is 0, 1 or 2; or the cationically ionizable lipid is selected from the following structures A through F: 【Table 2】 or the cationically ionizable lipid is selected from the group consisting of N,N-dimethyl-2,3-dioleoyloxypropylamine (DODMA), 1,2-dioleoyl-3-dimethylammonium-propane (DODAP), heptatriaconta-6,9,28,31-tetraen-19-yl-4-(dimethylamino)butanoate (DLin-MC3-DMA) and 4-((di((9Z,12Z)-octadeca-9,12-dien-1-yl)amino)oxy)-N,N-dimethyl-4-oxobutan-1-amine (DPL-14); (19) The LNP further comprises one or more additional lipids selected from the group consisting of polymer-conjugated lipids, neutral lipids, steroids, and combinations thereof; (20) The LNP comprises a cationically ionizable lipid, a polymer-conjugated lipid, a neutral lipid, and a steroid; (21) The LNP comprises a polymer-conjugated lipid as specified in claim 7, a natural lipid, and a steroid; (22) the mRNA is as defined in claim 8 or 9; and / or The pharmaceutical composition of any one of claims 89 to 126, wherein the ratio of is 2:1 to 12:
1. (23) The frozen pharmaceutical composition can be frozen and stored at a temperature in the range of about -30°C to about -10°C, or at a temperature in the range of about -25°C to about -15°C, or at a temperature of about -20°C, or the lyophilized pharmaceutical composition can be stored at a temperature in the range of about -25°C to about room temperature, at a temperature in the range of about -15°C to about 8°C, at a temperature in the range of about -10°C to about 2°C, or at a temperature in the range of about -5°C to about 0°C.
18. The pharmaceutical composition of claim 17.
19. A pharmaceutical composition according to any one of claims 14 and 16 to 18 for use in therapy.
20. A pharmaceutical composition according to any one of claims 14 and 16 to 18 for use in inducing an immune response.
